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Abstract 
β-thalassemia and sickle cell disease, which are caused by mutations in the 
β-globin gene, are two of the most common single gene disorders worldwide 
and the only available cure is allogeneic bone marrow transplantation that is 
limited by donor availability. Gene therapy, by delivery of a β-globin 
expression vector into autologous haematopoietic stem cells, is a valuable 
alternative but the technique is affected by unpredictable protein expression 
levels and, more significantly, by random integration of the vector and the risk 
of insertional oncogenesis. 
Gene correction by Homologous Recombination (HR) with a DNA repair 
template would avoid the above-mentioned issues, becoming ideal 
therapeutic approach. Although spontaneous HR events are very rare, Double 
Strand Breaks (DSBs) at the target locus can greatly stimulate them. 
Therefore, the development of Zinc Finger Nucleases (ZFNs), which are 
customised endonucleases capable of cleaving any desired DNA sequence, 
has created the opportunity to design molecular tools to treat many rare 
monogenic disorders.  
The aim of this thesis has been to develop a ZFN-based gene targeting at 
the β-globin locus as a basis for β-thalassaemia gene-correction therapy. 
Initially, six ZF domains specific for the β-globin gene were designed, 
assembled and tested using publicly available reagents, but these were found 
to have a low binding efficiencies. Therefore, a commercial approach was 
used to obtain a functional ZFN (ZFN4) and this was shown to produce DSBs 
at the β-globin gene in ≈ 1% of the transfected human erythroleukemia cells 
without detectably cleaving the most closely related sequence in the human 
genome (the δ-globin gene). Using a reporter assay, ZFN4 was also shown to 
promote gene correction through intrachromosomal HR but was found to be 
20 times less efficient than the homing endonuclease I-SceI. 
Ultimately, ZFN4-stimulated targeted integration of a drug resistance 
marker at the endogenous β -globin gene locus was tested: 95% of the drug-
resistant cells were targeted while the absolute frequency compared to the 
whole cell population resulted to be 0.1% The collected data show that ZFN4-
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mediated gene targeting of the β-globin locus is possible but further studies 
are required in order address the discrepancy between cutting and targeting 
efficiencies and to increase the absolute frequency of gene targeted cells.	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1 Chapter 1: Introduction 
 
Zinc Finger Nucleases (ZFNs) are a class of engineered, gene-specific, DNA 
cleavage proteins that have been selected as the preferred molecular tool to 
produce targeted gene editing in a variety of animal or human cell types and 
animal models. ZFNs produce Double Strand Breaks (DSBs) at specific target 
sequences that are then repaired by one of the cellular DNA-repair pathways. 
Researchers can take advantage of these repair mechanisms to induce a 
range of different gene modifications for scientific or therapeutic purposes. 
This thesis concerns the development of ZFNs for promoting gene 
correction of disease-causing mutations at the human β-globin gene with a 
particular focus on β-thalassaemia mutations. 
As an introductory overview, the nature of the β-thalassaemia disease, of 
gene therapy in general and of gene correction in particular will be 
considered.   
 
1.1 Thalassaemias  
 
Thalassaemias are hereditary autosomal recessive anaemias characterised 
by aberrations in synthesis and structure of the two different globin chains that 
compose the quaternary structure of the haemoglobin protein. Normal adult 
haemoglobin (HbA, α2β2) is a tetramer formed by two different sub-units: α-
globin and β-globin. Between 5% and 7% of the world population is a carrier 
for a globin variant including 1.7% of individuals who are heterozygous for α- 
or β-thalassaemia traits (Rund and Rachmilewitz 2005; Muncie and Campbell 
2009; Higgs, Engel et al. 2012). It is estimated that 60,000 individuals (or 4.4 
individuals every 10,000 births) are born every year with severe homozygous 
or compound heterozygosity for α- or β-thalassaemia traits (Rund and 
Rachmilewitz 2005; Muncie and Campbell 2009; Higgs, Engel et al. 2012) 
making thalassaemias one of the most common genetic diseases in the world. 
Most of the individuals who are born with one of these hereditary diseases 
are from the Mediterranean, Middle East, Central Asia, India and China where 
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thalassaemia traits reach frequencies of 5-30% in specific ethnic groups 
(Muncie and Campbell 2009; Higgs, Engel et al. 2012). The greatest burden 
of disease is found in low- and middle-income countries where diagnostic, 
therapeutic and management approaches are poor and the frequencies of 
thalassaemias are probably underestimated due to the high rate of infant 
mortality that affected most of these countries till recent times (Weatherall 
2011; Higgs, Engel et al. 2012). The diseases are therefore expected to rise 
in frequency due both to falling childhood mortality and also to the increase in 
migration. 
The reasons for the high frequencies of thalassaemias found in tropical or 
sub-tropical areas of the globe are to be found in the selective advantage that 
this type of inherited haemoglobin disorders confers to the carriers that are 
more protected against malaria, a disease that is, or was, endemic in these 
sorts of climate (Weatherall 2011; Higgs, Engel et al. 2012).  
 
1.2 β-thalassaemia  
 
β-thalassaemia is one of the most common genetic diseases and is caused 
by any of more than 200 point mutations or deletions in the β-globin gene. 
When the mutation completely removes any type of β-globin expression the 
disease is called β0-thalassaemia while if the mutation reduces the production 
of the protein, the disease is know as β+-thalassaemia. The clinical effects, in 
the most severe cases, are chronic haemolysis, ineffective erythropoiesis and 
transfusion dependent anaemia (Maniatis, Fritsch et al. 1980; Higgs, Engel et 
al. 2012).  
Although the severity of the disease may vary greatly from patient to 
patient even in the event of a shared β-globin genotype, β-thalassaemia can 
be divided into three broad categories: asymptomatic β-thalassaemia minor 
(also known as β-thalassaemia trait), in which the subject carries only one 
mutated copy of the gene (β/βT), an intermediate disorder with some need for 
blood transfusion known as thalassaemia intermedia, which is usually caused 
by mutations on both alleles but at least one of them is mild (βt/βT or β+/β0), 
and thalassaemia major (βT/βT or β0/β0) in which the subject is a homozygote 
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(same mutation on both chromosomes) or a compound heterozygote (two 
different types of severe mutations) and all patients are blood transfusion-
dependent (Weatherall and Clegg 2001; Rund and Rachmilewitz 2005; Higgs, 
Engel et al. 2012). 
Patients with β-thalassaemia major are asymptomatic for the first three-six 
months of life due to the persistence of foetal haemoglobin (HbF- α2γ2) but 
become progressively transfusion-dependent after that. Patients usually 
present with pallor and growth retardation but in more severe cases, where 
the diagnosis is delayed, they may also have abdominal swelling, skeletal 
abnormalities due to increase bone marrow haematopoiesis and jaundice due 
to haemolytic anaemia (Rund and Rachmilewitz 2005). If the patient is not 
transfused, death usually occurs by the age of ten years and, instead, if blood 
transfusion is carried out regularly, iron overload progresses and patients 
develop endocrinopathies (such as hypogonadism or diabetes mellitus), 
splenomegaly (enlargement of the spleen) and, later in life, most of the deaths 
occur due to cardiac complication secondary to accumulation of iron in the 
heart (Rund and Rachmilewitz 2005; Muncie and Campbell 2009).  
Two principal treatments are now available for β-thalassaemia: blood 
transfusion and bone marrow transplantation. Although blood transfusion 
increases the quality and expectancy of life of affected individuals, it is only a 
palliative treatment that has to be carried out for all the life of the patient. In 
addition to the risk of transfusion transmitted infections, the treatment is also 
time consuming, with prolonged sessions every month, and leads to iron 
overload (Sadelain, Boulad et al. 2007). Iron overload is characterised by the 
accumulation of iron inside the heart, liver and endocrine glands leading to the 
complications described above (Rund and Rachmilewitz 2005; Muncie and 
Campbell 2009). For this reason blood transfusion is always supported by iron 
chelation therapies that increase the life expectancy of the patients but may 
also be cumbersome and painful with serious side effects (Rund and 
Rachmilewitz 2005) .  
Finally, although blood transfusion with chelation allows patients with β-
thalassaemia major to reach adulthood, this therapy presents major 
drawbacks that reduce greatly the quality of life and are economically 
expensive (Rund and Rachmilewitz 2005; Sadelain, Boulad et al. 2007). 
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Economic adversities are especially relevant when it is considered that 
thalassaemias are characteristic diseases of African, Middle Eastern, South-
East Asian and Mediterranean areas where the cost of diagnosis and 
therapies are far too burdensome for the population and children with 
thalassaemia are often untreated or under-treated (Weatherall and Clegg 
2001; Muncie and Campbell 2009).  
Bone marrow transplantation with related donor haematopoietic stem cells 
is the only reliable cure but it is greatly limited by donor availability (only 30% 
of the patients with β-thalassaemia major has a matched sibling donor) and 
by economical issues (Sadelain, Boulad et al. 2007). Although low-risk 
patients (that is, patients with low levels of complications derived by other 
conditions) showed great improvements after bone marrow transplantation, 
mortality caused by transplant-related complications in patients with severe 
complications ranges between 5% and 30% depending on the age of the 
patients and their health conditions, especially in the case of patients with iron 
overload and hepatitis where the risk of graft rejection is increased (Rund and 
Rachmilewitz 2005; Sadelain, Boulad et al. 2007).  
The lack of suitable donors may be partially solved by the use of matched 
unrelated transplantation, by the use of related or unrelated umbilical-cord-
blood transplantation and by the creation of bone marrow donor registries; 
however, the mortality and morbidity of these approaches greatly limits their 
use for the majority of patients (Rund and Rachmilewitz 2005; Sadelain, 
Boulad et al. 2007).     
 
1.3 The β-globin locus 
 
The β-globin gene is located in the β-globin locus (HBB locus), a region of 
roughly 65 kb on the short arm of chromosome 11 (11p15.5) that comprises 5 
different genes and expresses 4 different globins in addition to the β-globin 
protein. 
These genes are all under the control of the same Locus Control Region 
(LCR, composed by five distinct DNase I HyperSensitive regions HS1, 2, 3, 4 
and 5) and are expressed at different times during embryonic and foetal 
Chapter 1: Introduction 
	   18	  
development (Levings and Bungert 2002). The spatial distribution of the β–like 
globin genes in the chromosome reflects the order of expression of the 
globins during development. Epsilon globin is the closest to the LCR 
sequence and is expressed in the very early stages of the embryo while β-
globin is the last of the globin cluster and is expressed in post-natal life 
(Efstratiadis, Posakony et al. 1980; Lawn, Efstratiadis et al. 1980; Maniatis, 
Fritsch et al. 1980; Levings and Bungert 2002) (Fig. 1.1).  
Studies conducted by measuring the sensitivity of both the entire locus, 
and the LCR region, to DNAse I treatment show that the locus is generally 
DNAse I-resistant in cells that do not express β-like globin proteins indicating 
that the chromatin presents a condensed DNA structure. In erythroid cells, 
however, the β-globin locus is more accessible to nuclease treatment showing 
a higher degree of accessibility of the chromatin to possible transcription 
factors (Bulger and Groudine 1999; Levings and Bungert 2002). While the 
LCR locus is DNase I-sensitive at all stages of erythroid development, the 
genes of the β-globin locus are sequentially nuclease-sensitive with the ε-
globin been highly accessible in the embryonic stage and the β and δ-globin 
being nuclease-sensitive in erythroid cells of adults (Gribnau, Diderich et al. 
2000).  
Although the role of the LCR region in opening the chromatin structure of 
the β-globin-like genes is not completely understood, the formation of a 
holocomplex (an higher order structure made of different proteins such as 
GATA-1 and EKLF that recruits activators, chromatin remodelling and 
transcription factors) at the LCR locus is vital for tight regulation and 
enhancement of the expression of β-globin-like genes (Levings and Bungert 
2002). The Chromosome Conformation Capture (or 3C) assay allowed Kim et 
al. to show in hybrid MEL (Murine Erythroleukemia) cells containing a 
complete human chromosome 11 how two regions of the LCR (more precisely 
HS2 and HS3) are spatially close to highly transcribed β- and δ-globin genes 
and recruit transcription factors that interact with the two globin genes (Kim, 
Kim et al. 2012).  The role of the LCR in the regulation of the β-globin locus 
has fundamental consequences for the development of gene therapy for both 
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β-­‐thalassaemia and sickle cell anaemia, which will be discussed in Section 
1.6. 
All five β–like globin genes share the same basic structure and gene 
organisation with 3 exons separated by 2 introns at almost identical positions. 
This seems to indicate a common origin for the β–like globin genes and 
evolutionary studies indicated that the divergence between β/δ and ε/γ globin 
genes started around 200 million years ago, after the divergence between 
birds and mammals, while divergence between β and δ occurred much later, 
around 40 million years ago (Efstratiadis, Posakony et al. 1980). The first 
intron, of roughly 120-150 bp, is located between codons 30 and 31 while the 
second one, of 800-900 bp, is located between codons 104 and 105 
(Maniatis, Fritsch et al. 1980). These two introns are conserved in both α- and 
β- globin genes of humans, mice, rabbits and chicken probably indicating that 
these interruptions were characteristic of the original proto-globin gene that, 
around 500 millions years ago, differentiated into the α- and β-like globin 
genes (Efstratiadis, Posakony et al. 1980; Maniatis, Fritsch et al. 1980). 
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Figure 1.1 HBB locus. 
Graphic representation of Chromosome 11 with highlighted HBB locus. The 
locus is composed by 5 different globin genes (ε, Gγ, Aγ, δ and β) that are 
sequentially expressed from the very beginning of embryo growth, through 
fetal development and, finally, to adult life. Expression of globin proteins is 
regulated by a single Locus Control Region (highlighted in yellow) 
characterised by 5 HS sites (HyperSensitive sites) all required for tight 
regulation and high expression of the different globins.  
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1.4 Gene Therapy 
 
Traditional gene therapy involves the delivery of genetic materials in the cells 
or tissues of individuals with some kind of genetic disorder or acquired 
disease. The expression of the novel exogenous genetic material should 
compensate for the disease-causing mutation and therefore restore the 
normal activity of the target cells or tissue.  
The initial hint of a possible gene therapy approach for the treatment of 
hereditary disease was envisioned in the late 1960s when studies on marked 
cell lines (Szybalska and Szybalski 1962) and on the mechanism of action of 
the SV40 polyomavirus  (that stably integrates its own DNA in the genome of 
the target cell) (Sambrook, Westphal et al. 1968) indicated the possibility of 
introducing and expressing the desired genetic information into mammalian 
cells. Unfortunately, the techniques to handle and modify desired genes to be 
transfected in target cells by viral methods were still at the early stages 
(Friedmann 1992). However, the idea of gene therapy turned into a concrete 
possibility when molecular cloning techniques became the base for the 
creation of recombinant DNA that could be tailored to satisfy the needs of 
possible gene therapy approaches (Friedmann 1992). 
Controversy about the feasibility of the approach and ethical debates 
about the possible use of gene therapy in human subjects divided the 
scientific community (Friedmann and Roblin 1972) but, thanks to successful 
preliminary results obtained by transfection of murine bone marrow cells by 
the non-viral calcium phosphate method (Cline, Stang et al. 1980; Mercola, 
Stang et al. 1980), Cline et al. decided to treat two β-thalassaemia patients’ 
bone marrow cells with a vector carrying the β-globin gene and then to auto-
transplant them back into the patients (Friedmann 1992). The decision to 
carry on with the trial was not backed by Cline’s university (UCLA) and the 
resultant outrage of both the general public and the scientific community 
ruined Cline’s reputation and greatly impaired the acceptability of gene 
therapy in the eyes of the world. 
Arguably, the first successful gene therapy trial was carried out much later 
(2000) by Cavazzana-Calvi et al. who successfully treated two children (aged 
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11 and 8 months) affected by Severe Combined Immunodeficiency-XI (SCID-
XI), an X-linked disease resulting from mutation of the gene encoding the 
interleukin-2 receptor gamma chain (IL2R-γc). Thus a retroviral vector capable 
of expressing the ILRR-γc gene was transduced ex-vivo into the patients' 
bone marrow cells that were then reinfused into the patients (Cavazzana-
Calvo, Hacein-Bey et al. 2000). Ten months after treatment the two patients 
showed signs of clinical improvement and the levels of T, B and NK cells 
detected were found to be comparable to those of control subjects. Following 
this success, a further twenty children suffering from SCID-X1 were treated 
with the same gene therapy approach. Although seventeen out of twenty were 
successfully treated, showing signs of recovery similar to the ones found in 
the previous two patients, 31-68 months later five of the twenty developed T 
cell leukaemia due to the activation of a proto-oncogene (LMO2) by the 
enhancer located in the therapeutic vector which had integrated adjacent to 
the LMO2 gene (Hacein-Bey-Abina, Garrigue et al. 2008; Fischer, Hacein-
Bey-Abina et al. 2010). The five patients were treated with chemotherapy and 
four of them recovered without losing the beneficial effect of the gene therapy 
but, unfortunately, the fourth child died. Traditional gene therapy through 
virus-mediated gene insertion had previously been linked to the risk of 
insertional oncogenesis. The random integration of the vector in the host 
genome can lead to misregulation of critical cellular pathways with later 
development of cancer (Sadelain, Boulad et al. 2007; Persons 2009). 
Although the leukaemias associated with the SCID-XI trial increased 
concerns about the safety of gene therapy and indicated the need for a better 
understanding of the mechanisms involved in the integration of therapeutic 
vectors in the human genome, the SCID-X1 gene therapy programme had a 
much lower mortality (5%) than conventional bone marrow transplantation 
(25% mortality), the only other cure for this disease (Sheridan 2011). 
A promising alternative to traditional gene therapy is in utero gene therapy. 
Foetal gene therapy has been considered a controversial approach with 
serious ethical and clinical issues such as the risk of germ-line modifications, 
risks to foetal and post-natal development and risks to the mother; usually the 
alternatives of embryo-selection and abortion are considered more favourably 
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due to their perceived reduced risk and also for ethical reasons (Coutelle and 
Rodeck 2002; Coutelle 2008). However, foetal gene therapy may offer 
practical advantages including an increased ability to target inaccessible 
tissues, the need for relative low doses of vector, permanent gene expression 
in stem cells and an increased immunological tolerance of the subject to 
vector antigens and therapeutic gene product (Coutelle and Rodeck 2002). At 
the moment, extensive studies have been carried out only on small and large 
animal models but promising results have been obtained for example on 
sheep’s foetuses (a suitable model for human prenatal gene therapy) using 
ultrasound-guided transthoracic injection to deliver an adenoviral vector 
encoding a β-galactosidase (used as a marker for a proof of concept 
assessment) (Peebles, Gregory et al. 2004).  
 
1.5 Viral vectors and non-viral delivery methods 
 
Viral vectors have been, since the early stages of gene therapy, the preferred 
method (due to their naturally developed system for gene delivery) for the 
delivery of therapeutic genes into target cells and many different types of viral 
strains have been adapted for efficient transduction. The first step in the 
design of novel viral vectors has been the need to limit the ability of the virus 
to propagate or to be pathogenic. The initial cycle of all viruses can be divided 
into two different phases: an infection phase where the virus “connects” with 
the host cell and introduces its own genomic DNA (or RNA in the case of 
retroviruses) and a replication phase where the genetic information of the 
virus is replicated due to both regulatory viral genes and to the cell machinery 
itself. At a later stage, viral structural genes induce the cell in producing viral 
particles for the encapsulation of novel viral genetic information and then a 
final lytic stage allows the discharge of novel viral particle and the infection 
propagates.  
The use of viral vectors for gene therapy focuses on the first infection 
phase used to deliver the desired DNA sequence into the target cell and, at 
the same time, aims to avoid uncontrolled replication and propagation of the 
viral vector. In order to do so, the standard approach has been to remove the 
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pathogenic genes and to separate viral coding genes from the cis-acting 
sequences that flank the viral DNA. The coding genes, which are essential for 
the replication and packaging of viral DNA, are expressed by plasmids or are 
directly integrated in the genome of producer cells (or packaging cells) while 
the therapeutic gene is cloned in the middle of the cis-acting sequences (Kay, 
Glorioso et al. 2001). In this way the therapeutic gene can be safely packaged 
into replication-deficient viral vectors that preserve only the infection 
properties of the original virus, do not uncontrollably replicate in the target 
cells of the patient and do not induce long term/chronic immunological 
response triggered by the delivery of those viral genes that encode for 
antigens.  
Two main types of viral vectors exist: integrating and non-integrating 
vectors. Both of them present advantages and disadvantages. Integrating viral 
vectors are necessary for ensuring continued gene expression in actively 
replicating target cells; however, uncontrolled integration into the host cell 
genome is associated with a risk of insertional oncogenesis. By definition, 
non-integrating viral vectors avoid the dangers of random integration but can 
only be transduced effectively into quiescent cells because in replicating cells 
the therapeutic genetic material would be lost (or “diluted”) during subsequent 
cell generations (Verma and Weitzman 2005; Sheridan 2011). Three of the 
main viral vectors used for gene therapy are described below. 
 
Retroviral vectors: Retroviral vectors contain a single-stranded RNA molecule 
of roughly 11 kb that is retro-transcribed in a double stranded DNA molecule 
and than integrated randomly into the genome (Kay, Glorioso et al. 2001). In a 
normal retrovirus the genetic information is composed of three viral genes gag 
(encoding for capsid proteins), pol  (encoding for the protease, reverse 
transcriptase and integrase) and env (encoding for the envelope 
glycoproteins) and these are flanked by two Long Terminal Repeats (LTRs) 
(Kay, Glorioso et al. 2001; Verma and Weitzman 2005). In order to generate a 
retroviral vector, the three gag, pol and env genes are moved from the viral 
genome to the genome of a packaging cell line while the therapeutic genetic 
material is cloned between the two flanking LTRs sequences (see Fig. 1.2). 
Thus, when transfected with the latter DNA construct, the packaging cells can 
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produce viral particles carrying an RNA genome encoding the therapeutic 
protein along with protein precursors of the protease, reverse transcriptase 
and integrase essential for the efficient integration of the vector into the host 
cell genome (Verma and Weitzman 2005). Retroviral vectors such as the 
Moloney retrovirus have been already used in clinical trials (Cavazzana-
Calvo, Hacein-Bey et al. 2000) and lentiviral vectors (retroviral vectors based 
on the HIV-type viruses) are extensively developed due to the apparent 
reduced risk of insertional oncogenesis (Montini, Cesana et al. 2006). 
Lentiviral vectors have been recently used in a first series of clinical trials for 
AIDS gene therapy (Manilla, Rebello et al. 2005), for X-linked 
adrenoleukodystrophy, for SCID-XI (Cavazzana-Calvo, Hacein-Bey et al. 
2000; Cartier, Hacein-Bey-Abina et al. 2009) and for β-thalassaemia (Bank, 
Dorazio et al. 2005). 
 
Adenovirus vectors: Human adenoviruses are a broad family of fifty or more 
serotypes capable of targeting a variety of tissues, such as the eye, 
respiratory tract, urinary bladder and liver (Verma and Weitzman 2005). The 
viral genome is a double stranded DNA sequence of ≈ 36 kb encoding more 
than fifty different proteins. In adenovirus-based vectors, the bulk of the “early 
genes” E1, E2 and E4 (responsible for viral genome replication) are removed 
to make space to the therapeutic gene and also to avoid viral replication in the 
host cell. The recombinant therapeutic gene is flanked by Inverted Terminal 
Repeats (ITR) and a packaging recognition signal that are required for 
efficient formation of viral particles (Kay, Glorioso et al. 2001). Unfortunately, 
this type of vector has been associated with the first person to die in a gene 
therapy trial. The patient was suffering from a nitrogen metabolism disorder 
(ornithine transcarbamylase -OT- disorder) and was treated with a gene 
encoding OT via transduction with adenovirus and died of a severe 
inflammatory response to adenovirus which caused progressive organ failure 
(Couzin and Kaiser 2005). More recently, adenoviruses have been used in 
clinical trials for the treatment of cancers where immunogenicity is less of a 
concern (Ganly, Kirn et al. 2000; Heise and Kirn 2000).  
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Adeno-associated viruses: Adeno-associated viruses (AAVs) are a non-
pathogenic family of human parvoviruses that need a helper virus like 
adenovirus to successfully replicate. Many different serotypes are known with 
the AAV2 serotype being the one that has been mostly used for the creation 
of recombinant viral vectors. The genetic information is carried as a linear 
single stranded DNA sequence of ≈ 5 kb and, in a AAV viral vector, only the 
two ITR sequences are left while the original viral genes (rec and cap) are 
replaced by the therapeutic cassette. Transduction with AAV vectors usually 
gives rise to an episomal therapeutic gene but can also randomly integrate in 
the genome and this integration has been associated with a slow but steady 
increase in the expression of the therapeutic gene that reaches a plateau after 
several weeks (Kay, Glorioso et al. 2001; Verma and Weitzman 2005). Initial 
clinical trials based on AAV2 vectors were carried out on cystic fibrosis 
patients by intranasal administration of a viral vector carrying the cystic 
fibrosis trans-membrane conductance regulator (CFTR) gene. Transduction 
efficiency and expression of the therapeutic gene were found to be 
satisfactory but high levels of gene expression lasted only for 60 days and 
due to antibody responses to AAV2 capsids developed by the patients, the 
treatment could not be repeated (Mueller and Flotte 2008; Conese, 
Ascenzioni et al. 2011). A similar transient expression was noticed in a clinical 
trial for haemophilia B where patients were transduced with an AAV2-FIX 
(factor IX) vector (Mueller and Flotte 2008). More encouraging results were 
obtained in patients suffering from Leber Congenital Amaurosis (LCA), an 
inherited retinopathy, where an AAV2 carrying the RPE65 gene were 
transduced by sub-retinal injection. These results showed no evidence that 
AAV2 gene therapy was associated with serious complications in humans and 
also showed that vision in the patients was improved although not with the 
efficacy found in dog models (Colella and Auricchio 2012) (see Figure 1.2).  
Viruses are highly developed, naturally occurring systems for the accurate 
delivery of exogenous genetic material in host cells therefore have been 
extensively researched to be used in possible therapeutic applications but 
many aspects of this delivery method have to be improved. The obstacles that 
should be overcome are the possible harmful effects of an immune response 
to viral capsid proteins, to transduced cells that the organism does not 
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recognise anymore as part of the original tissue or the immune response to 
the product of the therapeutic gene. Additionally, there is still the risk of 
insertional oncogenesis that could be overcome by the development of 
vectors capable of integrating at safe harbours in the genome of the target cell 
or by the use of episomes that do not integrate but can still replicate with the 
host cell. The small proportion of host cells that are transduced in the target 
tissue, the possible low levels or unregulated expression of the therapeutic 
gene and the risk of targeting aspecifically other tissues (including the germ 
lines) are reasons for concerns as well (Kay, Glorioso et al. 2001). Tissue-
specific viral vectors can be engineered by modification of the proteins that 
recognise specific cell receptors or, alternatively, by using tissue-specific 
promoters upstream of the therapeutic gene.  
 
Non-viral delivery methods: although viral vectors are the preferred method 
for gene delivery, alternatives have been sought in order to overcome the 
risks and downfalls related to the use of viruses. One approach used novel 
S/MAR (scaffold/matrix attachment region) minicircle vectors with reduced 
CpG bacterial sequences (to avoid the immune response triggered by the 
Toll-like receptors) which were successfully delivered into the liver of a mouse 
model by hydrodynamic injection in the tail vein. This led to higher expression 
of a luciferase marker gene as well as more prolonged expression compared 
to other similar vectors (Argyros, Wong et al. 2011). Alternatively, cationic 
lipids, such as GL67, have been used for the delivery of a CFTR therapeutic 
gene in cystic fibrosis patients (Alton, Stern et al. 1999) or “lipidoids” 
developed by Anderson et al. have been used for the delivery of RNA 
interference molecules (Akinc, Zumbuehl et al. 2008). 
Alternatives also exist to traditional DNA therapeutic genes like the use of 
non-viral delivered mRNA molecules that would be transiently expressed 
directly in the cytosol without having to penetrate the nuclear membrane 
(Yamamoto, Kormann et al. 2009) or exon-skipping techniques based on the 
delivery of antisense oligonucleotides. This last approach can be successfully 
used, for example, in the case of muscular dystrophy where mutations that 
disrupt the reading frame of the dystrophin gene can be “avoided” by 
alternative splicing of the mRNA molecule mediated by antisense 
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oligonucleotides (Foster, Popplewell et al. 2012). Exon skipping for Duchenne 
muscular dystrophy has been successfully tested in animal models (Malerba, 
Sharp et al. 2011; Yokota, Hoffman et al. 2011) and now clinical trials on 
human patients have been started (Cirak, Arechavala-Gomeza et al. 2011). 
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Figure 1.2 Viral vectors commonly used in gene therapy. 
 a) Standard expression cassette. From 5’ end to 3’ end: promoter in green, 
spacer sequence (intron) in orange and polyadenilation site for the termination 
of transcription in red. b) Types of viral vectors. The adenovirus has the 
dsDNA flanked on both sides by the ITR sequences. The packaging signal 
(Ψ) is immediately upstream of the E1, E2, E3 and E4 early genes that have 
been deleted to accommodate the expression cassette. The adeno-
associated virus has the genomic ssDNA substituted by the expression 
cassette that is flanked by the two ITR sequences and anticipated by the 
packaging signal (Ψ). The retrovirus and lentivirus have the expression 
cassette in place of the RNA genome. Both viruses are made replication 
defective thanks to the removal in the 3’ LTR of the promoter and enhancer 
regions. The figure is a modified picture from O’Connor et al. Nature Rev. 
2006.    
 
a) 
b) 
Expression cassette         Deleted E1, E2, E3 and 
E4 
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1.6 Gene therapy for β-thalassaemia 
 
Therapies for β-thalassaemic patients are limited to blood transfusion, which 
is only palliative and has to be administered for the lifetime of the patient or to 
bone marrow transplantation, which is mainly limited to the 25-30% of patients 
with HLA-matched donors as well as a 5-10% risk of fatal complications 
(Sadelain, Boulad et al. 2007). Gene therapy, therefore, is a promising 
alternative cure for β-thalassaemia. Due to the basic principle of the technique 
that involves the introduction of a functional β-globin gene into haematopoietic 
stem cells of the patient and their auto-transplantation, gene therapy avoids 
the major drawbacks of both blood transfusion and allogeneic transplantation. 
In theory, if the therapeutic gene is correctly delivered and stably expressed 
by the target cells, the treatment should be necessary only once in the life of 
the patient without the need for subsequent administrations (unlike blood 
transfusion) and such autologous transplantation should completely avoid the 
risk of graft rejection or the need for immune suppression treatments that are 
characteristic of allogeneic bone marrow transplantation. 
The first study showing an efficient gene therapy approach for β-
thalassaemia was carried out on transgenic mice in 2002 by May et al. (May, 
Rivella et al. 2002). Previous experiments had shown that transduction with a 
viral vector containing the β-globin gene with its own proximal promoter and 
enhancers sequences was not sufficient to induce expression of the gene at 
therapeutic levels (Bender, Gelinas et al. 1989; May, Rivella et al. 2002). On 
the other hand, the incorporation of distal regulatory sequences, normally 
located 25 kb upstream of the endogenous β-globin gene, was found to be 
essential for the high-level and long-term expression of the β-globin gene at 
therapeutic levels (May, Rivella et al. 2002). Thus portions of the Locus 
Control Region (LCR, see Section 1.2), were introduced into a viral vector 
along with the β-globin gene to induce long-term gene therapy in mice (May, 
Rivella et al. 2002).  
The recombinant lentivirus TNS9 was used to transduce and efficiently 
integrate in β-thalassaemic heterozygous mice (Hbbth3/+) a construct made of 
the human β-globin gene, specific enhancers and promoter and the H2, H3 
and H4 sequences of the LCR region which are essential for prolonged and 
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stable expression of the β-globin protein (May, Rivella et al. 2000) (see Fig. 
1.3 a). The Hbbth3/+ mice are the most accurate model of the disease and 
display a β-thalassaemia intermedia trait with chronic anaemia and abnormal 
red cell size and shape. Fifteen weeks after being transplantated with TNS9-
transfected bone marrow cells, however, these mice showed an improvement 
in the anaemia and aberrant red cell morphology. The expression of TNS9 
human β-globin in thalassaemic mice was of therapeutic relevance with 19% 
to 22% of total haemoglobin containing human β-globin 40 weeks after 
transplantation and stable levels of the β-globin protein detectable for up to 
one year (May, Rivella et al. 2000; May, Rivella et al. 2002). 
The success of these preliminary studies in mice led in 2005 to the 
development of a phase I-II clinical trial of β-globin gene therapy for β-
thalassaemia in humans (Bank, Dorazio et al. 2005). The study was started in 
Paris and it is still underway; it uses lentiviral vectors in order to deliver a β-
globin gene, regulated by the previously described LCR region, in harvested 
CD34+ hematopoietic stem/progenitor cells from patients with β-thalassaemia 
or sickle cell disease (Bank, Dorazio et al. 2005). The so-called LentiGlobin 
vector (a self-inactivating lentivirus, see Fig. 1.3 b) was chosen due to its 
superior qualities compared to previously tested oncoretroviral vectors. The 
lentivirus has several advantages. These include an increased viral titre, the 
ability to target non-dividing cells and the capacity to carry larger recombinant 
constructs (an important factor in gene therapies for globin pathologies). 
 LentiGlobin drives the production of a modified human β-globin chain that 
displays a single point mutation in codon 87 (βA-T87Q). The mutation, which is 
characteristic of the wild type form of the foetal γ-globin gene, was introduced 
for two main reasons: first of all, it has been shown to have a reduced 
interaction with sickle-cell haemoglobin (making it an anti-sickling protein) and 
therefore is useful in the treatment of sickle cell patients (Pawliuk, Westerman 
et al. 2001). Secondly, this modified protein has the same oxygen transport 
activity and haemoglobin assembly efficiency as the normal β-globin but after 
transplant it can be easily discriminated from the wild type β-globin by simple 
electrophoresis analysis. This last aspect has been fundamental for the 
assessment of the efficacy of the treatment (Bank, Dorazio et al. 2005). In 
order to reduce the risk of insertional oncogenesis (Hacein-Bey-Abina, 
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Garrigue et al. 2008), the LTRs of the LentiGlobin vector have been 
inactivated by mutation and the only promoter and enhancers are those in the 
recombinant β-globin gene. In addition, the chicken cHS4 chromatin insulator 
() (Evans-Galea, Wielgosz et al. 2007) has been introduced at the end of the 
3’ LTR sequence and, after reverse transcription, should flank both 
extremities of the vector further increasing the safety of the construct (Bank, 
Dorazio et al. 2005).  
To date 2 patients have been treated with the LentiGlobin treatment.  The 
first patient suffered severe complications and had to be transplanted with 
back-up autologous CD34+ cells for haematopoietic rescue. The second 
patient, an adult suffering from a severe form of β-thalassaemia (βE/β0 trait) 
and dependent on blood transfusion since childhood, received the treatment 
in June 2007 and in mid-2008 became transfusion-independent. The 
measurement of haemoglobin levels in peripheral blood was stable and 
quantitative analysis of β-globin chains showed that one third was made of 
the globin variant produced by the vector (Persons 2009; Cavazzana-Calvo, 
Payen et al. 2010). 
Although the results obtained in this trial were promising, in May 2009 the 
investigators reported to the NIH Office of Biological Activities (OBA) the 
presence of an excess in the transplanted cell population, from patient 2, of a 
dominant clone in which the vector had integrated into the HMGA2 gene 
(OBA ; Kaiser 2009; Persons 2009; Cavazzana-Calvo, Payen et al. 2010). 
The HMGA genes (High Mobility Group, HMGA1 and HMGA2) are 
responsible for the expression of the so called AT-hooks proteins, a group of 
architectural transcription factors. The HMGA proteins regulate in both 
positive and negative manners the expression of many genes involved in cell 
growth, proliferation and differentiation by altering the chromatin conformation. 
This family of proteins is usually expressed during the development of the 
embryo while suppressed in adult life, however, HMGA2 misregulation in 
adults has been associated with a number of different tumours like breast 
cancer, lung cancer and sarcomas while rearrangements of the gene have 
been linked to the onset of benign tumours.  
The over-expression of the gene in the Lentiglobin patient seems to be 
due to the loss, on one side of the LentiGlobin vector that has integrated close 
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to the HMGA2 gene, of one of the cHS4 insulators. However, because of the 
tissue-specific LCR regulator, the HMGA2 gene is only over-expressed in 
erythroid cells and the clone does not yet seem to have acquired a malignant 
status (Cavazzana-Calvo, Payen et al. 2010). The high number of mRNA 
copies in erythroblasts can also be ascribed to the lack of the 3' distal portion 
of the mRNA, which is known to contain binding sites for microRNAs that 
drive its degradation. The truncation of the mRNA seems to be due to the 
alternative splicing of the immature messenger mediated by the presence of 
the Lentiglobin (Cavazzana-Calvo, Payen et al. 2010). The reason for the 
dominant presence of this specific clone has not been fully explained but it is 
probably due to a stochastic effect due to the low number of transduced bone 
marrow cells or due to a proliferative advantage conferred by the HMGA2 
gene (Cavazzana-Calvo, Payen et al. 2010).  
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Figure 1.3 Lentiviral vectors for the gene therapy of β-
thalassaemia. 
 a) TNS9 lentiviral vector used in a mouse model of β-thalassaemia. The 
vector carries a β-globin expression cassette flanked by specific promoter and 
enhancer. Part of the LCR region (HS2, 3 and 4 in yellow) is located upstream 
of the expression cassette. b) LentiGlobin vector used in the first clinical trial 
for the gene therapy of β-thalassaemia. The vector presents similarities to the 
TNS9 vector with the β-globin expression cassette flanked by specific 
promoter and enhancer and preceded by part of the LCR region (HS2, 3 and 
4 in yellow). The β-globin carries a mutation (βA-T87Q) for easy detection in the 
patient blood samples. In addition, the 3’LTR has the promoter and enhancer 
deleted in order to make the vector replication defective and the cHS4 
(chromatin insulator, in blue) sequence has been introduced downstream of 
the LTR as an insulator in order to increase the safety of the vector.   
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1.7 Gene therapy by gene targeting/correction  
 
An alternative approach to traditional gene therapy is gene correction, a 
specific application of gene targeting. Gene targeting comprises a series of 
techniques that allow the specific “editing” of a desired gene in host cells or 
organisms. Gene correction is based on the modification of the mutant gene 
rather than the addition of a therapeutic gene. A DNA repair template, made 
of the desired mutation to be introduced flanked by two DNA sequences 
homologous to the target, is introduced into the cell to replace the 
homologous chromosomal segment through Homologous Recombination 
(HR, see Fig. 1.4). Gene targeting presents many theoretical advantages 
compared to traditional gene therapy: 1) its therapeutic action is not affected 
by dominant mutations; 2) it is not influenced by limited vector capacity 
because the technique does not require the delivery of a complete and 
sometimes very large functional gene; 3) the challenge of recreating 
appropriate physiological level/patterns of gene expression is eliminated 
because gene correction, by definition, restores the disease gene to its 
normal state and 4) gene targeting presents a reduced risk of insertional 
mutagenesis and oncogenesis that have been major issues at the centre of 
the debate about gene therapy clinical trials (Vega 1991; Yanez and Porter 
1998; Lanzov 1999).   
Gene targeting achieves gene correction through a form of HR, catalysed 
by the cellular DNA repair machinery, in which a DNA-fragment homologous 
to the target sequence is used as a repair template (Lanzov 1999) (Fig. 1.4). 
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Figure 1.4 Gene correction by Homologous Recombination. 
 A DNA repair template (green fragment) homologous to the target sequence 
is used to correct possible mutation (in red) through HR (represented by the 
two crosses).   
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The basis for the development of gene targeting techniques have been 
initially laid in the late 1970s with Saccharomyces cerevisiae yeast models 
(Scherer and Davis 1979) where, compared to other eukaryotic models, gene 
targeting is easily obtained. Subsequently, targeted gene modifications in 
mammalian models have been achieved during the 1980s by Smithies et al. in 
cancer cell lines (Smithies, Gregg et al. 1985) and by the pioneering 
experiments performed by Capecchi et al. in murine cells (Thomas, Folger et 
al. 1986; Thomas and Capecchi 1987) leading to mouse gene knockout 
technology.  
Initially, Smithies et al. were able to obtain gene targeting of the human β-
globin gene in different cancer cell lines using a circular targeting construct 
based on a neomycin resistance cassette and a 4.6 kb β-globin homology 
region. The authors of the research found also that gene targeting frequencies 
were significantly increased if the homology region was cut by a restriction 
enzyme creating a linear targeting construct with a selectable marker flanked 
by two human β-globin homology arms (Smithies, Gregg et al. 1985). 
Thanks to the use of positive selection induced by selectable markers, 
Capecchi et al. showed how a faulty neomycin resistance cassette randomly 
integrated in the genome of murine cells could be efficiently repaired by HR 
using as a repair template a second non-functional neoR cassette (carrying a 
different mutation) with frequencies of 1 cell in 103 acquiring neomycin 
resistance (Thomas, Folger et al. 1986). In a later stage the use of double 
selection based on the targeting of the HPRT gene (whose inactivation 
confers resistance to 6-thioguanine) by a functional neoR cassette (called 
gene addition, see Fig. 1.5) proved the feasibility of producing specific 
mutations at an endogenous locus in murine embryonic stem cells (Thomas 
and Capecchi 1987). These gene targeting experiments, coupled with the 
ability to produce embryonic stem cells from mouse blastocysts developed by 
Evans et al. (Evans and Kaufman 1981), paved the way to the creation of a 
robust and valuable method for the manipulation of the murine genome and 
the generation of “knockout” mice, one of the most useful models for the study 
of the functions of genes. Capecchi, Evans and Smithies were awarded the 
Nobel Prize for this work in 2007.   
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Although gene targeting has been widely used in mouse embryonic stem 
cells for study of specific cell functions (by selectively knocking out desired 
genes), the technique also had the potential to be used for the correction of 
many hereditary diseases in humans. This slow development is due to the 
inefficiency of gene targeting and progress is this area has depended on, and 
will continue to depend on, an understanding of the underlying mechanisms of 
HR. 
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Figure 1.5 Gene addiction mediated by HR. 
 A further application of gene targeting is the introduction of an exogenous 
gene (in this case a Neomycin resistance cassette) in a specific target locus. 
A DNA template composed by the desired gene (in blue) flanked by two 
homologous regions (in green) is introduced in the cell. HR (crosses) 
occurring between the homologous regions allows the introduction of the 
construct in the desired locus.  
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1.8 Double Strand Breaks and Homologous Recombination 
 
HR is an error-free mechanism for repairing chromosomal Double Strand 
Breaks (DSB) that usually occurs during or after DNA replication (i.e. during S 
phase and G2 phase of the cell cycle). HR is thus essential in order to 
maintain genomic integrity. In this process the broken chromosome is 
repaired by the cellular machinery using the “sister” chromatid as a template 
and the information stored is recovered without loss of functionality (Yanez 
and Porter 1998; Lanzov 1999). Gene targeting takes advantage of this HR 
mechanism; an exogenous DNA fragment, with the desired modification 
flanked by sequences homologous to the target locus, is delivered to cells 
where it is used as a template for HR mediated repair, instead of the sister 
chromatid, and so introduces the desired alteration into the target locus 
(Yanez and Porter 1998) (Fig. 1.4 and 1.5). 
Such HR-based gene modification events, however, occur in human cells 
with a very low frequency (typically fewer than 1 cell in 105 transfected cells 
undergoes the desired genetic modification). These frequencies, though 
useful for research purposes (e.g. production of knockout and knockin 
transgenic mice using murine embryonic stem cells) are too low to be useful 
in the context of gene therapy (Porter 2005). Crucially, however, it has been 
shown that the introduction of a DSB within the target gene greatly enhances 
the frequency of gene targeting.  
Due to the high risk of serious genome rearrangements, DSBs are 
probably the most dangerous type of DNA damage that can occur to a cell 
and, if not immediately repaired, they can easily trigger apoptosis: the last line 
of defence of an organism against oncogenesis derived by extensive genomic 
rearrangements (Kaina 2003). DSBs naturally occur by means of 
environmental factors, such as ionising irradiation, chemical agents and ultra 
violet light (UV) or by means of endogenous cellular products, such as 
reactive oxygen species. In addition, during DNA replication, any “nick” (single 
strand DNA damage) in the genome can be easily converted by the 
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replication fork in a DSB increasing the risk of genome instability (Kuzminov 
2001; Helleday, Lo et al. 2007). 
Two major repair pathways are used by cells to repair DSBs and maintain 
genome stability: Non Homologous End Joining (NHEJ) and Homologous 
Recombination (HR). NHEJ is the most direct way that the cell has to repair 
DSBs and is based, in its simplest form, on the direct ligation of the two 
severed DNA ends, if they are blunt or compatible ends. This simple process 
most of the time is associated with faithful repair of the DNA sequence without 
the introduction of mutations. However, most of the DSB events are also 
associated with damage at the severed DNA ends, such as aberrant 
phosphate groups, damaged backbone sugars and damaged DNA bases that 
make the two DNA ends incompatible which therefore have to be processed 
before DNA repair (Helleday, Lo et al. 2007). Repairs by NHEJ of these types 
of complex damage are quite often error-prone and can introduce mutations 
and deletions at the DSB site with the obvious risk of damaging important cell 
functions or inducing cancer. The NHEJ pathway involves many different 
proteins of which the most important are Ku70/80 that binds both DNA ends 
and recruits DNA-PK (DNA protein kinase) that interacts with Ku70/80 
proteins and brings the two DNA ends close together and, finally, the ligase IV 
complex that binds the two DNA extremities and repairs the DSB (Helleday, 
Lo et al. 2007) (see Fig. 1.6). 
Where possible, that is if a DNA template is available, DSBs will be 
accurately repaired by the error-free pathway HR. The preferred repair 
template used by this pathway is the sister chromatid and therefore this repair 
mechanism is limited to the S/G2 phases of the cell cycle where the repair 
template is readily available. The first step of the HR pathway is the resection 
in the 5’ to 3’ direction of the two DNA ends with formation of long 3’ stretches 
of single stranded DNA (that are stabilised and “protected” by the RPA 
protein). From this point, three main alternative modes are possible for the 
repairing of the DNA damage: the synthesis-dependent strand-annealing 
pathway (SDSA), the double-Holliday junction pathway and the single strand 
annealing pathway (SSA) (Helleday, Lo et al. 2007).  
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Figure 1.6 Model of the for Non-Homologous End Joining 
(NHEJ).  
DNA ends created by a DSB are recognised and bound by the Ku70/80 
proteins. Then the DNA-PKc proteins are recruited and interact with Ku70/80 
in order to bring close together the two DNA ends. Finally, the ligase IV 
complex (comprised of ligase IV, XRCC4 and XLF) binds the two extremities 
and repair the DSB. Picture obtained from Helleday, Lo et al. 2007. 
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Synthesis-dependent strand-annealing pathway (Fig. 1.7): SDSA is probably 
the most common way the cell has to repair DSBs and involves the single 
strand DNA invading the sister chromatid (mediated by the RAD51 protein) in 
order to form heteroduplex DNA. After this initial step DNA synthesis 
elongates the single strand DNA (carried out by DNA polymerase η) on the 
other side of the original DSB using the sister chromatid as a template while 
the single Holliday junction that has been formed at the other side of the 
elongation point slides in the same direction of the replication (branch 
migration) in order to release the single strand DNA. The newly created single 
strand DNA at this point can anneal back to its original single strand DNA 
counterpart (probably facilitated by the RAD52 protein). Finally, the excess of 
DNA produced by the replication is removed by endonucleases while the 
missing “gap” left on the other single strand originated in the initial processing 
of the DSB is filled by DNA replication recreating the error-free double 
stranded DNA (see Fig. 1.7).  
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Figure 1.7 Model of the Synthesis-Dependent Strand-
Annealing pathway (SDSA).  
The pathway involves the ssDNA invading the sister chromatid in order to 
form an heteroduplex DNA. After this initial step DNA synthesis is carried out 
using as a primer the invading ssDNA. Branch migration slides the single 
Holliday junction in the same direction of the replication in order to release the 
single strand DNA. The newly created ssDNA anneals to its original ssDNA 
counterpart. Finally, the excess of DNA produced by the replication is 
removed by endonucleases while the missing “gap” left on the other single 
strand originated in the initial processing of the DSB is filled by DNA 
replication recreating the error-free dsDNA. Picture obtained from Helleday, 
Lo et al. 2007. 
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Double-Holliday junction pathway (Fig. 1.8): The DSB may also be repaired 
by the “classic” double-Holliday junction pathway. This mechanism is not so 
commonly used to repair DNA damages but is probably more prevalent during 
meiosis. The pathway mainly follows the steps highlighted for the SDSA 
pathway but in this case both of the single DNA strands invade the template 
and DNA replication is carried out in both directions with the formation on 
other sides of two Holliday junctions. Depending on how the two Holliday 
junctions are resolved, this pathway can originate a simple gene conversion 
or a crossing-over event. Importantly, crossing-over events during DSBs 
repair are very rare and tend to occur more frequently during meiosis 
(Helleday, Lo et al. 2007) (see Fig. 1.8). 
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Figure 1.8 Model of the “classic” double-Holliday junction 
pathway. 
The pathway involves the two single DNA strands invading the sister 
chromatid in order to form two heteroduplex DNA regions. DNA synthesis is 
carried out on both strands with the formation, on other sides, of two Holliday 
junctions. Depending on how the two Holliday junctions are resolved, this 
pathway can originate a simple gene conversion or a crossing-over event. 
Picture obtained from Helleday, Lo et al. 2007. 
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Single strand annealing pathway (Fig. 1.9): while the pathways described 
above are characterised by faithful repair of DNA damage without loss of 
genetic information (conservative HR). In contrast, the third pathway, SSA, is 
associated with the loss of part of the DNA sequence (non-conservative HR). 
SSA uses two homology regions found on both sides of the DSB to repair the 
DNA damage by a mechanism that involves RAD52 and RPA but not RAD51. 
The two DNA ends are resected beyond the two regions of homology and the 
two newly formed 3’ overhangs are simply annealed thanks to the 
homologous sequences. At this point the excess of DNA is cleaved by 
endonucleases on both sides and gaps are filled repairing the damage. 
Unfortunately, with this pathway all the information stored in the sequence 
between the two homology regions is lost (see Fig. 1.9).    
Extensive studies on the repair mechanisms of DSBs in mammalian cells 
have been carried out at the beginning of the 1990s by Maria Jasin’s group 
(Memorial Sloan-Kettering Cancer Center). The group focused particularly on 
HR pathways and over the years has developed a set of repair assays for the 
easy detection of HR events. In one experiment the rare cutting endonuclease 
I-SceI was used in mammalian cells to stimulate HR by the means of a DSB 
(Jasin 1996). This endonuclease has a very long recognition sequence of 18 
nucleotides that enables it to produce a DSB in specific loci without the risk of 
producing damage in the rest of the genome of the host. The stimulated gene 
correction event was used to restore the expression of a selectable marker 
gene (a neomycin cassette in the first experiments and subsequently a GFP 
expression plasmid) in order to identify possible gene correction events. 
Results showed how gene targeting can be stimulated 50 to 1000 fold by a 
DSB and how there is an inverse correlation between the frequency of gene 
correction and the distance between the cutting site and the sequence 
modification (Jasin 1996; Elliott, Richardson et al. 1998).  
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Figure 1.9 Model of the Single Strand Annealing (SSA) 
pathway. 
The SSA pathway uses two homology regions (in dark color) found on both 
sides of the DSB to repair the DNA damage. The two DNA ends are resected 
beyond the two regions of homology and the two newly formed 3’ overhangs 
are simply annealed thanks to the homologous sequences. At this point the 
excess of DNA is cleaved by endonucleases on both sides and gaps are filled 
repairing the damage. Picture obtained from Helleday, Lo et al. 2007. 
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The ability to produce DSBs to stimulate HR, coupled with the introduction 
in the target host of a targeting construct to be used as a repair template for 
the correction of the induced DNA damage, has defined the current concept of 
targeted gene alteration. Depending on the type of targeting construct used, 
gene targeting may be used to inactivate a specific gene for genomic studies 
(gene knockout), to produce gene correction of a disease-causing mutation or 
to introduce, at specific loci, functional exogenous genes (gene addition) to 
exert a novel function in the host cell (Urnov, Rebar et al. 2010).  
Although different types of targeting constructs (or donor DNA) have been 
developed over the years, most studies have focused mainly on two types: 
double stranded DNA and single stranded DNA constructs. Single stranded 
oligonucletides (ssONs) of ≈ 100 bp complementary to one of the two strands 
of a possible target gene have been successfully used to produce targeted 
gene modifications. Although the mechanism by which the ssONs induce the 
gene editing is not clear, it seems that DNA replication is involved in the 
process (Jensen, Dalsgaard et al. 2011). McLachlan et al. showed in a recent 
study that the ssON-mediated repair of a faulty HPRT gene in mammalian 
cells was increased in frequency during the S phase of the cell cycle and that 
the frequency of gene editing was drastically reduced in cells deficient in HR 
but not in cells deficient in other DNA repair pathways (McLachlan, Fernandez 
et al. 2009).   
The double stranded donor DNA, instead, usually carries the desired point 
mutation or gene to be introduced flanked by two extended “homology arms” 
(each one of them usually between 500 bp to 2 kb in length) that mediate the 
homology directed recombination between the targeting construct and the 
endogenous locus. If the construct contains only a point mutation between the 
homology arms, donor DNA can be used to create or correct mutations. On 
the other hand, the targeting construct could carry a complete functional gene 
for the introduction of a novel gene function or could carry a therapeutic, 
promotorless cDNA fragment that could be introduced close to the 
endogenous promoter of the gene to be corrected. This last type of donor 
DNA has the advantage of being able to correct all possible mutations of the 
target gene and at the same time to be regulated by the endogenous 
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promoter. A cDNA targeting construct has been used successfully in a recent 
study for the correction of human haemophilia in a mouse model. As a result 
of DSB-induced gene replacement, a disrupted human factor IX gene located 
in the genome of liver cells of mice was corrected, in vivo, by the introduction 
at the end of exon 1 of a splicer acceptor immediately followed by a partial 
factor IX cDNA. Levels of human factor IX were detected in the circulation 
after the treatment and remained constant for at least thirty weeks (Li, 
Haurigot et al. 2011).  
Due to the low frequencies of gene targeting in the absence of an induced 
DSB at the target locus, most of the targeting constructs used for research 
purposes also carry between the homology arms a selectable marker allowing 
for the drug-mediated selection of cells that have incorporated the donor DNA 
(Yanez and Porter 1998). A more sophisticated approach makes use of 
positive-negative selection where in addition to the positive-selection marker a 
negative selection marker is located outside the homology arms. In this way 
the researcher is able to select not only the cells that incorporated the 
targeting construct, but also to select only the cells that introduced the donor 
DNA by means of HR (which do not incorporate the negative selectable 
marker) by excluding any possible random integration events (that do include 
the negative selectable marker). From a therapeutic point of view, due to the 
small number of cells that are usually targeted, the possibility of using a 
selection marker should be ideal for the enrichment of targeted stem cells for 
transplantation to correct genetic disorders although it is possible that the 
drug resistance gene might interfere with the normal homeostasis of the cell 
or could trigger gene silencing of the neighbouring genes. A possible 
alternative is based on the removal of the selection marker immediately after 
positive selection of targeted events. This approach has been used by 
Sebastiano et al. to correct the sickle-cell mutation in iPS (induced Pluripotent 
Stem) cells. The targeting construct used had a 1.6 kb β-globin sequence with 
a puromycin cassette flanked by two loxP sites located in the first intron. 
Using the Cre recombinase, Sebastiano et al. were able to remove the drug 
resistance cassette from corrected iPS cells leaving behind only a copy of the 
loxP site as a residual “scar” sequence (Sebastiano, Maeder et al. 2011).   
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For this observation to be useful for therapeutic gene targeting, however, a 
method had to be found for the development of customized endonucleases 
capable of targeting and cleaving any specific sequence in the genome in 
order to achieve, through stimulation via DSBs, acceptable frequencies of 
gene targeting. In order to be of any value these endonucleases have not only 
to be able to target a wide range of possible sequences but also need to 
recognise a specific target without producing DSB in other regions of the 
genome (Porter 2005). The engineering of customised endoncleases may 
address all of these requirements and establish a versatile and precise tool for 
future gene therapy. 
 
Customised endonucleases: Since the initial studies based on the I-SceI 
endonuclease, researchers have developed several different types of 
engineered nucleases based on naturally occurring proteins. Initially, 
researchers focused on the well-characterised meganucleases (of which I-
SceI is an example) by attempting to change their nucleotide binding 
specificity in order to increase the number of possible target sites. The 
process of engineering novel binding specificities for this class of enzymes 
has been particularly difficult for two main reasons. Firstly, the complexity of 
the tertiary structure of the proteins prevented the possibility of predicting the 
amino-acid sequence that would confer novel binding specificities. Secondly, 
the strong connection in meganucleases between the binding and cleavage 
domains meant that any modification of one of the two would greatly affect the 
efficiency of the other (Paques and Duchateau 2007). However, due to 
intensive structural characterisation of the meganuclease family, the 
modification of critical amino-acid residues and the development of highly 
efficient screening methods, the commercialisation of engineered homing 
endonuclease technology has now become feasible (Grizot, Epinat et al. 
2010; Arnould, Delenda et al. 2011). Two other classes of tailored nucleases 
have proved to be more flexible for therapeutic gene targeting: Zinc Finger 
Nucleases (ZNFs; described in detail in the following sections) and 
Transcription Activator-Like Effector Nucleases (TALENs).  
TALEN are the most recent class of efficient gene-editing molecules to 
have been developed and are very promising due to their highly modular 
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nature. The TAL effectors are DNA binding proteins found in Xanthomonas (a 
bacterial plant pathogen) and modulate gene expression in the host organism. 
These effectors are composed by modules of ≈ 33-35 conserved amino-acids 
and each module binds specifically to only one base pair due to only two 
variable residues (repeat variable di-residues RVD) in position 12 and 13 
(Cermak, Doyle et al. 2011). In contrast to the difficulties encountered during 
the development of novel ZFNs and meganucleases, TAL effectors, due to 
their ability to bind single nucleotides, have proved to be easily assembled in 
customised DNA binding proteins capable of recognising long DNA 
sequences and their fusion to the FokI nuclease domain has created a new 
family of nucleases that have already been used to cleave DNA sites with 
high specificity both in vitro and in vivo (Li, Huang et al. 2011; Miller, Tan et al. 
2011). The scientific community has taken great interest in this new 
technology and both commercial (Cellectis) and public (Cermak, Doyle et al. 
2011) approaches have been developed for the creation of customised 
TALENs. 
 
1.9 Zinc finger nucleases  
 
The most versatile molecular tools developed to date for targeted editing of 
DNA sequences in different organisms are ZFNs, which are fusion proteins 
composed of two different subunits: a zinc finger binding domain and a non-
specific nuclease FokI domain. The initial idea of using the nuclease domain 
for the production of targeted DSBs was conceived by Chandrasegaran’s 
group in 1992 when they realized that the type II restriction enzyme FokI was 
composed by two distinct units: one capable of specifically binding the DNA 
sequence and one that was catalysing the cleavage (Li, Wu et al. 1992). By 
altering the DNA binding domain it was possible to produce DSBs in different 
sites and therefore researchers focused on the search for optimal binding 
domains. The most effective was found to be a zinc coordinated finger-like 
structure called zinc finger (Kim, Cha et al. 1996).  
Zinc fingers (Cys2His2) are repeat units found in a wide range of naturally 
occurring proteins (mostly in the DNA-binding domains of transcription 
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factors) usually made of 30 amino-acids (arranged in an α-helix and two β-
sheets configuration) that are able to bind a wide range of trinucleotides. 
Structural stability is provided by a zinc ion coordinated in a tetrahedral 
pattern by two cysteine residues on the β-sheets and by two histidine 
residues on the α-helix (Wolfe, Nekludova et al. 2000). The DNA-binding 
feature is due to the insertion of the α-helix in the major groove of the double 
helix. A combination of key amino-acids in positions -1, 2, 3 and 6 on the α-
helix are responsible for the interaction (through hydrogen bonds or 
hydrophobic interactions) with three consecutive nucleotides of the DNA 
binding site (Choo and Klug 1997; Wolfe, Nekludova et al. 2000) (Fig. 1.10).  
One of the first steps towards the use of engineered zinc finger proteins 
was obtained by Klug et al. in 1994. The researchers created a three-finger 
protein domain that specifically recognised a 9 bp sequence in the bcr-abl 
oncogenes and showed that the novel protein was able to efficiently bind its 
target sequence in vitro. Subsequently, mouse cells carrying a copy of the 
bcr-abl gene were used to prove the ability of the ZF protein to bind, in vivo, 
the target sequence and suppress gene expression of the bcr-abl gene 
(Choo, Sanchez-Garcia et al. 1994).   
Natural zinc finger-based proteins are able to recognise different DNA 
sequences of different lengths through the combination of different zinc 
fingers in a tandem configuration (Wolfe, Nekludova et al. 2000). This 
“modular” configuration has inspired researchers to develop libraries of zinc 
fingers specific for all 64 possible trinucleotides and to use these to design 
new molecular tools capable of targeting any desired target site. The fusion of 
a specific binding domain with the non-specific cleavage domain of the 
endonuclease FokI gives rise to a brand new category of molecular tools able 
to produce DSBs in any locus of interest, thereby stimulating the HR pathway 
for possible gene correction at any desired disease-related gene (Kim, Cha et 
al. 1996; Porter 2005).  
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Figure 1.10 Zinc finger molecular structure.  
a) Structure of the ZF molecule with two β-sheets and α-helix coordinated by 
a zinc ion and key residues (-1, 2, 3 and 6) for the binding of the trinucleotides 
sequence. b) ZF domain composed of three different ZFs and the 9 
nucleotides target sequence. Picture from Sander et al. 2007.  
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Typically a ZFN is made up of three or four zinc fingers arranged in a row 
and then linked to the FokI domain. The DNA binding domain of the ZF guides 
the non-specific nuclease activity of FokI to a specific DNA target site. The 
FokI domain is active only in a dimer configuration, therefore two monomers 
use their ZF domains to recognize half-sites on either side of a “spacer” 
sequence (usually 6 nucleotides) where the dimerised FokI domains produce 
the DSB (Cathomen and Joung 2008) (see Fig. 1.11). 
A first study involving the expression of ZFNs in eukaryotes was carried 
out in 2002. A vector carrying the gene for zinc finger nucleases driven by a 
heat-shock promoter (Hsp70) was introduced into the genome of Drosophila 
Melanogaster (Bibikova, Golic et al. 2002). The ZFNs were able to recognize 
a target sequence on the y gene of Drosophila and to produce a DSB. 
Genetic analysis showed the presence of somatic mutations (deletions or 
small insertions) at the level of the target gene. These mutations are the 
expected outcome for repaired DSBs through NHEJ the mechanism by which 
the DNA is repaired in absence of a homologous DNA repair template 
(Bibikova, Golic et al. 2002). In a subsequent study from the same group a 
complete gene targeting procedure was performed in Drosophila. In this case 
y and ry genes were targeted by ZFNs and the DSBs produced were used to 
stimulate HR events with a marked donor DNA fragment as repair template. 
Of the 25% mutant progeny, produced after the mating of transfected parents, 
most of the offspring presented the gene correction expected by HR (Beumer, 
Bhattacharyya et al. 2006).  
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Figure 1.11 ZFN binding to target sequence and formation of 
FokI dimer.  
ZFs are numbered from 1 to 4 starting from the N-terminus, the FokI 
monomer is linked to the C-terminus of the ZF domain that binds to the target 
sequence in a “3’ to 5’” orientation.  
5’-GATTACAGATTACAGATTACAGATTACAGATTACA-3’!
3’-CTAATGTCTAATGTCTAATGTCTAATGTCTAATGT-5’!
ZF-L1 ZF-L2 ZF-L3 ZF-L4 
ZF-R4 ZF-R3 ZF-R2 ZF-R1 
FokI 
FokI 
Left half binding site 
Right half binding site 
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Another remarkable experiment was carried out in human cells for the 
correction of a mutation on the IL2Rγ gene that causes SCID-XI. In the early 
stage of the study, K562 cells were transfected with expression vectors for the 
two ZFN sub-units and a DNA repair template homologous to IL2Rγ. The 
expression of ZFNs stimulated gene targeting events at the endogenous locus 
with 11% of the transfected cells carrying one targeted allele and 6% of them 
both targeted alleles without selection (Urnov, Miller et al. 2005). In order to 
test the efficacy of targeted gene modification in primary cells, the experiment 
was then carried out using CD4+ T cells and 5% of these cells were 
successfully targeted. The final outcome showed how the permanent 
modification of the endogenous gene through gene targeting was effective in 
up to 20% of the chromatids and that 7% of the treated cells were 
homozygous for the exogenous sequence in absence of selection (Urnov, 
Miller et al. 2005).   
The ZFNs technique was later tested in combination with an Integrase-
Defective Lentiviral Vector (IDLV) in order to increase the efficacy of delivery 
into target cells. IDLV viral particles were loaded with two types of vector, one 
expressing ZFNs and the other containing the donor sequence and the 
efficiency of gene targeting was tested in different cell lines (Lombardo, 
Genovese et al. 2007). Correction of the IL2Rγ gene was achieved with an 
efficiency between 13% and 39%, depending on the type of cell line, while 
targeted integration of a GFP construct in the chemokine receptor 5 (CCR5) 
locus produced up to 50% of GFP positive cells in K562 and Jurkat cell lines 
(integration of the GFP gene in the target locus was confirmed by PCR 
analysis). These results led to similar experiments in human stem cells. 
 The same GFP construct specific for the CCR5 gene was delivered with 
ZFNs expression vectors into CD34+ haematopoietic progenitor cells and in 
human Embryonic Stem cells (ES) HUES-3 and HUES-1 with 0.11% and 
5.3% of them expressing GFP, respectively. Furthermore the induced 
differentiation of HUES cells into neural progenitor cells was not affected by 
the newly introduced construct and the expression of GFP was confirmed by 
confocal fluorescence microscopy (Lombardo, Genovese et al. 2007).  
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ZFN-mediated gene targeting was also used in a study where, for the first 
time, both human iPS and ES cells were targeted (Zou, Maeder et al. 2009). 
ZFN expression vectors and DNA repair templates were introduced into both 
cell types through nucleofection and  ZFN-mediated HR was used to correct a 
disrupted GFP reporter gene that had been randomly integrated in the 
chromosomes of both iPS and ES cells. GFP expression was enhanced 2400-
fold in ES cells transfected with both DNA repair template and ZFN 
expression vectors compared to cells transfected with only the DNA repair 
template. In iPS cells, GFP gene correction was increased 1400-fold when 
ZFNs expression vectors were co-transfected with the repair template (Zou, 
Maeder et al. 2009). In order to assess ZFN-stimulated gene correction at an 
endogenous locus, both ES and iPS cells were transfected with ZFNs specific 
for the endogenous PIG-A gene and a DNA repair template having a 
hygromycin cassette flanked by two PIG-A homologous regions. The use of 
ZFNs increased the frequency of HR-mediated gene correction 200-fold 
relative to cells transfected with the DNA repair template alone (Zou, Maeder 
et al. 2009).  
A case study carried out using probably one of the most effective ZFNs so 
far described highlights the challenges of applying ZFN technology to different 
types of cells and organisms. Li et al. used a very efficient ZFN (F9-ZFN) 
specific for the human factor IX gene in K562 (erythroleukaemia), Hep3B 
(human hepatocyte) cells and a humanised haemophilia mouse model (Li, 
Haurigot et al. 2011). The cutting efficiency of the F9-ZFN was initially tested 
in K562 cells by measurement of the frequency of “indels” (small deletions or 
insertions that are the products of DSBs repaired by NHEJ) produced at the 
endogenous gene. The F9-ZFN was found to be highly effective in producing 
DSBs with 45% of the treated cells showing the presence of indels. 
Frequencies of ZFN-induced HR events at the target locus were measured by 
detection of a stably integrated novel NheI restriction site (carried by the NheI-
targeting construct) and 18% of the alleles were found to be targeted in both 
K562 and Hep3B cells. For the in vivo study, Li et al. created a humanised 
mouse model carrying a defective factor IX gene. Initially, in order to test the 
F9-ZFN activity in mouse liver, the mice were injected through the tail vein 
with an AAV vector (AAV8) expressing, under a liver-specific promoter, the 
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F9-ZFN. Cutting frequencies, measured as the percentage of detected indels, 
were found to be as high as 47%, indicating that the combination of AAV8 
vector and the liver specific promoter results in very efficient ZFN induced 
gene modifications. To test the efficiency of gene targeting, Li et al. designed 
an AAV8 vector carrying donor DNA based on a partial cDNA of the human 
factor IX (the targeting construct already referred to in Section 1.8) and the 
two AAV8 vectors (F9-ZFN and donor DNA) were introduced by 
intraperitoneal injection into neonatal mice. The different injection technique 
was used due to the higher survival rate in young mice (compared to tail vein 
injections) but was also shown to induce lower frequencies of F9-ZFN-
induced indels (16% against the very high 47% previously detected). Gene 
targeting frequencies, measured by PCR assay, were found to be around 1-
3% (Li, Haurigot et al. 2011). The results obtained in this study show the 
feasibility of producing gene correction directly in vivo without the need for the 
isolation and ex vivo treatment of cells and subsequent auto-transplantation in 
the host but they also indicate a wide variability in cutting and gene targeting 
frequencies depending on the targeted host (cell lines or mice), delivery 
methods (transfection of cells or AAV8 vector) and, more importantly, 
methods of administration of the AAV8 vectors in mice (tail injection or 
intraperitoneal injection). The great variability in cutting and gene targeting 
frequencies observed in this study highlights the need for robust and highly 
efficient ZFNs in order to obtain acceptable therapeutic levels of gene 
targeting. Similar considerations can be applied also to the results in cell lines 
used for research purposes (like K562 or HEK293 cells) compared to more 
complex primary cell types like, for example, stem cells or iPS cells. 
iPS cells have been used in two recently published studies on gene 
targeting of the endogenous β-globin gene for the development of gene 
therapy for sickle-cell anaemia (Sebastiano, Maeder et al. 2011) and β-
thalassaemia (Zou, Mali et al. 2011). The two studies showed effective gene 
targeting of the β-globin gene in iPS cells but at very low frequencies. A more 
detailed description of the results of these two papers is reported in Section 
7.3.2). Factors that may affect the targeting efficiencies are the transcriptional 
status of the target locus, and therefore the accessibility of the gene to ZFNs; 
the levels of HR that depend on both the cell type and replication status of the 
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cells used; and the possible silencing effect that can suppress the expression 
of novel exogenous genes or corrected genes (Cathomen and Joung 2008; 
Hockemeyer, Soldner et al. 2009; Carroll 2011).  
DNA hypermethylation-mediated silencing of targeted genes that had 
undergone HR events is probably one of the greatest obstacles that will have 
to be addressed in order to develop efficient gene targeting techniques for 
therapeutic applications. This phenomenon was examined by Cuozzo et al. in 
a 2007 study where they used a Homology Directed Repair (HDR) reporter 
assay developed by the Jasin group (the reporter assay is described at length 
in Chapter 6) in Hela cells (Cuozzo, Porcellini et al. 2007). The reporter assay 
is carried out by transfecting cells that harbour a GFP expression plasmid 
disrupted by the I-SceI target site with an I-SceI expression plasmid. Cells will 
only express functional GFP proteins if the I-SceI-cleaved GFP plasmid is 
repaired by HR using a repair template located downstream of the GFP gene. 
Cuozzo et al. showed how the GFP reporter plasmids subjected to I-SceI-
induced HR were subsequently silenced by methylation and the levels of GFP 
expression tended to drop during the days after transfection. This effect was 
reversed if the cells carrying the reporter plasmid were treated with 5-aza-2-
deoxycytidine for 48h after transfection with the I-SceI expression plasmid. 
The silencing effect was not observed in Hela cells transfected with a wild 
type GFP expression vector and therefore this effect could only be related to 
GFP genes that were targeted by HR events (Cuozzo, Porcellini et al. 2007).   
  
1.10 Engineering ZFNs   
 
Since the discovery of the potential of ZF proteins as components of 
molecular tools for gene correction, gene knockout and gene addition, 
different techniques/reagents have been developed in order facilitate the 
synthesis of functional ZFNs with high specificity for novel target sequences. 
Sangamo BioSciences was one of the first to create a method to produce 
highly efficient ZF proteins capable of targeting endogenous genes in different 
types of cells (Urnov, Miller et al. 2005; Miller, Holmes et al. 2007; Moehle, 
Rock et al. 2007; Liu, Chan et al. 2009; Cavazzana-Calvo, Payen et al. 2010). 
Although the precise details of the technique that Sangamo uses to produce 
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effective ZFNs is not fully disclosed, due to intellectual property protection, it 
seems that a two-step process is involved. In the first step, four-finger 
domains are created by assembling a pair of two-finger units, chosen from a 
pre-characterised archive, and tested for their specificity to the target 
sequence. In the second step, the most efficient domains have their binding 
activity increased by optimisations made following the guidelines of an 
algorithm-based approach (Cathomen and Joung 2008). Sangamo’s ZFN 
engineering platform is extensively described in Chapter 4 of this thesis. 
Sigma Aldrich, which has acquired the licence for Sangamo’s proprietary ZFN 
technology, has made a variety of gene-specific ZFN by this method and they 
can be purchased "off the peg". Alternatively, customised ZFNs can be 
ordered from Sigma Aldritch (which is at the moment the only provider), but 
these are extremely expensive (£20,000) and for this reason not fully 
accessible to the scientific community.  
On the other hand, a group of academic laboratories has founded the Zinc 
Finger Consortium in order to promote the development of ZF engineering 
techniques that are reliable, user-friendly and freely available to the academic 
community. The “Modular Assembly” approach was the first technique 
developed by the Consortium and the protocol was published in 2006 while all 
reagents, including an archive of more than 140 plasmids, each encoding a 
different ZF 'module' and designed for convenient ligation at the DNA level. 
These reagents are available from the non-profit plasmid repository Addgene 
(Wright, Thibodeau-Beganny et al. 2006). As the name suggests, the process 
involves the linkage of different ZF modules, each one of them specific for a 
trinucleotide, in order to create a “ZF array” (a multi-finger domain, usually 
made of three or four ZFs) with the desired binding affinity for the target 
sequence. A web-based software package helps the identification of possible 
target loci in a given sequence that are suitable for the targeting through 
arrays created from the available ZF-module archives. A Bacterial Two Hybrid 
assay (B2H) enables a rapid and efficient test for the binding activity of the 
produced ZF array. In the end, successful ZF arrays are cloned into a vector 
carrying the FokI domain that allows the expression of complete ZFNs in 
mammalian or plant cells (Wright, Thibodeau-Beganny et al. 2006). This 
approach was successfully used in a series of experiments that targeted 
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genes in vitro (Segal, Beerli et al. 2003), in Drosophila melanogaster 
(Beumer, Bhattacharyya et al. 2006) and in Caenorhabditis elegans (Morton, 
Davis et al. 2006). A more recent large-scale evaluation of the Modular 
Assembly technique, however, showed a higher failure rate than expected: a 
set of ZF arrays designed for 104 different target sites was tested and the 
overall efficiency, measured as the binding efficiency of the ZF arrays in the 
B2H assay, was calculated to be less than 25% (Ramirez, Foley et al. 2008). 
This low rate of success for the Modular Assembly approach is probably due 
to a “context dependent” effect: neighbouring ZF units are not always 
independent from one another in their binding activity because of an 
overlapping effect in which one zinc finger “invades” the neighbouring 
trinucleotide influencing the activity of the following ZF (Cathomen and Joung 
2008; Ramirez, Foley et al. 2008). It seems that some ZFs have, in addition to 
the standard binding of the three-nucleotide, a propensity to make contact 
also with the base, on the parallel strand, complementary to the base 
immediately 5' of its trinucleotide binding site (Isalan, Choo et al. 1997). 
Depending on the adjacent base, this 'cross-strand' interaction can impair the 
affinity of the ZF for its trinucleotide binding site making trinucleotide 
recognition sequence context-dependent (Klug 2010). 
In order to overcome these problems the Zinc Finger Consortium 
developed a new strategy in late 2008: The Oligomerized Pool ENgineering 
(OPEN) system (Maeder, Thibodeau-Beganny et al. 2008). This approach has 
the advantage of taking notice of the context dependent effect through a 
“context-sensitive selection strategy”; an archive of ZF pools, each one of 
them containing ZF variants specific for a trinucleotide, is used to assemble a 
small library of different ZF arrays all specific for the target sequence. A B2H 
selection system, in which the binding of ZFs activate a selectable marker, is 
then used to search the newly produced library for ZF arrays with increasing 
binding activity (Maeder, Thibodeau-Beganny et al. 2008). OPEN was used in 
a first study to produce 37 efficient ZFNs that were able to modify 11 different 
target sites in three endogenous human genes (VEGF-A, HoxB13, CFTR) and 
one endogenous tobacco plant gene (SuRA); up to 50% of the transfected 
cells presented the specific gene modification. When ZF arrays produced with 
the Modular Assembly approach and with the OPEN system were compared, 
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only 18% of ZF arrays produced with the first method were effective in human 
cells while the second method gave a 75% efficiency (Maeder, Thibodeau-
Beganny et al. 2008).  
The OPEN system protocol was published in late 2009 and it is supported 
by a web-based software that, as in the previous protocol, helps to identify 
possible target sequences. Although this protocol yields a higher percentage 
of functional ZFNs, it requires high levels of expertise with phage-display 
technology and with the screening of combinatorial libraries and therefore it is 
not easily employed by research groups with limited experience or equipment 
(Maeder, Thibodeau-Beganny et al. 2009). 
In 2011 researchers from the Zinc Finger Consortium published a third 
protocol that should be easily applied by any laboratory but, at the same time, 
should also take in account possible context-dependent effects between 
neighbouring ZFs and therefore it should provide a more robust approach 
than the modular assembly protocol (Sander, Dahlborg et al. 2011). The 
Context Dependent Assembly (CoDA) protocol does not consider ZFs as 
single, independent modules but instead is based on ZF domains each one 
made of three different ZFs: ZF1-ZF2-ZF3 with ZF1 and ZF3 being at the N 
and C termini, respectively. The archive provided by the consortium contains 
319 different ZF1 and 344 different ZF3 that work efficiently when coupled on 
both sides of 18 fixed ZF2 units. New domains with binding affinity for different 
DNA sequences can be created by linking together different ZF1 and ZF3 
units interspaced by a common ZF2 unit (see Fig. 1.12) (Sander, Dahlborg et 
al. 2011). Although this protocol has still to be fully assessed and it is limited 
to the creation of functional ZFNs based on subunits made only of 3 ZFs 
each, it is a simple alternative to more complex (OPEN) or expensive 
(Sangamo-Sigma) approaches and at the same time promises to be more 
effective than the original modular assembly protocol. 
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Figure 1.12 CoDA approach for the creation of novel 3 fingers 
ZF domains.  
Two different 3 fingers domains are shown on top. Each one binds a specific 
9-bp target site but both of them have in common a middle F2 unit. The two 
domains can be rearranged in order to create a novel ZF domain with new 
specificity where F1 and F3 are derived from the two different domains but 
can be joined together thanks to the common middle F2 unit. Picture from 
Sander et al. 2011.  
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1.11 Aims  
 
The aim of this project was to develop ZFNs capable of promoting correction 
of specific mutations in the β-globin gene in order to develop a reliable gene-
correction therapy for patients with β-thalassaemia or sickle cell anaemia.  
The first step was to identify suitable target sequences in the β-globin 
gene to be targeted by customized ZFNs and to design and synthesise ZF 
domains specific for the selected target sites through a modular assembly 
approach. The ZF arrays would then be assessed for sequence-specific 
binding activity in a bacterial two hybrid assays (B2H) in order to identify the 
most promising ZFN to be used in subsequent experiments.  
The next step was to take possible ZF arrays that showed a low binding 
efficiency and improve them through one of the two directed evolution 
systems developed throughout the project. These systems would be based on 
the creation of libraries of mutated ZF arrays with different binding activities; 
members of these libraries would then be selected for efficient binding 
activities through newly designed bacterial selection methods based on a 
zeocin selection cassette or on a double selectable system to take advantage 
of a streptomycin resistance cassette and a histidine pathway gene. 
Alternatively, a ZFN specific for the β-globin gene would be acquired from 
Sigma Aldrich in order to increase the chances of obtaining efficient ZFNs to 
be used in the following gene targeting experiments and possibly to be used 
in future therapeutic applications. 
All ZFNs created during the development of this project would be tested in 
three different assays: 
1. ZFN cutting efficiencies would be assessed through the Cel-I assay in 
two different cell lines (K562 and HT1080) to detect “indels”, small 
mutations or deletions derived from the correction of possible DSBs 
through the non-conservative NHEJ repair pathway. 
2. The ability of the ZFNs to promote HR would be tested using a 
Homology Directed Repair (HDR) assay based on a GFP reporter 
plasmid to compare the HR levels induced by ZFNs with the “gold 
standard” I-SceI endonuclease. 
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3. Finally, successful ZFNs would be used to produce gene targeting at 
the β-globin endogenous locus in K562 cells using as a repair template 
a puromycin cassette flanked by two homology arms for easy selection 
of successful targeted events. 
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2 Chapter 2: Materials and Methods 
 
2.1 Preparation of nucleic acids 
	  
2.1.1 Bacterial plasmid isolation 	  
Plasmid DNA extraction and purification from liquid cultures was carried out 
through alkaline lysis, high-salt precipitation and DNA isolation using Zyppy 
Plasmid Miniprep Kit (ZYMO RESEARCH CORP.) for up to 10-15 µg of 
plasmid DNA and E.Z.N.A. Plasmid Maxi Kit (OMEGA bio-tek) for up to 100 
µg of plasmid DNA. Isolated DNA was re-suspended in TE buffer (10 mM 
Tris-HCl, 1 mM EDTA, pH 8.0). 
	  
2.1.2 Ethanol precipitation and phenol extraction of DNA 
samples 	  
Ethanol precipitation and phenol/chloroform extraction techniques were used 
for the purification of DNA samples. 
Ethanol precipitation: 1/10 (vol/vol) of 3 M sodium acetate and 3/1 (vol/vol) 
of cold 100% ethanol (Fisher Scientific) were added to the DNA solution. The 
sample was centrifuged at 15000 g for 30 min at 4⁰C, the supernatant was 
removed and the pellet was washed with 70% ethanol, centrifuged at 15000 g 
then dried and re-suspended in suitable amounts of TE buffer. 
Phenol extraction: 1/1 (vol/vol) of phenol solution (25:24:1 
phenol:chloroform:iso-amyl alcohol, by volume, Sigma) was added to the DNA 
solution, vortexed for 1min and then centrifuged at 13000 g for 5 min in order 
to separate the inorganic/organic phases. Inorganic phase containing the 
DNA was then collected and ethanol precipitated. 
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2.1.3 Mammalian genomic DNA isolation 	  
“Simplified mammalian DNA isolation procedure”: DNA from adherent cells 
HT1080 was isolated following the Liard et al. protocol (Laird, Zijderveld et al. 
1991). In brief: a confluent 10 cm diameter petri dish (~1-2x106 cells) was 
washed with PBS and 10 ml of lysis buffer (100 mM Tris.HCl pH 8.5, 5 mM 
EDTA, 0.2% SDS, 200 mM NaCl, 100 µg Proteinase K/ml) was added to the 
dish and incubated at 37°C on a rocking table for 5 hours. 10 ml of 
isopropanol (Fisher Scientific) were then added to the lysate and the plate 
was agitated until white fibres of genomic DNA became visible. The DNA 
fibres were then recovered with a disposable pipette tip and the excess of 
fluid was removed from the fibres by dabbing them on the inside of the petri 
dish lid. Genomic DNA was then dissolved in a tube containing 100 µl TE 
buffer. 
“Commercial genomic DNA purification kit”: Genomic DNA from ~1x106 
K562 cells was isolated using Wizard Genomic DNA Purification Kit 
(Promega) following the manufacturers instructions. The kit is based on a 
four-step protocol: lysis of cells and nuclei, RNase treatment, salt-precipitation 
of proteins and isopropanol precipitation of genomic DNA. Genomic DNA was 
then resuspended in 100 µl of TE buffer. Assuming ~100% recovery of 
genomic DNA, 1 million cells should generate ~ 6 µg of genomic DNA.   	  
2.1.4 DNA purification from agarose gel or from solution 
	  
DNA bands resolved on an 1 or 2% agarose gel were isolated using a sharp 
blade and the gel fragment containing the DNA band was melted in 600 µl of 
ADB buffer (ZYMO RESEARCH CORP.) at 37°C. The DNA sample was 
isolated using Zyppy Plasmid Gel-extraction Kit (ZYMO RESEARCH CORP.). 
In alternative to ethanol precipitation, in order to exchange solution or to 
concentrate DNA samples were purified adding 2 volumes of DNA Binding 
Solution (ZYMO RESEARCH CORP.) to the samples and then using the 
Zyppy Plasmid Gel-extraction Kit 
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2.2 Handling of bacteria (Escherichia coli) 
	  
2.2.1 Liquid and solid media  	  
Standard Luria Bertani (LB) liquid medium or LB agar plates (9 cm petri 
dishes, Sterilin) were used for the growth of bacterial strains throughout the 
project unless differently specified (J. Sambrook 1982). All liquid cultures were 
grown with aeration at 37°C in a shaker-incubator and bacterial growth was 
monitored by measuring the Optical Density (OD) at 600 nm using a 
spectrophotometer (BioPhotometer, Eppendorf). LB agar plates or liquid LB 
were used in conjunction with different antibiotics for the selection of bacterial 
transformants (see Section 2.2.4). Depending on the transformed plasmid, the 
following antibiotics and relative concentrations were used: 
• 100 µg/ml ampicillin (Sigma) 
• 12.5 µg/ml chloramphenicol (Sigma) 
• 30 µg/ml kanamycin (Sigma) 
• 12.5 µg/ml tetracycline (Sigma) 
Low salt LB liquid media with pH corrected to 7.5 with 1 M NaOH and low 
salt LB agar plates were used in conjunction with 25-50 µg/ml Zeocin 
(Invitrogen) during the creation and testing of the Zeocin selectable system. 
M9 minimal medium agar plates were used for the selection of CSH100 
bacterial strain. A 500 ml solution was prepared as follows: 439 ml of H2O 
with 7.5 g of Bacto-Agar (Becton-Dickinson) were autoclaved; when the 
solution was cooled at 65⁰C, 50 ml of 10x M9 salts (1l of solution contain: 70 
g of Na2HPO4-7H2O (BDH), 30 g of KH2PO4 (BDH), 5 g of NaCl (BDH) and 10 
g of NH4Cl (BDH)), 1 ml of 1 M MgSO4 (BDH), 10 ml 20% (wt/vol) glucose 
(Sigma) and 0.5 ml of 100 mM CaCl (BDH) were added. The solution was 
then poured into plates.  
Once set, all agar plates were dried by removing their lids in a laminar flow 
hood for 30 min, and then stored at 4°C. 
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LB agar plates with 12.5 µg/ml tetracycline, 30 µg/ml kanamycin and 5% 
(wt/vol) sucrose were used for the selection of conjugation products between 
KJ1C and CSH100 bacterial strains during the OPEN selectable system. 	  
2.2.2 Bacterial strains 	  
The following Escherichia coli (E.coli) strains were used throughout the 
development of the project: 
• KJBAC1 (F- lacIq ΔhisB463 Δ(gpt-proAB-arg-lac)XIII zaj::Tn10) 
provided by Addgene was used in the B2H assay and in the Zeocin 
selectable system. 
• CSH100 (F’ lacproA+proB+(lacIq lacPL8)/ara ∆(gpt-lac)5) provided by 
Addgene was used in the OPEN selectable system. 
• KJ1C (F- ∆hisB463 ∆(gpt-proAB-arg-lac)XIII zaj::Tn10) provided by 
Addgene was used in the OPEN selectable system. 
• Transformax EPI300 (F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 
ΔlacX74 recA1 endA1 araD139 Δ(ara, leu)7697 galU galK λ- rpsL 
(StrR) nupG trfA dhfr) provided by Epicentre Biotechnologies was used 
for the amplification of the low copy plasmid pBAC-LacZ. 
• NEB 10-β (araD139 ∆(ara,leu)7697 fhuA lacX74 galK16 galE15 mcrA 
f80d(lacZ∆M15)recA1 relA1 endA1 nupG rpsL rph spoT1∆(mrr-
hsdRMS-mcrBC)) provided by NEB was used in all standard cloning 
procedures.	  
• JM109 (endA1, recA1, gyrA96,thi, hsdR17(rk-, mk+), relA1, supE44, 
Δ(lac-proAB), (F’ traD36, proAB, laqIqZΔM15)) provided by NEB. 	  
• NEB 5-α (F’ Iq (F´ proA+B+ lacIq ∆(lacZ)M15 zzf::Tn10 (TetR) / 
fhuA2∆(argF-lacZ)U169 phoA glnV44 Φ80Δ(lacZ)M15 gyrA96 recA1 
endA1 thi-1 hsdR17)) provided by NEB was used for the amplification 
of pGP-FF-ZF plasmids.	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2.2.3 Preparation of competent cells for chemical 
transformation 	  
The protocol used for creating bacterial competent cells was derived from 
Wright et al. (Wright, Thibodeau-Beganny et al. 2006). 1ml of saturated 
bacterial inoculum from an overnight 4 ml culture was added to 50 ml of LB 
media containing 15 mM MgCl2 (BDH) and incubated with agitation for 1.5 
hours at 37˚C. The cells were then pelleted by centrifuging at 5000 g for 20 
min at 4˚C. The pellet was re-suspended in 3 ml of ice-cold, filter sterile 
Solution A (10 mM MnCl2 (BDH), 50 mM CaCl2 (BDH), 10 mM MES (2-(N-
morpholino)ethanesulfonic acid) pH 6.3 (Sigma)) containing 15% glycerol and 
it was left in ice for 20 min. The solution was then aliquoted into sterile tubes, 
frozen in dry ice and then stored at -80˚C. 	  
2.2.4 Chemical transformation  	  
The protocol used for the chemical transformation of bacteria cells was 
obtained from Sambrook et al. (J. Sambrook 1982). 50-100 ng of DNA 
plasmids were added to 50 µl ice-cold competent cells and left on ice for 30 
min. Samples were heat-shocked for 30-45 sec in water-bath at 42˚C and 
then returned to ice for 2 min. The cells were then recovered with 500 µl LB at 
37˚C for 1.5 hours and then plated on LB plates containing a suitable 
antibiotic. Single colonies were collected after overnight incubation at 37°C 
and were expanded overnight in 4 ml of liquid LB with a suitable antibiotic at 
37°C with agitation. Around 3 ml of culture were used for the isolation of 
plasmids (see Section 2.1.1) while 0.5-1 ml of the same culture were used for 
long-term storage. Bacterial transformants were stored in 20% glycerol (v/v) 
(Sigma) at -80°C.	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2.3 Gel electrophoresis  	  
2.3.1 Agarose gel electrophoresis of DNA (DNA-AGE) 	  
Casting of 1% and 2% agarose (w/vol) gel was carried out using Agarose 
Molecular Grade (Bioline) or agarose “Iberose” (WebScientific) melted in 1x 
TAE with addiction of 1x Syber Safe DNA stain (Invitrogen). DNA samples 
were prepared by mixing the DNA solutions with 6x loading buffer (10 ml of a 
6x stock solution: 3 ml glycerol, 25 mg bromophenol blue, 7 ml H2O) and then 
loading them on agarose gel immersed in 1x TAE running buffer in a 
horizontal electrophoresis unit Horizon 58 (Life Technologies) with an applied 
voltage of 50-100 Volts. Samples dimensions were calculated using as 
reference 1 kb DNA ladder (New England Biolabs or Invitrogen) or 100 bp 
DNA ladder (NEB). DNA bands were visualized by exposing agarose gels 
with UV light on a transilluminator (BioDoc-It imaging system, UVP). 	  
2.3.2 Polyacrylamide electrophoresis of DNA (DNA-PAGE) 	  
Polyacrylamide gel electrophoresis was used for higher resolution of small 
DNA fragments. 12 ml of 8% polyacrylamide gel solution was obtained by 
mixing 3.2 ml of 29:1 acrylamide:bis-acrylamide solution (Sigma), 8.6 ml of 
H2O, 1.2 ml of 10x TBE, 200 µl of 10% (wt/vol) ammonium persulfate (Sigma) 
and 10 µl of TEMED (Sigma). The gel was cast on a vertical electrophoresis 
unit (Biorad) and then immersed in 1x TBE running buffer. DNA samples with 
6x loading buffer were loaded along 100 bp DNA ladder and a voltage of 50 
Volts was applied for 3 hours. The obtained gel was then stained in a solution 
of 1xTBE plus 1x ethydium bromide (Sigma) and DNA bands were visualized 
by exposing gels with UV light on a transilluminator (BioDoc-It imaging 
system, UVP). 	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2.3.3 32P-labelling of 1kb DNA ladder   	  
1µg of 1 kb ladder (NEB) was mixed with dNTPs (dATP, dGTP and dTTP 50 
µM final concentration (NEB)), 0.5 µl α-32P-dCTP (10 mCi/ml Perkin Elmer), 
buffer 2 (NEB) and 5 U Klenow fragment (3’-5’ exo-) in a 20 µl reaction 
volume and incubated at 37°C for 30 min. Labelled ladder was separated 
from the reaction mix using a IllustraTM ProbeQuantTM G50 micro columns 
(GE Healthcare) and resuspended in 1x loading buffer. 	  
2.3.4 Probe creation and labelling 	  
The probe to be used during the Southern blot analysis (see Chapter 6) was 
created by PCR amplification using Phusion Hot Start II high-fidelity DNA 
polymerase from Finnzymes (Thermo Fisher Scientific) and K562 genomic 
DNA as a template. 
The primers used were: 
Primer 
name 
Sequence (5’-3’) 
HBB-P-F GATTTGAAACTGAGGCTCTGACC 
HBB-P-R CAAGACCCTGTTTCACATCCCTG 
 
And the PCR conditions were: 
Initial denaturation 98˚C 5 min 
Denaturation 98˚C 1 min 
Annealing 57˚C 30 sec 
Extension 72˚C 1min 
Final extension 72˚C 10 min 
Number of cycles: 30 
100 ng of purified probe (see Section 2.1.4) and 250 ng of random 
hexamer primers (Promega) were boiled in 20 µl of TE for 2 min and then 
quickly placed in ice. Afterwards, dNTPs (dATP, dGTP, dTTP 50 µM final 
concentration (NEB)), 3 µl of α-32P-dCTP (10 mCi/ml), 2 µl buffer 2 (NEB) and 
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5 U Klenow fragment (3’-5’ exo-) were added in a final volume of 20 µl 
solution. The reaction mix was incubated for 1h at 37°C.  
The probe was separated from the reaction mix using the previously 
mentioned mini column and the percentage of radiolabelling was estimated 
measuring counts before and after purification. Around 50% of the α-32P-
dCTP was incorporated in the probe. 
	  
2.4 Molecular cloning and manipulation of DNA samples 	  
2.4.1 Plasmid digestion with restriction enzymes 	  
All restriction enzymes used in this project were obtained from New England 
Biolabs. Digestions were performed following protocols provided by the 
supplier. Unless differently stated, reactions were carried out in a 20 µl 
volume containing the appropriate 1x buffer, ≈ 1 µg of DNA sample to be 
digested and 2-3 units of restriction enzyme. Digestions were carried out 
usually for 1-2 hours. 	  
2.4.2 Dephosphorylation of DNA 5’-ends 	  
Removal of phosphate groups from the 5’ ends of DNA samples was carried 
out using Antarctic Phosphatase (New England Biolabs). DNA plasmids were 
incubated at 37˚C with 5 U of Antarctic Phosphatase for 15 min and then the 
reaction was heat inactivated at 65˚C for 5 min.   	  
2.4.3 Ligation 	  
Standard ligations were performed with T4 DNA Ligase (NEB) following 
manufacturer’s protocol. Usually, 10-20 ng of digested vector and an excess 
of DNA insert were ligated at room temperature for 30 min in a volume of 10 
µl. Ligations of blunt products were carried out as follow: 10-20 ng of linear 
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vector was ligated with an excess of DNA insert in a reaction volume of 10 µl 
containing 1 µl (3 U) of T4 DNA ligase for 16 hours at 15˚C. 	  
2.4.4 End-filling of 5’ ends 	  
End-filling of 5’ overhangs was carried out using Klenow enzyme (NEB) and 
following manufacturer’s instruction. Briefly, 20 µl reactions were carried out 
at room temperature for 15 min. Each reaction was supplied with 0.5 µg of 
DNA sample supplemented with 33 µM dNTPs and 1 unit of Klenow enzyme. 	  
2.4.5 Sequencing 	  
300-600ng of DNA samples containing 3.2 pmoles of primers were 
suspended in 10 µl of H2O and sent to the Sequencing Service, MRC CSC 
Genomics Laboratory (Hammersmith Hospital, London). Sequencing is 
performed by an automated fluorescent DNA sequencing instrument 
ABI3730XL. Results were received as .seq files and analyzed with 
SerialCloner 1.3 software or Ape Plasmid Editor 2.0.37. 	  
2.4.6 Polymerase Chain Reaction (PCR)  	  
All PCR reactions were carried out using either a Multi Gene thermo-cycler 
TC9600-G (Labnet Internetional Inc.) or a PTC-200 DNA Engine thermo-
cycler (MJ Research). Unless otherwise stated, standard PCR reactions were 
carried out using Taq DNA Polymerase with Standard buffer (NEB) or 
DreamTaq DNA Polymerase (Fermentas) and the following conditions:  
 
-  5 U of Taq DNA Polymerase, 5 µl 10x buffer, 200 µM (final concentration) 
dNTPs, 0.4 µM (final concentration) primers, 39 µl H2O, ≈10 ng of DNA 
sample. 
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Initial denaturation 95˚C 1/5 min 
Denaturation 95˚C 30 sec 
Annealing 50-60˚C* 30 sec 
Extension 68˚C 1 min/kb 
Final extension 68˚C 5 min 
 Number of cycles: 30 
* Annealing temperatures varied depending on primers 
 
- 2.5 U DreamTaq polymerase, 5 µl 10x DreamTaq buffer, 200 µM (final 
concentration) dNTPs, 0.4 µM (final concentration) primers, 39.5 µl H2O, ≈10 
ng of DNA sample. 
Initial denaturation 95˚C 1/5 min 
Denaturation 95˚C 30 sec 
Annealing 50-60˚C* 30 sec 
Extension 72˚C 1min/kb 
Final extension 72˚C 5 min 
 Number of cycles: 30 
* Annealing temperatures varied depending on primers 
 
High-fidelity PCR was carried out using the Phusion Hot Start II high-
fidelity DNA polymerase from Finnzymes (Thermo Fisher Scientific) using the 
following condition: 1 U Phusion polymerase, 10 µl 5x PCR buffer, 200 µM 
(final concentration) dNTPs, 0.4 µM (final concentration) primers, 32.5 µl of 
H2O, ≈10 ng of DNA sample.  
Initial denaturation 98˚C 1/5 min 
Denaturation 98˚C 1 min 
Annealing 50-60˚C* 30 sec 
Extension 72˚C 1min/kb 
Final extension 72˚C 5 min 
Number of cycles: 30-40 
* Annealing temperatures varied depending on primers 	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2.4.7 Colony PCR  	  
1x103 cells from HT1080 or K562 cells were collected and mixed with 25 µl 
lysis solution (1.125 µl of 10% NP40, 1.125 µl of 10% Tween, 0.8 µl 
Proteinase K (Invitrogen), 2.5 µl 10x Dream Taq PCR buffer (Fermentas) and 
19.45 µl of H2O). The samples were then incubated at 50˚C for 1 hour and 
then at 94˚C for 10 min. 
In a second step 25 µl of PCR solution (5 U of Dream Taq (Fermentas), 
2.5 µl PCR buffer (Fermentas), 200 µM (final concentration) dNTPs, 0.4 µM 
(final concentration) primers, 16.5 µl of H2O) was added to the samples. PCR 
reactions were carried out as follow: 
 
Initial denaturation 95˚C 5 min 
Denaturation 95˚C 1 min 
Annealing 57˚C 30 sec 
Extension 72˚C 1min 
Final extension 72˚C 10 min 
Number of cycles: 30 
The primers used were the same described in Section 2.7.4. 
	  
2.5 Construction of novel plasmids  	  
2.5.1 pBAC-ZFTS-LacZ reporter plasmids 
 
Oligonucleotides used as target sites (TSs) in the B2H assay (see Section 
2.7.1) were as follows:  
• TS-1(L) target sequence: forward oligonucleotide 5’-
tgtggaagatcttcgacagccctgggcaggtt-3’ and reverse oligonucleotide 5’-
taatgtaataacctgcccagggctgtcga-3’. 
• TS-1(R) target sequence: forward oligonucleotide 5’-
tgtggaagatcttcgacagcaccaacttcatt-3’ and reverse oligonucleotide 5’-
taatgtaataatgaagttggtgctgtcga-3’. 
• TS-2(L) target sequence: forward oligonucleotide 5’-
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tgtggaagatcttcgacatccaagctaggccc-3’ and reverse oligonucleotide 5’-
taatgtaatgggcctagcttggatgtcga-3’. 
• TS-2(R) target sequence: forward oligonucleotide 5’-
tgtggaagatcttcgacagaataatccagcct-3’ and reverse oligonucleotide 5’-
taatgtaataggctggattattctgtcga-3’. 
• TS-3(L) target sequence: forward oligonucleotide 5’-
tgtggaagatcttcgacacaatagaaactggg-3’ and reverse oligonucleotide 5’-
taatgtaatcccagtttctattgtgtcga-3’. 
• TS-3(R) target sequence: forward oligonucleotide 5’-
tgtggaagatcttcgacagaataatccagcct-3’ and reverse oligonucleotide 5’-
taatgtaatagacaggtttaagctgtcga-3’. 
For each TS, equal amounts (50 fmol) of forward and reverse oligonucleotide 
were annealed in 100 µl of annealing buffer (40 mM Tris pH 8, 20 mM MgCl2, 
50 mM NaCl) by heating the solution at 95°C for 2 minutes and then slowly 
(around 1 hour) cooling it to 25°C. Each pBAC-ZFTS-LacZ plasmid was made 
by linearization of the vector pBAC-LacZ (1µg) with 0.5 µl of BsaI (10 U/µl) at 
50°C for 1 hour. Annealed oligonucleotides were ligated to the digested 
pBAC-LacZ in order to form the pBAC-ZFTS-LacZ reporter plasmids (ligations 
were carried out following the protocol of Section 2.4.3). 
 
2.5.2 pDR-GFP-ZFN4 reporter plasmid 
 
The GFP reporter plasmid for the testing of ZFN4-induced HR was created by 
modification of pDR-GFP-HR plasmid previously developed by Maria Jasin’s 
group (Pierce, Johnson et al. 1999). In order to introduce the specific target 
sequence for ZFN4, two oligonucleotides were designed: 
Oligos name Sequence (5’-3’) 
pDR-TS-4-
Fwd 
CAGGGTAATATAGGTCTGCCGTTACTGCCCTGTG
GGGCAAGGTGAACGTGGATGAATAA 
pDR-TS-4-
Rev 
TCATCCACGTTCACCTTGCCCCACAGGGCAGTAA
CGGCAGACCTATATTACCCTGTTAT 
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The two oligos were annealed in presence of 1x Annealing buffer (40 mM 
Tris pH 8, 20 mM MgCl2, 50 mM NaCl) by incubation in a thermocycler: 
 
Denaturation 95˚C 2 min 
95˚C ramping to 85˚C -2˚C/sec 
85˚C ramping to 25˚C -0.1˚C/sec 
4˚C hold 
 
1 µg of pDR-GFP-HR was linearised by enzymatic digestion with 5 units of 
I-SceI (NEB) in presence of 1x I-SceI buffer. The reaction was carried out at 
37˚C for 1h and then the enzyme was inactivated at 65˚C for 20 min. ≈ 0.2 µg 
of the linearised plasmid were subsequently ligated with an excess of 
annealed oligos following the procedure described in Section 2.4.3. The oligos 
were designed in a way that, when ligated in the pDR-GFP-HR plasmid, 
would reconstitute the I-SceI site on the left of TS-4. Successful introduction 
of TS-4 was confirmed by sequencing with the primer: 
Primer 
name 
Sequence (5’-3’) 
TS-4-pc CTCTGCTAACCATGTTCATGC 
 
2.5.3 pBL-TV-TC, pTV-TC4 targeting constructs and pBL-TV-
pc positive control  	  
The left and right homology arms were created by PCR amplification using a 
high fidelity DNA polymerase with K562 genomic DNA as a template (see 
Section 2.4.6).  
Chapter 2: Materials and Methods 
	   80	  
 
Primer 
name 
Sequence (5’-3’) 
HAL-F CATTGTGCGGCCGCATATCAGGGATGTGAAACAGG 
HAL-R CATTGTGAATTCTCCTCAGGAGTCAGATGCAC 
HAR-NF TCCTGAGGAGAAGTCTGCCGTTAC 
HAR-R CATTGTGGTACCTGACTGGGAGAGAGGACAAGGAC 
HAR-F CATTGTATCGATCCTGGGCAGGTTGGTATCAAG 
PC-F 
CATTGTGAGCTCGGTGACAATTTCTGCCAATCAGGAC
TAGTATATCAGGGATGTGAAACAGGGTC 
PC-R CATTGTTCTAGACTGCATTCTAGTTGTGGTTTGTCC 
 
HAL-F and HAL-R were used to amplify the 2 kb left homology arm and at 
the same time to introduce a NotI and EcoRI restriction sites (underlined in 
the above table) upstream and downstream of the sequence, respectively.   
The right homology arm was created through a nest PCR approach. 
Initially a 2489 bp fragment was amplified using the primers HAR-NF and 
HAR-R. This PCR product was then used as a template to amplify the final 
2420 bp right homology arm using the primers HAR-F and HAR-R. The 
primers also introduced the two restriction sites ClaI and KpnI upstream and 
downstream of the PCR product (restriction sites are underlined in the above 
table).  
Cloning of the left and right homology arms in the pBL-Puro plasmid using 
the aforementioned restriction sites created the initial targeting construct pBL-
TV-TC where the Puromycin resistance cassette is flanked by the two 
homology arms. 
The second and final targeting construct pTV-TC4 (a shortened version of 
pBL-TV-TC) was created by restriction digestion with ApaI and KpnI of pBL-
TV-TC plasmid, isolation of the fragment carrying the PuroR cassette flanked 
by the two homology arms and cloning it in the pBSKS+ plasmid. pTV-TC4 
has a left homology arm of 1.3 kb and a right homology arm of 2.5 kb.  
The PC-F and PC-R primers were used during the creation of the positive 
control pBL-TV-pc plasmid to amplify the left homology arm of pBL-TV-TC 
and at the same time to introduce a 23 bp sequence to the end of the left 
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hand homology arm homologous to the PT1-F primer and including a SpeI 
site immediately upstream of the left homology arm. The two primers also 
introduced the unique SacI and XbaI restriction sites (underlined in the above 
table). Enzymatic digestion of pBL-TV-TC with SacI and XbaI was used to 
remove the left homology arm and to replace it with the newly amplified 
“extended” left homology arm creating the pBL-TV-pc positive control plasmid. 
In order to create cell populations to be used as a control during the PCR 
screening of puromycin resistant cells, pBL-TV-pc was linearised with PvuI 
and then stably transfected in both HT1080 and K562 cells (see Section 
2.6.6). 
 
2.5.4 Zinc Finger DNA Binding Domains (ZF-DBDs) created by 
Modular assembly approach or commissioned to Mr 
Gene Company 	  
Four of the ZF-DBDs (ZF1-R, ZF1-L, ZF2-R and ZF3-R) described in Chapter 
3 were created following the protocol described by Wright et al. (Wright, 
Thibodeau-Beganny et al. 2006) while the remaining two (ZF2-L and ZF3-L) 
were synthesised by Mr Gene Company (now a subsidiary of GeneArt, 
http://order.geneart.com/).  
The ZF plasmids (pc3XB) archive, containing 141 different zinc finger 
modules, used for the cloning of ZF1-R, ZF1-L, ZF2-R and ZF3-R was 
obtained from Addgene (http://www.addgene.org/). The plasmid used were: 
• ZF1-R: pc3XB60, pc3XB71, pc3XB106 and pc3XB94.	  
• ZF1-L: pc3XB92, pc3XB103, pc3XB89 and pc3XB90.	  
• ZF2-R: pc3XB73, pc3XB104, pc3XB83 and pc3XB93.	  
• ZF3-R: pc3XB106, pc3XB75, pc3XB82 and pc3XB77.	  
The sequences of the ZF2-L and ZF3-L were assembled in silico using 
data from the web archive provided by Addgene and were sent to Mr Gene. 
The company synthesised the desired sequences, linking synthetic 
oligonucleotides and amplifying them by PCR, and the final product, flanked 
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by two restriction sites compatible with the modular assembly protocol, was 
then cloned into a standard plasmid and shipped. 
 	  
2.6 Mammalian cell culture 	  
2.6.1 Culturing 	  
All mammalian cells were cultured at 37˚C and 5% CO2 in a humidified 
incubator NAPCO 5410 (Precision Scientific). Handling was carried out in a 
laminar flow hood (Faster BHA36, Jencons-PLS) using sterile techniques. 
Three different human cell lines were used throughout the development of this 
project: HT1080 adherent cells (fibrosarcoma cell line), K562 suspension cells 
(erythroleukemia cell line) and DG75 suspension cells (Burkitt lymphoma cell 
line).  
 
2.6.2 Adherent cells 
 
HT1080 adherent cells were cultured in 10 cm plates (Corning) with DMEM 
medium from Gibco supplemented with 10% fetal calf serum FCS (heat 
inactivated, Gibco), 10 mM sodium pyruvate (Gibco), 20 mM L-glutamine, 400 
I U/ml Penicillin-Streptomycin (Invitrogen) and 10 ml of a 100x MEM-NEAA 
solution (Gibco). Cells were passaged at 80% confluency washing first with 
PBSA (137 mM NaCl, 10 mM Na2HPO4 • 2 H2O, 2.7 mM KCl, and a pH of 7.4) 
and then using 1 ml of 0.5% 10x trypsine-EDTA (Gibco) in order to detach the 
cells. Afterwards, cells were diluted 1:8 in fresh DMEM medium with 
supplements and plated. 
 
2.6.3 Suspension cells 	  
K562 and DG75 suspension cells were cultured in 75 cm2 or 25 cm2 flasks 
(Corning) using RPMI 1640 medium (Gibco) supplemented with 10% fetal calf 
serum FCS (heat inactivated, Gibco), 10 mM sodium pyruvate (Gibco), 20 mM 
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L-glutamine, 400 I U/ml Penicillin-Streptomycin (Invitrogen) and 10 ml of a 
100x MEM-NEAA solution (Gibco). Cells were subcultured by removing part 
of the culture and adding fresh RPMI medium with supplements.  	  
2.6.4 Long term storage of mammalian cells 	  
Long-term storage of ≈106 cells was carried out resuspending cells in 0.5 ml 
of Freezing media (40% [v/v] standard DMEM medium with supplements, 
50% [v/v] FBS and 10% [v/v] DMSO) and transferring them to cryotubes (Cryo 
Tube, Nunc). Vials were slowly frozen at -80°C by means of a polystyrene 
holder and after 24-48h were transferred to a liquid nitrogen container for 
indefinite storage. 	  
2.6.5 Cell counting and vital staining assay  	  
Counting of HT1080, K562 and DG75 cells was performed by adding ~ 10 µl 
of medium containing cells to a haemocytometer (Superior, Marienfeld) and 
the number of cells was visually established under an inverted phase contrast 
microscope Olympus CK2. K562 and DG75 cell viability was assessed 
through vital staining adding 50% (v/v) of Trypan Blue (Sigma) and then 
visualising the sample with the haemocytometer under the inverted 
microscope. Death of cells was measured by counting the number of cells that 
incorporated the staining. 
 
2.6.6 Transfection by electroporation  
 
Stable transfections of HT1080, DG75 and K562 cells were carried out 
through electroporation of ≈ 5x106 cells. Cells were centrifuged at 400 g for 5 
min in order to remove the media and then washed once in PBS, centrifuged 
again and resuspended in 0.8 ml of cold PBS. 10 µg of vector to be 
transfected was linearised using a suitable restriction site (PvuI unless 
differently specified) and then was ethanol precipitated and resuspended in ≈ 
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10 µl of sterile TE buffer. Chilled cells (in 0.8 ml PBS) were then mixed with 
the linearised DNA and immediately transferred to an electroporation cuvette 
(0.8 ml with 4 mm gap BTX Harvard Apparatus). Electroporation was 
achieved with a Gene-Pulser (BioRad): HT1080 cells were electroporated at 
400 V/250 µF while K562 and DG75 cells at 240 V/960 µF. Immediately after 
the electroporation, cells were resuspended in warm media and left to recover 
at 37°C and 5% CO2 for 48h before starting antibiotic selection.  
Transient transfections in DG75 and K562 cells were carried out through 
electroporation of 2, 4, 6 or 8x106 cells. Cells were centrifuged at 400 g for 5 
min in order to remove the media and then washed once in PBS, spun again 
and resuspended in 0.4 ml of cold PBS. Chilled cells (in 0.4 ml PBS) were 
then mixed with 6 µg of DNA and immediately transferred to a 0.4 cm cuvette 
(BTX Harvard Apparatus). Electroporation was obtained with a Gene-Pulser 
(BioRad) at 240 V/960 µF. Cells were resuspended in warm media and left to 
recover at 37°C and 5% CO2 for 48h before flow cytometry analysis.  
 
2.6.7 Transfection by lipofection  	  
HT1080 and DG75 cells were transfected using Lipofectamine2000 
(Invitrogen) according to manufacturers instructions. The day before 
transfection, cells were plated on 24 wells plate at a density of 0.5, 1, 1.5 or 
2x105 cells per well using DMEM (HT1080) or RPMI (DG75) medium without 
antibiotics (penicillin or streptomycin). Unless differently specified, 0.8 µg of 
DNA (for each well to be transfected) were mixed in 50 µl of opti-MEM 
reduced-serum medium (Gibco). At the same time 2 µl Lipofectamine2000 
were added to 50 µl opti-MEM. The two solutions were incubated for 5 min, 
mixed together and then left to incubate for another 20 min. The 100 µl 
solution was then added to each well of the 24 wells plate and cells were left 
in incubation at 37°C and 5% CO2 for 5 hours before replacing the medium 
with standard DMEM or RPMI medium. Alternatively, lipofection of HT1080 
cells was scaled-up plating 4x105 cells in a 6-wells plate and transfection was 
carried out the day after using 4 µg of DNA. Transfection reactions were 
performed following the above protocol but, in order to take into account the 
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increased number of cells and µg of vector, the amount of lipofection reagents 
was modified following the manufacturer’s guidelines.  	  
2.6.8 Transfection by nucleofection 	  
Transfections of K562 suspension cells were carried out using two different 
sets of reagents. The Ingenio Electroporation Kit (Mirus) was used in 
combination with the Nucleofector II apparatus (Lonza-Amaxa) set using the 
T-016 program (suggested by Lonza for this specific cell line). Briefly, 1x106 
(per reaction) of actively dividing cells were spun at 1500 rpm for 5 min, were 
resuspended in PBS and spun again to remove traces of medium. Cells were 
then resuspended in 100 µl Ingenio Solution, mixed with 2 µg of DNA (unless 
differently specified) and transferred in a 0.2 cm cuvette (Eppendorf). Cells 
were electroporated with the Nucleofector II machine and immediately 
transferred to 5 ml pre-warmed RPMI medium. Transfection efficiencies, 
measured by nucleofecting 2 µg of pmaxGFP (Lonza-Amaxa), resulted lower 
than expected (≈40% transfection efficiency) and therefore the Mirus reagent 
was exchanged for the Amaxa Nucleofector Kit V (including also Amaxa 
cuvettes). The protocol used was the same as the one used for the Mirus 
reagent. Transfection efficiencies increased with respect to previous 
experiments, reaching at least 70-80% GFP expression. 	  
2.6.9 Transfection efficiency assay and flow cytometry 	  
Transfection efficiencies were measured by transfecting cells with pmaxGFP 
plasmid (Lonza-Amaxa), assessing GFP expression after 48h with flow-
cytometry. 0.8 µg or 2 µg pmaxGFP were used for lipofection or 
nucleofection, respectively. Efficiencies were measured for each transfection 
experiment and were carried out, on the same day, using the same cell 
population.  
Flow cytometry was used to measure the percentage of GFP positive cells 
in sample populations during the Homology-directed Repair Assay and to 
generally assess transfection efficiencies during nucleofection, lipofection and 
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electroporation experiments. Each measurement was performed on 20-
50x103 cells per sample (depending on cell viability). HT1080 cells were 
trypsinised and resuspended in DMEM medium before performing flow 
cytometry while K562 and DG75 cells were counted (with haemocytometer) 
and directly used for the assay. All measurements were carried out using a 
FACSCalibur machine (BD). Data were acquired with the CellQuest Pro 
software (BD) and analysed with the Flowjo software package (Treestar).	  	  
2.6.10 Selection of clones  	  
HT1080 clones were obtained by plating HT1080 cells on a 10 cm plate 
immediately after stable transfection (see Section 2.6.6) and by leaving them 
to recover for 48h. After this period of time, 0.4 µg/ml puromycin selection was 
carried out for 15 days (DMEM medium with antibiotic was exchanged every 3 
days) and then single colony forming units were selected and expanded in 
new 10 cm plates with fresh DMEM medium supplemented with puromycin. 
Potential K562 clones from experiments 1,2 and 3 (Chapter 6) were obtained 
by limiting dilution: transfected cells (see Section 2.6.8) were left to recover for 
48h after transfection and then plated on a 96 wells plate at a density of 0.5-
1x103 cells/well (depending on the amount of transfected construct) in 
presence of 0.4 µg/ml puromycin. Selection was carried out for 15 days and 
then Puro resistant wells were expanded in fresh RPMI medium with 
puromycin for further studies. 	  
2.6.11 Limiting dilution and Poisson distribution  	  
Frequencies of gene targeting events in K562 cells during experiments 1, 2 
and 3 (Chapter 7) were measured by limiting dilution analysis. 48h after 
transfection 103 cells/well were plated on 96 wells plates in presence of 0.4 
µg/ml puromycin. Selection was carried out for 15 days and then Puro 
resistant wells were counted. In order to estimate the average of Puro 
resistant cells per well the formula n = –lnF0 was used (Poisson distribution). 
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F0 is the number of wells not containing resistant cells while n is the average 
of Puro resistant cells per well. 
	  
2.7 Assays for targeted DNA binding or mutagenesis 	  
2.7.1 Bacterial Two Hybrid (B2H) assay  
 
Binding affinity of the produced ZF arrays were tested by the use of the B2H 
assay based on the β-galactosidase assay. The experiments were carried out 
following the protocol described by Wright et al. (Wright, Thibodeau-Beganny 
et al. 2006). For each KJBAC1 bacterial strain harbouring pGP-FF-ZF, pAC-
KAN-alphaGal4 and pBAC-ZFTS-LacZ 4 ml of liquid mini-cultures containing 
100 µg/ml ampicillin, 12.5 µg/ml cloramphenicol, 30 µg/ml kanamycin, 500 µM 
IPTG and 10 µM ZnSO4 were genertaed by inoculation with a single colony 
and overnight incubation. Control cultures contained pGP-FF (without any ZF 
domain), pAC-KAN-alphaGal4 and pBAC-ZFTS-LacZ and were grown in 
liquid mini-cultures containing 100 µg/ml ampicillin, 12.5 µg/ml 
cloramphenicol, 30 µg/ml kanamycin, 500 µM IPTG and 10 µM ZnSO4. The 
minicultures were sub-cultured by dilution (1:40) in 4 ml containing 100 µg/ml 
ampicillin, 12.5 µg/ml chloramphenicol, 30 µg/ml kanamycin, 500 µM IPTG 
and 10 µM ZnSO4, the growth was monitored by measuring the OD at 600 nm 
and the cells were harvested at log phase (OD=0.3-0.8) and immediately 
lysed (see following description). The OD600 at the time of harvesting was 
recorded for each sample and the cultures were lysed in a 96-well plate by 
adding 100 µl of culture to 11 µl of Lysis Master Mix (10:1 [v:v} mixture of 
Popculture reagent to 400 U R-lysozyme, both reagents are from Novagen). 
Lysis was carried out for 30 min at room temperature. 15 µl of each lysate 
was added to 135 µl of Z-buffer (1 l of Z-buffer was prepared with 16.1 g of 
Na2HPO4-7H20, 5.5 g of NaH2PO4-H20, 0.75 g of KCl, 0.246 g of MgSO4-7H20 
and 2.7 ml of β-mercaptoethanol dissolved in ddH20 and filter sterilized) and 
30 µl of 4 mg/ml ONPG (ortho-Nitrophenyl-β-galacotiside). The 96-wells plate 
containing the samples was then placed in a plate reader at room temperature 
and serial measurements of absorbance at 420 nm were taken every minute 
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during a period of 30 min.  
Velocity of cleavage of ONPG molecules was calculated plotting the 
values of the absorbance at 420 nm against time and then calculating the 
slope of the line. Binding efficiencies of the ZF arrays were expressed as the 
ratio of velocities from the experimental and control cultures, after normalising 
each to account for any differences in cell density. Thus binding was 
measured using the formula [V/OD600]/[VNC/ODNC600] where V and VNC are the 
rates of increase in OD420 obtained from the experimental and control 
cultures, respectively, while OD600 and ODNC600 are the OD600 measurements 
at the time of harvesting the experimental and control cultures, respectively.  
2.7.2 Surveyor Assay 
 
Surveyor mutation detection kit was provided by Transgenomic and is used to 
detect Single Nucleotide polymorphisms (SNPs), point mutations, insertions 
and deletions in a specific DNA sequence. The assay uses the Cel-I 
endonuclease from celery that is able to recognise small mismatch regions in 
a heteroduplex DNA fragment. The protocol is based on 3 main steps: PCR 
amplification of the desired DNA sequence, creation of mismatch regions and 
Cel-I digestion. 
PCR reactions were performed using the Phusion Hot Start II high-fidelity 
DNA polymerase from Finnzymes (Thermo Fisher Scientific). Reaction 
reagents were: 0.5 µl Phusion polymerase, 10 µl 5x PCR buffer, 200 µM (final 
concentration) dNTPs, 0.4 µM (final concentration) primers, 32.5 µl of H2O, 4 
µl genomic DNA originated from cells transfected with ZFN4 expression 
plasmids and mRNA (Chapter 4).  
The primers used to amplify the region of interest in the β-globin gene were: 
 
Primer 
name 
Sequence (5’-3’) 
HBB-F AGGGTTGGCCAATCTACTCC 
HBB-R CAAAGAACCTCTGGGTCCAA 
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The primers used for the δ-globin region were instead: 
Primer 
name 
Sequence (5’-3’) 
HBD-F AACTGCTGAAAGAGATGCGGTGG 
HBD-R AATGTGGGAGAAGAGCAGGTAGG 
 
Cycles conditions: 
Initial denaturation 98˚C 5 min 
Denaturation 98˚C 1 min 
Annealing 57(β)-58(δ) ˚C 30 sec 
Extension 72˚C 1min 
Final extension 72˚C 10 min 
Number of cycles: 30 
PCR products were purified using the commercial DNA recovery kit from 
NEB (previously described, Section 2.1.4) and resuspended in 20 µl of 1x 
Annealing buffer (40 mM Tris pH 8, 20 mM MgCl2, 50 mM NaCl). The 
amplified DNA fragments were hybridised in order to form heteroduplex using 
a thermocycler:   
Denaturation 95˚C 2 min 
95˚C ramping to 85˚C -2˚C/sec 
85˚C ramping to 25˚C -0.1˚C/sec 
4˚C hold 	  
Newly formed heteroduplexes were subject to digestion with Cel-I 
following the manufacturer’s instructions. Possible DNA fragments derived by 
digestion of mismatched regions were then visualised on an 8% 
polyacrylamide gel (previously described, Section 2.3.2). 
Estimation of the frequencies of heteroduplexes formation was used as an 
indicator of ZFN4 activity at the target locus. To evaluate the frequencies, a 
known amount of Cel-I digested product (≈ 1 µg) was loaded on a 8% 
polyacrylamide gel in conjunction with a known amount of 100 bp ladder (0.5 
µg, NEB). The estimation was carried out by comparing the relative intensities 
of the two digested products (219 bp and 175 bp) and the ones of the 100, 
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200 and 300 bp bands of the ladder. By manufacturer’s specification, the µg 
of the 100, 200 and 300 bp bands in 0.5 µg of ladder are 48 ng, 25 ng and 29 
ng respectively.  
 
2.7.3 MwoI restriction digestion 	  
In order to confirm, by alternative means, the presence of ZFN4 induced gene 
modifications at the β-globin locus, PCR reactions were carried out as 
described in Section 2.7.2 using the same primers and genomic DNA. 
PCR products were purified using the commercial DNA recovery kit 
(previously described, Section 2.1.4) and resuspended in 20 µl H2O. 
Restriction digestions with MwoI were performed following the manufacturer’s 
protocol (NEB) within the space of 2 hours. Restriction digestion products 
were then visualised on an 8% polyacrylamide gel (described in Section 2.3.2) 
and ZFN4 cleavage efficiencies were estimate as in Section 2.7.2. 	  
2.7.4 Homology Direct Repair (HDR) assays 
 
Plating densities for HT-DR-ZFN4, DG-DR-ZFN4 and HT-DR-GFP cells in 
lipofection experiments were chosen based on the ones suggested by the 
manufacture’s protocol (Lipofectamine 2000, Invitrogen). Experiments 
performed on DG-DR-ZFN4 and K-DR-ZFN4 by use of electroporation 
followed a similar timeline but the protocol was modified to take in account the 
differences in transfection technique (see below for further description of the 
used protocol).   
Briefly, on day 1 HT-DR-ZFN4, HT-DR-GFP or DG-DR-ZFN4 cells were 
plated on 24-well plates at different densities: 1x105 and 1.5x105 cells per well 
for HT-DR-ZFN4 and HT-DR-GFP and 4x105 and 6x105 cells per well for DG-
DR-ZFN4. On day 2 cells were transiently transfected by use of lipofection 
(see Section 2.6.7) with 0.4 µg of ISceI expression plasmid and 0.4 µg of a 
control plasmid (pGP-FF) or with 0.4 µg of both ZFN4 expression plasmids. 
Negative controls were performed by transfection of 1x105 and 1.5x105 HT-
DR-ZFN4 and HT-DR-GFP cells or 4x105 and 6x105 DG-DR-ZFN4 cells with 
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0.8 µg of pGP-FF control plasmid. Transfection efficiencies for each cell line 
were assessed by transfection of 0.8 µg of pmaxGFP plasmid (Lonza).  
Using an alternative approach, 2x106 DG-DR-ZFN4 and K-DR-ZFN4 cells 
were electroporated on day 2 with 3 µg of ISceI expression plasmid and 3 µg 
of a control plasmid (pGP-FF) or with 3 µg of each ZFN4 expression plasmid. 
Negative controls were performed transfecting the same amount of of DG-DR-
ZFN4 and K-DR-ZFN4 cells with 6 µg of pGP-FF control plasmid and 
transfection efficiencies were assessed by transfection of 6 µg of pmaxGFP 
plasmid (for the electroporation protocol see Section 2.6.6). All samples were 
left to recover for 48h at 37°C in presence of 5% CO2 and then, on day 4, 
GFP expression levels were measured by flow cytometry (see Section 2.6.9 
for the flow cytometry protocol). 
 
2.7.5 PCR screening of genomic DNA from puromycin 
resistant cells  
 
Screening of puromycin resistant cells for the detection of possible targeting 
events was carried out using DreamTaq DNA Polymerase (Fermentas) with 
the following reaction conditions: 
0.5 µl DreamTaq polymerase, 5 µl 10x DreamTaq buffer, 200 µM (final 
concentration) dNTPs, 0.4 µM (final concentration) primers, 37.5 µl H2O and 4 
µl of genomic DNA.  
Initial denaturation 95˚C 1 min 
Denaturation 95˚C 30 sec 
Annealing 57˚C 30 sec 
Extension 72˚C 1min 
Final extension 72˚C 5 min 
Number of cycles: 30 
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The primers used in the PCR reactions were: 
Primer 
name 
Sequence (5’-3’) 
PT1-F GGTGACAATTTCTGCCAATCAGG 
PT2-F TAGGCTCCAGATAGCCATAGAAG 
PT3-F AGAGCTGAAAGGAAGAAGTAGGAG 
PT1-R CCCGCAAGCCCGGTGCCTGA 
PT2-R GCATTCTAGTTGTGGTTTGTCC 
 
PT1-F, PT2-F and PT1-R were initially used in the preliminary PCR tests 
using pBL-TV-pc positive control plasmid as a template (see Section 2.5.3). 
PT3-F and PT2-R were selected to be used during PCR screening of 
puromycin resistant cells that were transfected with pTV-TC4 (see Sections 
2.5.3).  
2.7.6 Southern blot analysis 
 
6 µg of genomic DNA to be analyzed were digested overnight with 100 U of 
HindIII in presence of 5 mM Spermidine (Sigma) in 100 µl volume. 1 µg of 
radiolabelled 1kb ladder and the digested DNA were then separated on a 
0.8% agarose gel at 15 V overnight. The gel was then immersed in 
denaturation solution (1.5 M NaCl, 0.5 M NaOH) for 45 min, twice in 
neutralization solution (1 M Tris-HCl, 1.5 M NaCl, pH 7.4) for 20 min and then 
briefly rinsed in deionized water. The denaturated DNA in the gel was then 
blotted onto a positively charged nylon membrane (HybondTM-N+, 
Amersham) by capillary transfer. The transfer was carried out by following the 
protocol described by Sambrook et al. (J. Sambrook 1982). The DNA sample 
was left to transfer overnight. The day after the nylon membrane was washed 
with 2x SSC, baked for 1h at 80°C and then the transferred DNA was cross-
linked to the membrane using a Stratalinker UV Crosslinker 1800 (Stratagene) 
for 2 min. 
The membrane was then pre-hybridized with 50 ml of Church mix (0,25 M 
Sodium Phosphate pH 7.2, 1 mM EDTA, 1% BSA, 7% SDS) in a roller 
bottle at 68°C for 1h. The 32P-labelled probe was boiled for 5 min and then 
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added to the Church mix in the roller bottle. The solution was left to incubate 
over night at 68°C. The following day the excess of probe was washed away 
at 68°C with first 2x SSC, two times with 50 ml of 1x SSC and in the end with 
50 ml of 0.5x SSC. A Hyperfilm MP (GE Healthcare) was set with the 
membrane between two layers of intensifying screens, exposed for 4 days at -
80°C and then developed. 
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3 Chapter 3: Creation of zinc finger binding domains 
by modular assembly and development of a 
“directed evolution approach” 
	  
3.1 Overview 	  
At the beginning of this project, ZFNs specific for the β-globin sequence were 
designed and developed using a modular assembly approach protocol that 
was published in 2006 by a group participating in the Zinc Finger Consortium 
(Wright, Thibodeau-Beganny et al. 2006). This protocol, in theory, allows 
users to generate ZFNs specific for any desired sequence through a simple 
succession of standard molecular cloning steps in which single ZF modules 
are linked together to form a DNA Binding Domain (DBD). The ZF-based 
DBDs are tested for their ability to bind the desired target sequences through 
a Bacterial 2 Hybrid assay. Pairs of DBDs that bind their target sequences 
well are then fused to the FokI nuclease domain and tested for their ability to 
cleave the target locus in human cell lines.  
The first step of the protocol is to identify potential target sequences in a 
desired region of the genome that can be targeted by ZFNs produced using 
this specific approach. This process is based on the use of the ZiFiT (Zinc 
Finger Targeter, http://zifit.partners.org/ZiFiT/) web-based software that was 
designed initially to be used in combination with the modular assembly 
protocol but that has been updated in order to support recent and more 
efficient approaches like the OPEN or CoDA protocols (Sander, Zaback et al. 
2007; Sander, Maeder et al. 2010). The program was developed as a web 
tool capable of analyzing a specific DNA sequence and, scanning through a 
depository of ZF modules, to identify possible combinations of ZF modules 
specific for small sequences of 6, 9 or 12 nucleoitdes in the desired genomic 
region.  
In a second step, DNA encoding the ZF-DBDs is assembled using 
standard cloning techniques. Plasmids, based on the vector pc3XB (Wright, 
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Thibodeau-Beganny et al. 2006) and encoding each single ZF module 
(capable of recognising a specific trinucleotide), are provided by the Zinc 
Finger Consortium through Addgene. Each ZF module sequence is flanked by 
two restriction enzyme sites (XmaI, BamHI) that are used to isolate and then 
sub-clone the ZF module DNA. In this way, DNA encoding the different 
modules is assembled, by DNA ligation, in order to form a sequence encoding 
the desired DBD composed of 3 or 4 ZF modules (Fig. 3.1 a). 
The newly created ZF-DBDs are then tested for their ability to bind their 
specific target sequence by use of a Bacterial 2 Hybrid assay (B2H assay) 
that was developed to easily test protein-protein interactions or DNA-protein 
interactions (Joung, Ramm et al. 2000; Wright, Thibodeau-Beganny et al. 
2006). The assay is based on the use of the KJBAC1 bacteria strain 
transformed with three different plasmids (Fig. 3.1 b). DNA for each 
assembled ZF-DBD is cloned into an expression plasmid (pGP-FF). The 
resulting plasmid (pGP-FF-ZF) confers resistance to ampicillin and encodes a 
fusion protein with the Gal11 subunit (ZF-Gal11) which is expressed in an 
IPTG-inducible manner. A second plasmid (pAC-KAN-αGal4) confers 
resistance to kanamycin and expresses the fusion protein αGal4-RNA 
polymerase, also in response to IPTG. Finally, a third plasmid (pBAC-lacZ) 
confers resistance to chloramphenicol and is used to clone the target 
sequence for the ZF-DBD to be tested close to a lacZ cassette (Fig. 3.1 b). 
The assay tests the ability of ZF-Gal11 to bind to its target sequence in pBAC-
lacZ and so to recruit the αGal4-RNA polymerase that is able to promote the 
expression of the lacZ cassette (Fig. 3.1 c).  
In this way, the binding of the ZF-DBD to its target sequence is measured 
as the expression of the lacZ cassette. For this a standard β-galactosidase 
assay is used in which the velocity of cleavage of ONPG (a colorimetric 
artificial substrate of the β-galactosidase) is measured spectrophotometrically 
as increasing absorbance at 420nm with time. 
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Figure 3.1 (a) Overview of the modular assembly approach.   
Restriction digestion and ligation of ZF modules (F1-F2-F3). The example 
shows the successive cloning steps for the assembly of DNA encoding ZF-
DBD. The pc3XB-F1 plasmid is digested with AgeI and BamHI to create the 
recipient vector while pc3XB-F2 is digested with XmaI and BamHI to isolate 
the F2 fragment. The vector and the ZF2 fragment are then ligated to create 
the pc3XB-F1-F2. Similar steps can be repeated in order to add one ZF at a 
time and so to build up ZF-DBDs made of 2, 3 or 4 ZF modules (picture 
obtained from Wright et al. 2006).  
 
a)  
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Figure 3.1 (b and c) Overview of the modular assembly 
approach.  
b) Creation of the B2H reporter system. The XbaI-BsgI digested pGP-FF 
plasmid is ligated to the XbaI-BsgI fragment ZF-DBD (encoding for F1-F2-F3) 
creating the IPTG-inducible expression vector pGP-FF-F1-F2-F3. The 
expression vector is then co-transformed with pAC-KAN-alphaGal4 in the 
KJBAC1 bacteria strain already harbouring the reporter plasmid pBAC-ZFTS-
LacZ.  c) Baterial two hybrid (B2H) assay. Co-expression of ZF-F1-F2-F3-
Gal11 and Gal4-RNA-polymerase is induced by IPTG. Successful binding of 
the ZF domain to the target sequence recruits the fusion protein Gal4-RNA-
polymerase that activates the expression of the LacZ reporter gene. A 
standard colorimetric assay is then used to quantify the binding efficiencies of 
any produced ZF domain.   
b)  
c)     
Target sequence lacZ 
F3 F1 F2 
RNA 
Pol. 
Gal4 Gal11 
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ZF-DBD-TS LacZ 
Co-transform 
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AmpR 
XbaI 
BsgI 
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RNAP-Gal4 
KanR 
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3.2 Results 	  
3.2.1 Identification of target sequences in the human β-globin 
gene 	  
The first step of the modular assembly approach was to identify possible 
target sequences in the human β-globin gene that could be targeted by ZFNs 
produced following this protocol. It was decided to look for 12-nucleotide 
sequences for each half site (4 ZF units) in order to increase the specificity of 
the binding and to avoid possible off-target cleavage. ZFNs produced in this 
way would target a sequence of 24 nucleotides: left and right ZF domains 
would bind to 12 nucleotides on each sides of a 6-nucleotide spacer 
sequence where the FokI domain would produce a DSB (Fig. 3.2 a). 
The ZiFiT software identified 50 possible targets; from this group, three 
(TS-1, TS-2 and TS-3) were selected on the basis of their positions relative to 
known β-thalassemia mutations (TS-1 being close also to the sickle cell 
mutation) and for their reduced risk of possible off-target cleavage events 
(Fig. 3.2 b). The risk of off-target cleavage is a particularly limiting factor in the 
development of ZFNs specific for the β-globin gene because it has high 
homology with the other globin genes, especially with the δ-globin gene. A 
search for possible homologies was carried out by use of the BLAST 
algorithm (Basic Local Alignment Search Tool) (BLAST). The BLAST query 
was performed by search of the “human genomic database” for regions of 
partial homology with the human β-globin sequence (obtained from the NCBI 
Nucleotide database as a FASTA format sequence) with the settings 
optimised for “highly similar sequences” (megablast). As expected, the result 
of the query indicated the δ-globin gene as the one with the highest level of 
homology with the β-globin gene. This partial homology was especially 
significant in the regions of the three exons (for a more detailed analysis see 
Appendix 1). TS-2 and TS-3 were considered sufficiently different from their 
corresponding δ-globin analogues and therefore a reduced risk of off-target 
cleavage was expected. On the other hand, TS-1 differed from its own δ-
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globin analogue by only one bp indicating the risk of potentially unwanted 
gene modifications that could affect the overall safety and efficacy of a 
possible therapeutic application for a ZFN specific for this target sequence 
(the alignment of the three target sequences to their δ-globin analogues is 
shown in Appendix 1). However, the synthesis of the ZF-DBDs for TS-1 was 
still carried forward because of the opportunity of studying off-target cleavage 
events in the highly homologous globin family and also for the possibility, in 
the future, to improve the specificity and safety of ZFNs.   
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Figure 3.2 ZFN binding and cleavage example and β-globin 
gene sequence.  
a) ZFN binding and cleavage overview. The picture represents a generic ZFN: 
half binding sites are coloured in red and indicated by dashed lines. ZF left 
and right domains are coloured in blue and green, respectively. The FokI 
domain, in its dimeric form is represented in yellow. b) β-globin gene and 
ZFNs binding sites. Exons are in black capitalized characters while introns are 
in blue lower case characters. Residues highlighted in orange are known sites 
for mutations-causing β-thalassaemia and the sickle-cell mutation is 
highlighted in purple. Target sequences TS-1, TS-2, TS-3 are highlighted in 
red, green and yellow, respectively. Left and right half-sites to be bound by 
the proposed ZF domains are underlined.    
 
5’-GATTACAGATTACAGATTACAGATTACAGATTACA-3’!
3’-CTAATGTCTAATGTCTAATGTCTAATGTCTAATGT-5’!
ZF-L1 ZF-L2 ZF-L3 ZF-L4 
ZF-R4 ZF-R3 ZF-R2 ZF-R1 
FokI 
FokI 
Left half binding site 
Right half binding site 
a)  
b) 
caccctgtggagccacaccctagggttggccaatctactcccaggagcagggagggcaggagccaggg
ctgggcataaaagtcagggcagagccatctattgcttacatttgcttctgacacaactgtgttcacta
gcaacctcaaacagacACCATTTGCTTCTGACACAACTGTGTTCACTATAGCAACCTCAAACAGACAC
CATGGTGCACCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATG
AAGTTGGTGGTGAGGCCCTGGGCAGgttggtatcaaggttacaagacaggtttaaggagaccaataga
aactgggcatgtggagacagagaagactcttgggtttctgataggcactgactctctctgcctattgg
tctattttcccacccttagGCTGCTGGTGGTCTACCCTTGGACCCAGAGGTTCTTTGAGTCCTTTGGG
GATCTGTCCACTCCTGATGCTGTTATGGGCAACCCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGG
TGCCTTTAGTGATGGCCTGGCTCACCTGGACAACCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGC
ACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGGgtgagtctatgggacgcttgatgttttctt
tccccttcttttctatggttaagttcatgtcataggaaggggataagtaacagggtacagtttagaat
gggaaacagacgaatgattgcatcagtgtggaagtctcaggatcgttttagtttcttttatttgctgt
tcataacaattgttttcttttgtttaattcttgctttctttttttttcttctccgcaatttttactat
tatacttaatgccttaacattgtgtataacaaaaggaaatatctctgagatacattaagtaacttaaa
aaaaaactttacacagtctgcctagtacattactatttggaatatatgtgtgcttatttgcatattca
taatctccctactttattttcttttatttttaattgatacataatcattatacatatttatgggttaa
agtgtaatgttttaatatgtgtacacatattgaccaaatcagggtaattttgcatttgtaattttaaa
aaatgctttcttcttttaatatacttttttgtttatcttatttctaatactttccctaatctctttct
ttcagggcaataatgatacaatgtatcatgcctctttgcaccattctaaagaataacagtgataattt
ctgggttaaggcaatagcaatatctctgcatataaatatttctgcatataaattgtaactgatgtaag
aggtttcatattgctaatagcagctacaatccagctaccattctgcttttattttatggttgggataa
ggctggattattctgagtccaagctaggcccttttgctaatcatgttcatacctcttatcttcctccc
acagCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAG
TGCAGGCTGCCTATCAGAAAGTGGTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCT
CGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGG
ATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAAtgatg
tatttaaattatttctgaatattttactaaaaagggac!
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3.2.2 Modular assembly of DNA encoding ZF-DBDs for TS-1, 
TS-2 and TS-3 	  
Six different ZF-DBDs (2 for each target sequence) were assembled through 
a process of restriction enzyme digestions and ligations where each single ZF 
module was isolated and then linked to one another in order to obtain 
functional recognition domains (Fig 3.1 a). In order to reduce the time spent in 
the creation of ZFNs, it was decided to commission the synthesis of two ZF 
domains (ZF2-L and ZF3-L) to a third party: the Mr Gene company (see 
Section 2.5.4). Although the use of a third party increased the cost of 
production of the ZF-DBDs, this approach greatly reduced the time spent in 
the assembly process. 
Plasmids encoding the four remaining ZF-DBDs were created following the 
standard modular assembly protocol. Each ZF module was provided, in a 
standard pc3XB plasmid, by the Zinc Finger Consortium through Addgene 
(see Section 2.5.3). The plasmids encoding ZF1-R and ZF1-L DBDs, specific 
for the TS-1 target sequence, were assembled and tested for their binding 
activity by Hitoshi Kurata, a post-doctoral researcher in the Porter lab who 
was involved in the first stages of the project. 
A summary of the six ZF-DBDs is reported in Table 3.1 while the complete 
sequence for each one of the ZF domains is shown in Appendix 1. 
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Table 3.1 Nomencaltue and composition of ZF-DBDs and their target 
sequences in the β-globin gene 
a ZF -DBD b ZF modules 
c Target 
sequences 
name 
d DNA sequence 
ZF1-R ZF60-71-106-94 TS-1 (R) 5’-TGGACGGGTCCC-3’ 
ZF1-L ZF92-103-89-90 TS-1 (L) 5’-TACTTCAACCAC-3’ 
ZF2-R ZF73-104-83-93 TS-2 (R) 5’-CCGGATCGAACC-3’ 
ZF2-L ZF73-93-77-77 TS-2 (L) 5’-CCGACCTAATAA-3’ 
ZF3-R ZF106-75-82-77 TS-3 (R) 5’-GGTCAAAGATAA-3’ 
ZF3-L ZF69-96-74-103 TS-3 (L) 5’-CTGTCCAAATTC-3’ 
 
a  Right and left ZF DBDs are designated by R and L, respectively. 
b ZF modules (arranged from N terminus to C terminus) used during the assembly of 
each domain. Labelling follows the Addgene catalogue’s nomenclature (see 
Appendix 1 for the complete sequence of the ZF-DBDs). 
c Half target sites corresponding to each ZF domain. The highlights are color-coded 
as in Fig. 3.2 
d Actual DNA sequences of each target site.  
 
3.2.3 Assessing ZF-DBD binding activity in the B2H assay 	  
Binding efficiencies of ZF-DBDs created with this type of approach can vary 
greatly due to unwanted interactions between one module and the opposite 
strand of the following binding site. For this reason, each domain’s binding 
activity must be individually tested by use of the bacterial two-hybrid assay 
(Joung, Ramm et al. 2000; Wright, Thibodeau-Beganny et al. 2006).  
The six half-site target sequences (Table 3.1), in the form of short 
oligonucleotides, were cloned in the pBAC-lacZ (carrying a chloramphenicol 
resistance cassette) reporter plasmid immediately upstream of the lacZ 
cassette (pBAC-TS-1(R)-lacZ, pBAC-TS-1(L)-lacZ, pBAC-TS-2(R)-lacZ, 
pBAC-TS-2(L)-lacZ, pBAC-TS-3(R)-lacZ and pBAC-TS-3(L)-lacZ). Each 
pBAC-TS-lacZ was then individually transformed in the bacterial reporter 
strain KJBAC1 (Fig. 3.1 b, see Section 2.5.1 for details).  
Following the modular assembly protocol (Wright, Thibodeau-Beganny et 
al. 2006), the six ZF-DBD's coding sequences were isolated from the pc3XB 
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plasmid by digestion with restriction enzymes and then cloned into the 
expression plasmid pGP-FF (carrying an ampicillin resistance cassette), 
which expresses each domain as a fusion protein with a Gal11 subunit, to 
generate pGP-FF-ZF1-R, pGP-FF-ZF1-L, pGP-FF-ZF2-R, pGP-FF-ZF2-L, 
pGP-FF-ZF3-R and pGP-FF-ZF3-L (Fig. 3.1 b).   
Each newly created pGP-FF-ZF domain was then individually co-
transformed with the pAC-KAN-αGal4 (carrying an kanamycin resistance 
cassette) plasmid into the KJBAC1 reporter strain, already harbouring the 
pBAC-lacZ plasmid (e.g. pBAC-TS1-lacZ) with the appropriate target 
sequence, selecting for bacteria that were resistant to all three antibiotics: 
ampicillin, kanamycin and chloramphenicol (Fig. 3.1 b).  
The transformed KJBAC1 cells were cultured overnight in the presence of 
IPTG and antibiotics in order to express the two fusion proteins (ZF-Gal11P 
and the αGal4-RNA polymerase) and the cultures were tested for expression 
of β-galactosidase (Section 2.7.1). In order to quantify the binding efficiency, 
each experiment was carried out in parallel with a negative and a positive 
control and was repeated multiple times (Fig. 3.3). The negative control was 
created simply by co-transforming the KJBAC1 strain (carrying the relative 
pBAC-ZFTS-LacZ reporter plasmid) with the empty pGP-FF vector and pAC-
KAN-αGal4. Expression of these two plasmids enables the interaction 
between the Gal11P subunit and αGal4-RNA polymerase, but in the absence 
of any ZF-DBD these direct minimal expression of the lacZ cassette. As a 
positive control, a pGP-FB-BA plasmid (Addgene) was used in place of the 
experimental pGP-FF-ZF plasmids. The positive control is provided by 
Addgene and it is based on a previously tested ZF domain that has been 
shown to be highly efficient (Wright, Thibodeau-Beganny et al. 2006). The 
positive control was created by transforming KJBAC cells with the relative 
plasmids (pGP-FB-ZF, pAC-KAN-αGal4 and pBAC-BA-LacZ) as previously 
described. The pGP-FB-ZF plasmid expresses a highly efficient ZF domain 
linked to the standard Gal11 subunit which specifically recognise its own 
target sequence carried by pBAC-BA-LacZ (Fig. 3.3).  
The optical density at 600nm of each culture was determined, as a 
measure of cell density, as well as the β-galatosidase actvity, as measured by 
the velocity of ONPG cleavage (methods). Data collected were analyzed 
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using the formula [V/OD600]/[VNC/ODNC600] where V is the slope of the line 
(velocity) obtained from kinetic data of an experimental culture (such as those 
in Fig 3.3 a), VNC is the equivalent velocity derived from the negative control, 
and OD600 and ODNC600 are the optical density measurements at 600nm of the 
two cultures (sample and negative control, respectively) at the time of the 
experiment. This ratio thus measures fold-increase, relative to the negative 
control, in the β-galactosidase activity for each test culture, normalising for 
any differences in cell density, and the ratio can be taken as a measure of the 
ability of the ZF-DBD in that culture to bind its target sequence. (Fig. 3.3, see 
also Section 2.7.1). 
It is suggested in the modular assembly protocol that, in order to be 
effective in a mammalian model, the binding efficiency of each ZF domain, as 
measured by this ratio, should have a value of at least 3 (Wright, Thibodeau-
Beganny et al. 2006). Unfortunately, of all six ZF-DBDs tested, only one (ZF1-
R) showed a highly satisfactory ratio of 7 (compared with a ratio of 5 for the 
positive control). Of the other five ZF-DBDs, ZF3-R showed a ratio of 2.7 
while the remaining four had a binding efficiency no higher than 1, i.e. no 
better than the negative control (data are summarized in Fig. 3.3).     
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Figure 3.3 β-galactosidase assay and ZF domains’ binding 
efficiencies.  
a) β-galactosidase assay example. The velocity of ONPG cleavage is 
measured as the variation of absorbance at 420nm during time. The positive 
control pGP-FB-BA and the relative negative control are reported in orange 
and blue, respectively. b) ZF domains’ binding efficiencies. This graph 
represents the binding efficiency of all ZF domains (colour coded as in table 
3.1) plus the positive control expressed as the ratio [V/OD600]/[VNC/ODNC600] 
with standard deviation. Each experiment was repeated 4 times except for 
ZF1-R that was repeated 5 times and for the positive control that was 
repeated 6 times.  
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3.2.4 Development of a directed evolution system  	  
Although two early large-scale surveys of the modular assembly approach 
identified a success rate in producing effective ZF domains of 100% and 60% 
(Bae, Kwon et al. 2003; Mandell and Barbas 2006), a more recent and wider 
analysis highlighted how these figures were actually completely inaccurate 
(Ramirez, Foley et al. 2008). The study, which tested a greater number of ZF-
DBDs and a wider spectrum of target sequences, showed a failure rate that 
was calculated to be around 76% with the obvious outcome of a high risk of 
producing ineffective ZF domains.  
Unfortunately this high failure rate matched perfectly with the data 
obtained assessing the newly created ZF domains specific for the β-globin 
gene: only 1 domain out of 6 showing satisfactory binding, indicating a failure 
rate of 83%. In order to obtain more efficient domains and to take advantage 
of the ones already produced, it was decided to modify the newly created ZF 
domains with the aim of enhancing their binding efficiencies.  
A two-step protocol was designed where, in the first step, a library of 
mutated ZF domains, based on the ones already produced, would be created 
through random mutagenesis. Thus, error-prone PCR would introduce 
random mutations in the coding sequence generating a number of similar ZF 
domains with a wide range of binding efficiencies that could then, in a the 
second step, be screened to select the most effective ones. This second step 
would be carried out through a selection system based on the B2H assay 
where a higher binding efficiency of the ZF protein would confer a survival 
advantage to the cells expressing it (Fig. 3.4). 
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Figure 3.4 Directed evolution system.  
a) ZF domain variants library. The first step of the directed evolution approach 
involves the creation of a wide library of ZF domain mutants through error 
prone PCR. b) Zeocin selectable system. In the second step, the newly 
created library is screened for ZF domains with improved binding efficiencies. 
A modified B2H system carrying a ZeoR selectable marker in place of the 
original lacZ cassette is used to rapidly select between different ZF domains. 
Efficient binding of a possible domain leads to the expression of the ZeoR 
cassette providing a survival advantage to the cell expressing it. c) OPEN 
selectable system. This alternative version of the selectable system was 
based on a double selection approach where two different markers (the 
recovery of the histidine pathway by HIS3 and streptomycin resistance by 
aadA) should increase the efficiency of the screening process. 
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Zeocin selection approach: The first selection system to be tested was 
based on the activation, through the binding of ZF domains, of a zeocin 
resistance cassette (Fig. 3.4 b). The lacZ cassette from pBAC-TS-1(R)-lacZ 
and pBAC-TS-1(L)-lacZ reporter plasmids was removed by restriction enzyme 
digestion and substituted with a zeocin resistance cassette creating the 
pBAC-TS-1(R)-ZeoR and pBAC-TS-1(L)-ZeoR plasmids that were then 
transformed into the standard KJBAC1 strain (this cloning step was performed 
by Hitoshi Kurata, a post doc working on the initial phase of this project). 
In order to confirm the ability of the system to effectively discriminate 
between different ZF binding activities, the pGP-FF-ZF1-R and pGP-FF-ZF1-L 
were selected as positive and negative controls, respectively, based on their 
behaviour in the B2H assay (fig 3.3 b). Each plasmid was co-transformed with 
pAC-KAN-αGal4 into KJBAC1 cells harbouring the appropriate pBAC-ZeoR 
selection plasmid. pGP-FF-ZF1-R was paired with the pBAC-ZeoR containing 
the TS-1(R) target sequence (pBAC-TS-1R-ZeoR) while pGP-FF-ZF1-L was 
paired with the one containing the TS-1(L) target sequence (pBAC-TS-1L-
ZeoR). Transformants (from now on called KJ-Zeo-pos and KJ-Zeo-neg for 
positive and negative controls, respectively) were selected overnight on agar 
plates with all three antibiotics (ampicillin, chloramphenicol and kanamycin). 
To test for ZF-DBD dependent zeocin-resistance, the day after, individual 
colonies were picked and grown overnight in 4 ml low-salt LB (high ionic 
strength inhibits the antibiotic activity) containing ampicillin, chloramphenicol 
kanamycin and IPTG (from now on shorten to amp-kan-cam-I) but not zeocin. 
The day after, 10 µl of the inoculum were collected and used to start a fresh 
culture in 4 ml low-salt LB (amp-kan-cam-I) and 25 µg/ml zeocin (Section 
2.2.1).  
Bacteria growth was monitored by periodically measuring (by means of a 
spectrophotomiter) the OD of the culture at 600 nm until OD reached values 
of 0.8. Unfortunately both controls grew in presence of zeocin without any 
significant distinctions between positive and negative. For this reason, 
different concentrations of zeocin (between 25 and 50 µg/ml, as suggested by 
the manufacturer) were used in order to increase the stringency of the 
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selection but the negative control was still growing in presence of the 
antibiotic. The genotype of KJBAC1 (obtained from Addgene and reported in 
Section 2.2.2) seems to indicate a lack of inactivation of the recA1 pointing 
out the risk of internal recombination between the three different plasmids 
(pGP-FF-ZF1, pAC-KAN-αGal4 and pBAC-TS-1-ZeoR). In order to rule out 
any possible acquired constitutive zeocin resistance derived from a 
recombination event, a different cell line (JM109, a known recA1 strain) was 
tested. JM109 cells were transformed with pBAC-ZeoR harbouring the two 
different target sequences (creating novel positive and negative control) and 
the test was repeated following the previously described approach.  
Unfortunately, also in this case, both positive and negative controls grew in 
presence of zeocin reaching OD600 0.8 at the same time. The results at this 
point apparently indicated that the problem was related not to the host strain 
or to the antibiotic concentration, therefore it was supposed that the ineffective 
selection was due to some characteristic of the medium itself. The 
manufacturer (Invitrogen) protocol for the zeocin states that the antibiotic is 
stable and effective in a very narrow pH window (around pH 7.5). Therefore it 
was decided to test the pH of the medium by measuring it using a pH meter 
(Hanna Instruments, HI 931410). The pH of the low-salt LB medium, before 
any bacteria growth was started, was found to be around pH 6.3 and thus 
identified as a possible cause of the antibiotic inefficiency. The pH of the low-
salt LB was therefore corrected to the desired value of pH 7.5 with NaOH and 
the medium was then used in the next series of experiments using fresh KJ-
Zeo-pos and KJ-Zeo-neg transformants. Using this medium it became 
possible to discriminate between positive and negative controls but this test 
was carried out, due to the small volume of the culture (4 ml), only during a 
period of 4-5 hours therefore a prolonged test was carried out overnight in 
order to assess the stability of the zeocin selection during a prolonged period 
of time. 
The novel test was carried out for both positive and negative controls by 
picking single colonies from fresh KJ-Zeo-pos and KJ-Zeo-neg transformants 
and by directly inoculating 4 ml low-salt LB (amp-kan-cam-I) containing 25 
µg/ml zeocin and incubating overnight. Unfortunately, the pH was shown (by 
use of pH paper indicators, Whatman narrow range indicator) to change 
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during the night with an acidification of the medium. This pH variation 
probably reduced the effectiveness of zeocin and, although the negative 
control didn’t grow during the first 16-18h (the overnight incubation), presence 
of bacteria growth was identified immediately after (20 to 24 h) by direct 
observation and confirmed by OD600 measurement. This result was 
considered unacceptable for a strong and reliable selection system and for 
this reason it was decided to move the selection step in solid medium.  
Low-salt LB agar plates were shown, by use of pH paper indicators, to 
have a pH of ≈ 7 and to maintain it constant during a period of 48 h in 
presence of both the three antibiotics (ampicillin, kanamycin and 
chloramphenicol) and in presence of KJ-Zeo-pos and KJ-Zeo-neg.  
A new set of experiments was carried out by picking single colonies from 
KJ-Zeo-pos and KJ-Zeo-neg transformants and starting overnight inoculi (in 4 
ml low salt LB amp-kan-cam-I). The day after, 105 cells from these overnight 
cultures were plated on low-salt LB agar plates (amp-kan-cam) containing 25 
µg/ml zeocin with or without IPTG (to test if the system was still under the 
control of IPTG).  
Plates were incubated at 37°C for 16-18h and then the number of colonies 
was counted. This experiment was repeated 4 times in order to confirm 
reproducibility. The number of colonies for each experiment is shown in Table 
3.2.  
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Table 3.2 Zeocin selection test on low-salt LB agar plates 
 Sample +IPTG -IPTG 
d Age of 
transformants 
b Positive control 143 25 
a Experiment 1 
c Negative control 0 0 
1 day 
b Positive control 100 20 
a Experiment 2 
c Negative control 0 0 
1 day 
b Positive control >100 >100 
a Experiment 3 
c Negative control >100 >100 
6 days 
b Positive control 30 11 
a Experiment 4 
c Negative control 0 1 
2 days 
a	  Positive and negative controls were grown at 37°C for 16-18h on low-salt LB agar 
(amp-kan-cam), pH 7 in presence 25 µg/ml zeocin with or without IPTG.  
b KJ-Zeo-pos.  
c KJ-Zeo-neg. 
d This column reports the age of the KJ-Zeo-pos and KJ-Zeo-neg transformants at 
the time when the four different selection experiments were carried out.  
 
The data obtained from experiment 1, 2 and 4 showed how the selectable 
system on a solid-state medium was able to discriminate between positive 
and negative control and between presence and absence of IPTG, however, 
the number of colonies, for the positive control, was extremely low compared 
to the number expected from a plating of 105 cells probably suggesting low 
levels of activation of the zeocin resistance cassette by the ZF1-R domain.  
Furthermore, unclear results were found in experiment 3 where six days 
old KJ-Zeo-pos and KJ-Zeo-neg transformants were used (measured as the 
time elapsed between transformation of KJBAC1 cells with the three pGP-FF-
ZF1, pAC-KAN-αGal4 and pBAC-TS-1-ZeoR plasmids and the carrying out of 
the zeocin selection experiment). Colonies were obtained on all plates without 
any distinction between positive or negative control and presence/absence of 
IPTG and the number of colonies was higher than in the other experiments.  
These results probably suggest that zeocin resistant cells developed with 
time in a manner that does not require IPTG indicating that, perhaps, DNA 
Chapter 3: Creation of zinc finger binding domains by modular assembly and 
development of a “directed evolution approach” 
	   112	  
rearrangements of the zeocin resistance cassette were occurring conferring a 
constitutive resistance to the antibiotic.  
Although the reasons are not clearly explained, the modular assembly 
protocol states that KJBAC1 cells transformed with the three plasmid pBAC-
lacZ, pGP-FF and pAC-KAN-αGal4 are stable only for a week, after which, 
the cells grow poorly or not at all (Wright, Thibodeau-Beganny et al. 2006). 
Although experiment 3 showed the opposite outcome, it was decided to check 
further the importance of time elapsed between the transformation and the 
starting of the zeocin selection of each single experiment (Table 3.2). 
In order to confirm a possible connection between the age of the cultures 
and the acquired zeocin resistance, one-week-old KJ-Zeo-pos and KJ-Zeo-
neg transformants, created by transforming KJBAC1 cells with the three pGP-
FF-ZF1, pAC-KAN-αGal4 and pBAC-TS-1-ZeoR plasmids and then storing 
the agar plates containing the transformants at 4°C for 7 days, were used to 
repeat the experiment previously described in Table 3.2. The results obtained 
from this novel experiments mirrored the one found for experiment 3 (Table 
3.2) and therefore confirming the initial observation that old transformants 
were all resistant to zeocin showing a possible constitutively expressed 
resistance cassette.  
Although the selectable system proved to be more effective in a solid 
medium support than in a liquid one, in addition to the very low number of 
colonies detected on the positive controls for experiments 1, 2 and 4 (≈ 100 
colonies compared to the 105 cells plated), a new reason for doubting the 
reliability of the whole process was identified by examining the shape and size 
of colonies obtained during zeocin selection. Colonies growing on the positive 
controls from the previous 4 experiments did not present homogeneous sizes, 
on the contrary, 3 different types of colonies were identified: small, medium 
and big. This could have reflected different expression of zeocin resistance 
gene in different clones, but when different colonies were picked, cultured 
overnight in 4 ml low-salt LB (amp-kan-cam-I) and then plated again on low-
salt LB agar plates (amp-kan-cam-I) containing 25 µg/ml zeocin the same 
mixed population of small, medium and big colonies was detected on all 
plates without any distinction. It therefore seemed that the ability of clones to 
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grow in zeocin was variable during time and that single cells in the same 
“clone population” acquire different sensitivity to the antibiotic. 
 The testing of the zeocin selectable model identified a series of flaws that 
seriously reduced the efficiency of the selection system. The stability of the 
antibiotic plus the different sizes of the colonies and the actual inefficiency of 
the selection (with a very small number of zeocin resistant colonies for 105 
plated cells in the positive control) pointed towards a possible genomic 
instability of the KJBAC1 strain, to plasmid incompatibility problems or to 
some inefficiency of the zeocin resistance cassette and were considered 
enough to decide to discard the zeocin selection in favour of a more reliable 
selectable marker. 
 
 
OPEN selection approach: At the same time that the zeocin selectable 
system was developed, an alternative B2H selection system was designed 
and published by the same group that created the modular assembly protocol 
(Maeder, Thibodeau-Beganny et al. 2009). Although it was designed to 
screen large libraries of ZF domains produced through a phage expression 
technology, the system employed an attractive selection strategy, where the 
resistance to streptomycin and the rescue of the histidine pathway confer a 
powerful double selection, that was considered as a potential improvement on 
the zeocin selection used in the previous section. 
This new selectable system is based on a modified B2H system were the 
pBAC-lacZ plasmid is substituted by an F’ episome containing the possible ZF 
target site close to a HIS3 and aadA (histidine pathway gene and 
streptomycin resistance, respectively) cassette (Fig. 3.4). As in the standard 
B2H assay, pGP-FF and pAC-αGal4 (an analogue of pAC-KAN-αGal4 that 
differs from it for having a chloramphenicol resistance instead of kanamycin 
resistance) plasmids are co-transformed in cells containing the F’ selection 
episome: co-expression of the pGP-FF and pAC-αGal4 plasmids, followed by 
the effective binding of the ZF domain and recruitment of the αGal4-RNA 
polymerase fusion protein, leads to the transcription of the selectable markers 
conferring resistance to streptomycin and, at the same time, rescuing the 
histidine pathway. 
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In order to assess the efficiency of this model, the same pGP-FF-ZF1-R 
and pGP-FF-ZF1-L were used as positive and negative controls, respectively. 
The first step involved the creation of the two F’ episomes carrying the target 
sequences for both positive and negative controls. TS-1(R) and TS-1(L) 
sequences were initially cloned in the pKJ1712 plasmid close to the HIS3 and 
aadA cassette creating pKJ1712-TS-1(R) and pKJ1712-TS-1(L). This region 
of the plasmid is flanked by a lacIq and lacZ genes that are homologues to the 
lacIq and LacZ sequences found on the F’ episome harboured by the CSH100 
bacteria strain (Fig. 3.5 a). 
Transformation of the CSH100 strain with the pKJ1712 plasmid allows 
double crossover events to occur between the homology regions of both 
pKJ1712 and the F’ episome and, therefore, the transfer of the target 
sequence HIS3 and aadA cassette (Fig. 3.5 a). As a final step, the mating of 
the newly created CSH100 cells with the KJ1C (F-) bacterial strain, through 
conjugation, permitted the transfer of the episome and the creation of the final 
KJ1C selectable strain. Presence of F’ episomes that underwent effective 
double-crossover events was ensured by double selection with kanamycin 
and sucrose. The presence of the KanR cassette would confer resistance only 
to cells harbouring the newly created HIS3-aadA cassette while negative 
selection through the sacB gene would exclude any F’ episome that 
underwent only one crossover event with the pKJ1712 plasmid (Fig. 3.5 b). 
The positive control was created co-transforming pGP-FF-ZF1-R (ampR) 
and pAC-αGal4 (CamR) in the KJ1C strain harbouring the TS-1(R) F’ 
episome (KanR) and the negative control was created co-transforming pGP-
FF-ZF1-L (ampR) and pAC-αGal4 (CamR) in the KJ1C strain harboring the 
TS-1(L) F’ episome (KanR). 
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Figure 3.5 OPEN selection system. 
 a) Creation of the F’ selectable episome. Double cross-over event between 
the identical lacIq and LacZ present on both the pKJ1712 plasmid and F’ 
episome creates the final selectable episome carrying the target sequence 
and the two selectable markers HIS3-aadA. KanR selectable marker is used to 
positively select for recombinant in KJ1C bacterial strain after conjugation, 
sacB instead is used as negative selection for single recombinant. b) KJ1C 
bacterial strain after conjugation with CHS100. The mating between the two 
bacterial strains permits the transfer of the F’ selectable episome to the KJ1C 
cell and creation of the final selectable bacterial strain. Conjugated KJ1C cells 
are then selected in kanamycin and sucrose for the acquisition of a double 
recombinant F’ episome. Only KJ1C carrying a double recombinant episome 
will be able to grow thanks to the acquired KanR and the absence of the 
counter-selectable marker sacB that kills cells in presence of sucrose.  
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The reliability of the system was assessed through a series of preliminary 
tests in order to identify possible problems like the one encountered during 
the zeocin approach. Positive and negative controls were picked up as single 
colonies from fresh transformants plates and were grown overnight in a 4 ml 
liquid culture in presence of ampicillin, kanamycin, chloramphenicol and IPTG 
in order to start to express the ZF domains. The day after ≈ 105 cells were 
plated on minimal medium agar plates in presence of 20 µg/ml streptomycin 
and incubated at 37°C (minimal medium was used in order to enforce the 
HIS3 selection step). The OPEN protocol suggests carrying out selection on 
minimal plates for 48h. After 18h it was not possible to identify any kind of 
growth on the positive and negative controls but after 48h, instead, ≈ 200 
colonies of variable sizes started to form on the positive control. 
Unfortunately, it was immediately evident that also this new approach suffered 
of selection problems: some kind of bacterial growth was detected also on the 
negative control in the form of a very thin layer of bacteria. This thin layer was 
not growing enough to form colonies but was still discernible from samples 
plated with ≈ 105 cells of untransformed KJ1C where no kind of growth was 
detected.  
In order to assess the contribution of the levels of antibiotic during the 
selection, standard LB agar plates with different concentrations of 
streptomycin (between 5 µg/ml and 40 µg/ml) were used. Positive and 
negative controls were picked up as single colonies from fresh transformants 
plates and were grown overnight in a 4 ml liquid culture in presence of 
ampicillin, kanamycin, chloramphenicol and of IPTG. The day after ≈ 105 cells 
were plated and then incubated for 24h. Also in this case the results obtained 
were unclear: a small number of colonies (≈ 100) were detected on both 
negative and positive controls for antibiotic concentrations below 15 µg/ml 
and no colonies at all were detected for concentrations above 20 µg/ml. The 
OPEN protocol suggests to proceed with two steps of selection: the first with 
the expression of the ZF-DBD plus the αGal4-RNA polymerase driven by 
IPTG and the second, more stringent, without IPTG induction. For this reason, 
the selection test described above was repeated using a streptomycin 
concentration of 20 µg/ml in absence of IPTG induction. In this case a small 
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number of small colonies (≈ 20) were detected after 48h on both positive and 
negative controls without distinction.  
At this point it was decided to rule out possible effects due to the presence 
of IPTG. Cells from both fresh positive and negative controls transformants 
were grown overnight in a 4 ml liquid culture in presence of ampicillin, 
kanamycin, chloramphenicol but in absence of IPTG. The day after ≈ 105 
were plated on standard LB agar plates (with ampicillin, kanamycin, 
chloramphenicol) in presence or absence of IPTG and without streptomycin. 
While cells from negative control were growing on both ± IPTG plates (more 
than 500 colonies for each plate), cells from the positive control were growing 
in absence of IPTG (more than 500 colonies) but, in presence of IPTG, 
showed a highly reduced growth rate (≈ 100 colonies). This last experiment 
highlighted a possible toxic effect probably due to the expression and binding 
of the ZF domain to its target sequence. 
Due to the ongoing problems that occurred during the creation of the two 
selectable systems, it was decided to seek an alternative approach to obtain 
functional ZFNs specific for the β-globin gene. After raising enough funds, it 
was possible to take advantage of a commercially available platform offered 
by Sigma-Aldrich that, during that period of time, had acquired the patent from 
Sangamo Bioscience to use their technologies to commercially produce ZFNs 
under the name of CompoZr. Although the service provided by Sigma is 
highly expensive (£20,000 at the time of the purchase), the company supplies, 
in a short amount of time, functional ZFNs designed for any desired gene and 
that have been already validated in a mammalian model. For this reason and 
also for the increasing amount of time required to optimize the selectable 
systems, it was decided to indefinitely postpone the development of the 
directed evolution approach and concentrate the effort towards the 
characterization of the newly acquired ZFN.  
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3.3 Discussion 
 
3.3.1 Identification of target sequences in the human β-globin 
gene 	  
A traditional induced gene correction is achieved thanks to homologous 
recombination between the desired targeted gene and a DNA donor template 
that carries the desired mutation (or correction) to be introduced, flanked by 
two regions homologues to the target sequence. Typically, only a small tract 
of the gene is corrected and, if the genetic disease to be cured can be caused 
by any one of possible mutations localized in the gene (as is the case for β-
thalassaemia), multiple ZFNs and donor templates have to be created (one 
for each mutation or cluster of mutations). An alternative to this approach is to 
introduce, through targeted gene insertion into a suitable location, an 
expression cassette for the therapeutic gene. This approach may present 
some problems in the regulation of protein levels and also because the 
defective endogenous protein is still expressed. The fine regulation of 
expression of β-globin protein and the balance with the α-globin are of 
paramount importance for the effective development of functional hemoglobin 
molecules. For this reason it was decided to use the first type of approach and 
to introduce corrections in the endogenous gene in order to restore the natural 
levels of β-globin protein.  
The choice of the nuclease (ZFN) target sequences is a critical step 
because the efficiency of correcting a specific mutation by HR decreases with 
increasing distance between the DSB produced by the ZFN and the location 
of the mutation. β-thalassemia is caused by more than 200 point mutations 
and deletions that are located along the β-globin gene not evenly but 
clustered mostly in the region of the 3 exons. Of the 50 possible target 
sequences, identified using the ZiFiT software, three were chosen for their 
specific position in the β-globin gene. It has been shown that, although the 
frequency of gene correction decreases with an increase of the distance 
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between mutation and DSB, gene correction of mutations as far as 400 bp 
upstream or downstream of the DSB produced by a ZFN can be corrected 
(Porteus 2006). The three target sequences chosen are actually no further 
away than 200 bp from all known β-thalassemia mutations and therefore are 
potentially useful for a possible therapeutic approach. 
 TS-1 and TS-2 are located in the first exon and first intron respectively 
close to a know cluster of β-thalassemia mutations and, in the case of TS-1, 
also close to the sickle cell mutation (allowing the possible correction of two 
different diseases). TS-3, instead, is found at the end of the second intron, 
close to a second group of mutations located on the third exon. 
A further consideration that affected the selection of the target sequences 
was the risk of possible off-target cleavages. The β-globin gene shares a 
strong homology to the other family of the human globin genes and for this 
reason there is a high risk that poorly designed ZFNs could produce DSBs 
also in other region of the chromosome, inducing a higher rate of cell death 
after transfection and, more importantly, the risk of chromosome 
rearrangements and oncogenesis following DNA damage. In order to assess 
this problem, the chosen target sequences were analyzed, using the BLAST 
algorithm, for possible homologies or partial homologies with other regions of 
the human genome. Although a BLAST query is able to detect regions of 
partial homology, the algorithm was not specifically developed to identify 
possible ZFNs off-target sites and therefore could miss potential critical sites. 
An alternative to BLAST queries was developed in recent years (2011) in the 
form of the web-based software ZFN-site (Cradick, Ambrosini et al. 2011). 
This program has an improved algorithm that helps in the search for ZFN 
cleavage sites and at the same time identifies a wider range of possible off-
target cleavage using “degenerate specificities” that take in account 
ambiguities in the binding activity of each ZFN subunit.  
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3.3.2 Modular assembly of DNA encoding ZF-DBDs for TS-1, 
TS-2 and TS-3. 	  
The process of assembling ZF domains, although being based on simple 
steps involving standard cloning techniques, is time consuming and, due to 
the many cloning steps involved, can be affected by errors especially during 
the enzymatic digestion and ligation steps. For this reason each cloning step 
had to be checked for possible inaccuracy by sequencing and, when 
detected, errors had to be corrected by stepping back to the previous cloning 
step increasing the amount of time spent in the creation of the ZF-DBDs. If it 
is considered that, in order to employ the ZFNs in a mammalian model, the ZF 
domains have to be produced by time consuming cloning techniques and 
have to be tested in a bacterial two hybrid assay (that has itself to be created) 
the time spent in the process is substantial, especially considering that 6 
different ZF domains (2 for each target sequence) had to be created. For this 
reason it was decided that, although more expensive, two of the ZF domains 
(ZF2-L and ZF3-L) would be produced by a company effectively reducing the 
time employed in creating all ZF domains and reducing also the risk of 
introducing errors in the final ZF domain expression plasmids. On the other 
hand, the kit provided by Addgene has a complete library of ZF modules that 
can be used to create multiple binding domains specific for almost any 
possible target sequence and therefore, after an initial period of optimisation 
of the protocol, a research group could be able, in theory, to create a wide 
range of ZFNs without the need of external support or new materials, reducing 
greatly the costs.  
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3.3.3 Assessing ZF-DBD binding activity in the B2H assay 	  
The modular assembly protocol was chosen for this project mainly for its 
affordability and (perceived) simplicity in creating effective ZF domains. The 
choice was supported even more by the, supposedly, high efficiency in 
creating effective ZFNs highlighted in two different papers (Bae, Kwon et al. 
2003; Mandell and Barbas 2006). Unfortunately, both assessments largely 
overestimated the real efficiency of the approach due to limited sampling of all 
possible ZF modules. Although these two studies examined the binding 
activity of a wide number of ZF domains made of 3 modules (specific for a 9 
bp target sequence), most of the domains were composed by at least 2 
modules that would recognize a GNN (where NN are any bases) sub-site. A 
later paper, which was published concurrently with the development of this 
project, assessed the discrepancy between the expected efficiency and the 
actual higher failure rate (Ramirez, Foley et al. 2008). Ramirez et al examined 
168 different ZF domains capable of binding also target sites containing 1 or 
no GNN sub-sites (that are the majority of all possible target sequences made 
of 9 bp). The study highlighted how ZF domains, created through the modular 
assembly approach and that would bind to target sequences containing no 
GNN sub-sites, would be highly ineffective reducing the overall efficiency of 
the approach to a mere 25%.    
These results were unintentionally confirmed by the assessment of the 
newly created ZF domains specific for the β-globin gene, where only one 
showed a satisfactory binding efficiency. Considering that a ZFN in order to 
produce a DSB has to be composed of two different ZF domains, the overall 
efficiency in producing effective ZFNs will be reduced to 6%. Even these low 
estimate, which is based on the B2H assay, may be misleading because in 
mammalian cells it could be even lower due to difference of binding activity of 
ZF domains in bacterial and mammalian cells (Cathomen and Joung 2008). 
A second factor that almost certainly contributes to poor binding activity of 
ZF domains, may be the inability of the modular assembly approach to take 
account of the so called “context dependent effect” (explained in more details 
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in Section 1.10) that involves the interaction of neighbouring ZF modules with 
the final outcome of a general reduction of the binding efficiency of the 
domain (Cathomen and Joung 2008). 	  
 
3.3.4 Development of a directed evolution system 
  
In order to assess the problems identified in the modular assembly protocol, 
members of the Zinc Finger Consortium developed in 2009 a completely 
different approach for the creation of new ZFNs: the OPEN system (Maeder, 
Thibodeau-Beganny et al. 2009). This protocol still has the advantage of 
being completely open-source and affordable but at the same time has a 
higher success rate due to a totally different approach in selecting effective ZF 
domains. While the modular assembly protocol considered each single ZF 
module more or less as an independent unit when binding to the target 
sequence, the OPEN approach takes in account the possible interactions 
between neighbouring modules and the effect on their binding efficiency. 
Although this newly developed approach promised to be a reliable 
alternative to the modular assembly protocol, when the ZiFiT software (that 
has been adapted to be used in conjunction with this new protocol) was used 
to identify possible target sequences in the β-globin gene, it was not able to 
identify any. The reason for this was that the ZF libraries to be used were still 
under development and the choice of possible ZF modules was still very 
limited. Furthermore, the techniques involved in the OPEN protocol are time 
consuming and labour-intensive requiring the creation of phage-based 
combinatorial ZF libraries that would take expertise and time to set up.  
Instead, the approach that was taken, which was conceived before the 
OPEN protocol was published, did not involve small ZF libraries but took 
advantage of the already created ZF domains that would not be discarded but 
instead would be improved through a directed evolution system. The idea was 
based on the combination of two techniques: the creation of pools of randomly 
mutated ZF-DBDs, based on the ones that were already produced by the 
modular assembly approach, and a selectable system where effective binding 
would confer a survival advantage to the cell expressing it. The latter was a 
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simple extension of the B2H system replacing the lacZ cassette with a gene 
conferring an antibiotic resistance. This would have the advantage of reducing 
the time spent in generating new ZF domains and could overcome the 
problematic of context dependent effects. In the case of this project this 
approach was potentially attractive because one of the six ZF domains 
already showed a very high binding efficiency (ZF1-R) and the possibility of 
improving the corresponding domain (ZF1-L) would have lead to the quick 
and effective creation of a functional ZFN.  
The creation of mutated ZF libraries is a method that has already been 
used with success in order to produce the wide range of ZF modules capable 
of targeting all possible 64 trinucleotides. Binding specificity of ZF proteins is 
determined by a very small number of amino acid residues (see Section 1.9) 
located in the N-terminus of the ZF α-helix and the modification of these key 
residues has been shown to greatly affect binding activities (Rebar and Pabo 
1994; Segal, Dreier et al. 1999). 
The selectable system developed was based on zeocin selection and, 
although it was able to discriminate between positive and negative controls, it 
presented a series of problems that cast doubts on the usefulness of the 
system. Although low-salt LB, optimized pH and solid media were used in 
order to increase the effectiveness of the zeocin selection, the results 
obtained during the preliminary tests where unsatisfactory due to the lack of 
stability of the antibiotic at different pH values, to the variable response of the 
bacteria cells to the antibiotic (identified by different sizes of colonies) and due 
to a low growth also from the ZF1-R-DBD positive control (that, by contrast, 
responded incredibly well in the standard B2H assay). 
A deeper analysis of the problems would be required in order to 
understand clearly all the factors involved in the poor efficiency of the 
selectable system but a possible explanation could be the presence, in the 
bacterial strain, of multiple plasmids carrying different antibiotic resistances (to 
ampicillin, kanamycin, chloramphenicol and zeocin) and a possible genetic re-
arrangement between this multiple DNA molecules. A possible sign of genetic 
instability is the presence on plates of colonies of different sizes and their 
ability to form also from one single clone. A possible internal re-arrangement 
could be also explained through the mechanism of action of zeocin antibiotic 
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that is a copper-chelated glycopeptide that, after activation inside the cell 
through the removal of the copper ion, binds and cleaves the DNA producing 
extended DNA damage. If the antibiotic, for any reason, is not able to kill 
immediately the cells, it could instead promote a possible genetic re-
arrangement between the different plasmids present in the cell. 
For these reasons the zeocin approach was discarded in favour of a more 
complex, and possibly more robust, selection system based on the one 
already developed by the Zinc Finger Consortium group for the OPEN 
protocol (Maeder, Thibodeau-Beganny et al. 2009). This approach also 
resembles the original B2H system but it relies on the action of two selectable 
markers combined together.  
Although this double selection has been shown to be effective for the 
OPEN protocol, it was clear that, in the context of the directed evolution 
approach, it presented similar difficulties to the zeocin system. The problems 
involved in the double selection, the presence of a partial bacterial growth on 
the negative control and the unclear effect of IPTG on the positive control are 
factors that have to be addressed in order to create a robust selection 
method. From the data collected, it seems that expression of the ZF domain 
and its binding to the target sequence were connected to a decrease in 
bacterial growth, probably due to toxic effects related to the expression of the 
selectable markers or expression of the two fusion proteins expressed by 
pGP-FF and pAC-αGal4.  
The difficulties experienced during the development of the two directed 
evolution approaches and the increasing amount of time spent were 
considered excessive and a different system was sought in order to obtain 
functional ZFNs. The arrival of new fundings and, at the same time, the 
creation of a commercially available platform by Sigma for the creation and 
testing of novel ZFNs were two decisive factors in the decision to set aside 
the directed evolution approach and concentrate the effort not in the actual 
creation of the ZFNs proteins but in the development and characterization of a 
feasible technique to introduce gene corrections at the level of the β-globin 
gene.  
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4 Chapter 4: Assessing the ability of commercially 
sourced zinc finger nuclease to cleave the human 
β-globin gene 
 
4.1 Overview 
 
The process of producing and testing ZF-DBDs using the modular assembly 
approach for the creation of novel ZFNs specific for the β-globin gene has 
been time consuming and, more importantly, ineffective. Although the Zinc 
Finger Consortium groups have worked towards the creation of an improved 
protocol (Maeder, Thibodeau-Beganny et al. 2009) that would be more 
effective in the creation of functional ZFNs, the archive of novel ZF modules 
was still under development when this project was in need of an alternative 
approach for the creation of β-globin-specific ZFNs and therefore the 
acquisition of a commercially produced ZFN was chosen as an alternative. 
Commercial ZFNs are now produced and sold by Sigma-Aldrich using 
technologies and resources developed by the American biotech company 
Sangamo Bioscience.  
Although during the 1990s various institutions and private companies have 
steadily filed patents based on ZF proteins technologies, Sangamo 
Bioscience has proved to be the more competitive and effective company in 
the field of ZF proteins and, since then, has acquired most of the licences like 
the one owned by Chandrasegaran for the fusion of DNA binding proteins to 
the cleavage domain of the FokI endonuclease (Scott 2005) or directly buying 
entire companies like Gendaq Ltd, a British biotech company founded by 
Aaron Klug and that had patents on methods for the creation of ZF binding 
proteins based on libraries of “two-zinc-finger“ domains (Chandrasekharan, 
Kumar et al. 2009). 
Sangamo Bioscience is a biotech company founded in 1995 with the aim 
of developing and commercialising DNA binding proteins for regulation and 
modification of plant and animal genomes in the research and therapeutic 
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fields. Their strategy was based on the creation of a proprietary technology 
platform based on natural occurring ZF proteins: DNA binding proteins that 
are present, as transcriptional factors, in many different higher organisms. In 
the following years Sangamo tested its technology platform creating ZF 
proteins specific for novel DNA target sequences with the aim of creating two 
main molecular tools: ZF protein activators/repressors to be used as 
therapeutic gene regulators and ZFN to be used as gene-editing tools 
(Sangamo-Bioscience).  
The Sangamo approach has proved to be highly successful and the 
developed technology has led to creation of a therapeutic program in 
advanced stage (a phase 2 trial for the treatment of HIV/AIDS), a therapeutic 
program for haemophilia (in a preclinical stage) and research programs in the 
treatment of cancer, Parkinson’s disease, monogenic disease and 
neuropathic pain (Sangamo-Bioscience 2012).  
Sangamo has established commercial partnership with different 
companies including, in 2007, a deal with Sigma-Aldrich Corporation for 
research purposes in order to develop Zinc-Finger based laboratory reagents 
(Sangamo-Bioscience 2007). 
In 2008, Sigma-Aldrich, under the name CompoZr, started to 
commercialize the production of customised ZFNs to be used for production 
of gene knock-outs, gene corrections or gene additions (see Section 1.10). 
The custom design technology provided by the company allows the creation 
of ZFNs for specific target sequences following a 4 stages process. In a first 
step, the Sangamo proprietary algorithm (Super Finder Algorithm) is used to 
design a group of possible ZFNs specific for the desired genomic region. A 
selection of target candidates is then sent back to the custumer for approval. 
ZFN candidates are then assembled using ZF modules derived from 
Sangamo’s archive and, in a final step, the candidates are tested and 
validated in a relevant cell line using a mismatch assay (Cel-I assay). The 
process typically takes 10-15 weeks, after which the best performing ZFN pair 
is sent to the costumer to be used for research purposes (Sigma-Aldrich).  
Ordering functional ZFNs directly from a company such as Sigma is 
financially demanding but has a series of advantages: while the “DIY” 
approaches, such as the Modular Assembly or the OPEN systems, are 
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cheaper and can be used in theory to produce ZFNs specific for a great 
variety of possible target sequences, the techniques involved are time 
consuming and the process requires the creation of multiple ZFNs for the 
same gene due to the risk of low cutting efficiencies. These limiting steps are 
particularly onerous for small research groups with limited experience and a 
small workforce. In contrast, Sigma has a dedicated and experienced team 
that, in theory, in a short period of time is able to design, test and deliver 
functional ZFNs reducing the workload for the researcher. Two additional 
advantages make Sigma’s approach a more valuable option: first of all Sigma 
uses for the creation of novel ZFNs the Sangamo’s proprietary archive of 
“two-zinc-finger“ domains that seems to work better than assembling single 
module, probably because its use minimises the context dependent effect 
(described in Section 1.10 and Chapter 3). A second important advantage is 
the type of engineered obligate heterodimer FokI domain that the company 
use and that was not included in the original Modular Assembly approach. 
Creating DSBs at specific loci has opened the way to potentially engineer 
the genome of many different organisms but, unfortunately, expression of 
ZFNs can lead to high levels of cytotoxicity that are probably due to off-target 
cleavage events (Porteus and Baltimore 2003; Alwin, Gere et al. 2005; 
Beumer, Bhattacharyya et al. 2006). Off-target cleavage is a major concern in 
the development of a successful and safe gene-editing technique for two main 
reasons. First, increased cytotoxicity in treated cells reduces the number of 
viable cells and therefore the overall efficiency of gene editing. Second, 
unwanted ZFN-induced modifications at off-target loci increase the risk of 
mutagenesis and, in a clinical setting, oncogenesis (Cathomen and Joung 
2008). The risk of off-target cleavage is greatly increased by the formation of 
ZFN homodimers (i.e. left-left or right-right ZFNs) that depend on the 
interaction between wild-type FokI subunits (Fig. 4.1 a). With the aim of 
reducing the risk of homodimer interactions, different groups have developed 
a variety of approaches to modify the protein structure of the FokI domain in 
order to create obligate heterodimer-ZFNs with reduced cytotoxicity (Miller, 
Holmes et al. 2007; Szczepek, Brondani et al. 2007; Doyon, Vo et al. 2011).  
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Figure 4.1 Homo- and heterodimerisation of FokI domains in 
ZFNs.  
a) Possible dimers involving the normal of FokI domain: heterodimers (top) or 
homodimers (middle, bottom). Left and right ZFN domains (circles) and their 
target sequences (colored lines) are shown in yellow and orange, 
respectively. The homodimer FokI domain is colored in purple. b) Use of 
modified FokI domains limits heterodimer formation. Smbols are as in a) 
except the normal FokI domain are replaced by two modified domains 
one(ref)  linked to ZFN-L the other (black) to ZFN-R. The + and – symbols 
indicate amino acid residues with opposite charges. With these modified FokI 
domains heterodimers (top)are stable but not homdimers (middle, bottom) are 
not. 
+ !  
+ + 
! ! 
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Although the approaches were different, these three groups identified a set 
of key amino acids, located at the dimerisation interface, that when modified 
greatly affected the interaction of the two FokI subunits. These residues were 
changed in order to introduce charge-charge interactions where amino acids 
positively and negatively charged would only allow obligate heterodimer 
configurations eventually reducing the risk of off-target cleavage (Fig. 4.1 b). 
During the development of ZFNs one of the first steps immediately after 
the synthesis of the novel nuclease is the assessment of its ability to produce 
DSBs at the desired target locus. Cutting efficiency of novel ZFNs is assessed 
using the Surveyor Mutation Detection kit (Transgenomic).  
This technique is based on the use of the Cel-I nuclease, a specific 
mismatch endonuclease that is able to recognise and cleave mismatches in 
heteroduplexes containing single nucleotide polymorphisms (SNPs) or small 
deletions/insertions in one strand (Oleykowski, Bronson Mullins et al. 1998). 
In the absence of a DNA repair template, ZFN-induced DSBs are 
preferentially repaired by NHEJ but this pathway, due to its non-conservative 
nature, also tends to introduce deletions or insertions (indels) at the cutting 
site. These mutations can be used in the Surveyor assay to detect, and 
possibly quantify, the cutting activity of novel ZFNs. After initial expression of 
ZFNs in a cell population, genomic DNA is extracted and the region of interest 
(the ZFN target and surrounding sequences) is amplified by PCR reaction 
(Fig. 4.2 a and b). At this point the sample will contain a heterologous 
population of PCR products: some will be amplified from unmodified target 
loci, others from modified target loci with ZFN-induced indels. PCR products 
are next subjected to a melting and re-annealing step in order to promote the 
formation of heteroduplex DNA between unmodified and modified PCR 
products (Fig. 4.2 c). Finally, the samples are subjected to enzymatic Cel-I 
digestion and the digested products are then visualised by DNA PAGE 
electrophoresis (Fig. 4.2 d and e).  
The following chapter describes the β-globin specifc ZFN that was 
commissioned from Sigma-Aldrich and the use of the Cel-I assay to assess its 
efficiency and specificity.   
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Figure 4.2 Cel-I assay schematics.  
a) Genomic DNA extraction from ZFNs-expressing cells. b) PCR amplification 
of the region encompassing the ZFN target site. The PCR sample is 
composed by a mixed population of wild-type and mutated sequences 
(derived from un-cleaved and cleaved genes, respectively). A mutation 
generated by NHEJ-mediated repair of a ZFN-induced DSB is depicted as a 
red circle. c) Melting and re-annealing of the PCR products allows the 
formation of heteroduplexes from wild-type and mutated strands. d) The Cel-I 
nuclease recognises and cleaves these mismatch substrates but does not cut 
reformed homoduplexes. e) Digested samples are resolved by DNA PAGE as 
represented in this example. Lane 1) DNA ladder. Lane 2) Negative control 
derived from cells not treated with ZFNs: the only band is the full length 
homoduplex PCR product. Lane 3) Products derived from ZFNs-treated cells: 
a mix of uncut homoduplex (top band) and Cel-I-digested heteroduplex 
(arrowed bands) is seen, the latter indicating ZFN-induced cleavage at the 
desired locus. 
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4.2 Results 
 
4.2.1 Choice of the target sequence, ZFN development and 
delivery 
 
Initially, a specific region located in the first exon of the β-globin gene was 
chosen for analysis by Sigma’s bio-informatics team in search of possible 
sequences that could be targeted by ZFNs designed with Sangamo’s 
proprietary platform (Fig. 4.3 a and b). The region was selected for its 
proximity to both the sickle cell mutation and a cluster of known β-thalassemia 
mutations, and also for the presence of heterologies with the δ-globin gene 
(Fig. 4.3 b). This last aspect was of paramount importance to reduce to a 
minimum the risk of off-target cleavages that could occur at the δ-globin locus 
that has a high degree of homology with the β-globin gene. When the 
sequence was analysed with the SuperFinder algorithm, 26 possible ZF-
DBDs were identified that could be combined in order to create 16 different 
ZFNs (Fig. 4.3 c). Sigma assembled expression plasmids for the 26 the 
candidate ZFN monomers using Sangamo’s proprietary ZF-archive, and then 
transfected them in the 16 combinations in a suitable human cell line (K562). 
Using the mismatch-sensitive Cel-I assay, ZFN activity was estimated as the 
ability to produce DSBs and promote NHEJ at the target locus. The best ZFN  
(ZFN4), with an efficiency in promoting NHEJ estimated by Sigma at 10%, 
was supplied to the Gene Targeting group in the form of both expression 
plasmids and mRNA molecules (for the map and sequence of the ZFN4 
expression plasmids see Appendix 2).  
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Figure 4.3 Potential β-globin ZFN target sequences identified 
by the SuperFinder algorithm.  
a) Graphic representation of the β-globin gene with exons coloured in red. 
The region (81 bp) chosen for analysis by the SuperFinder algorithm is 
highlighted in yellow. b) The sequence examined by the Sigma bio-informatics 
team includes nucleotides mutated in sickle-cell disease (yellow) and β-
thalassaemia (red). Nucleotides that differ from the equivalent region of the δ-
globin sequence are underlined. c) The SuperFinder algorithm identified 26 
different ZF-DBDs that combined together could give 16 different ZFNs. Left 
and right target sequences for each ZFN are displayed in brown and blue, 
respectively. Numbers to left and right of the sequences represent the 
possible different ZF-DBDs that could be created for that specific target 
sequences. 
 
 
!-globin gene 
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The newly created ZFN4 is composed by two different subunits: ZFN4-L 
made of 4 ZF modules and ZFN4-R made of 6 ZF modules. The engineered 
nuclease targets a 37 nucleotides sequence (from now on called TS-4) 
located 22 bp downstream of the sickle cell mutation. ZFN4-L binds to a 12 bp 
recognition sequence while ZFN4-R binds 18 bp. More specifically, the right 
binding site is made by a 12 bp sequence, that is recognised by the first 4 ZF 
modules of ZFN4-R, followed by a 1 bp spacer and then other 6 bp that are 
bound by the last 2 ZF modules (Fig. 4.4 b).  
 
4.2.2 Transient expression of ZFN4 in human cells  	  
In order to confirm the ability of ZFN4 to specifically edit the desired target 
sequence in the human β-globin locus, adherent HT1080 fibrosarcoma cells 
and suspension K562 myeloid leukemia cells were transiently transfected with 
expression plasmids or in vitro synthesised mRNA encoding for ZFN4-L and 
ZFN4-R. Cells were transfected with 2µg of each ZFN4 expression plasmid or 
2µg of each mRNA. Lipofection and nucleofection were used to transfect 
4x105 HT1080 cells and 1x106 K562 cells, respectively (see Section 2.6.7 and 
2.6.8 for transfection protocols). After transfection, cells were incubated for 
48h at 37°C in presence of 5% CO2 and afterwards genomic DNA was 
extracted with a commercial genomic isolation kit (Section 2.1.3). To detect a 
possible increase in ZFN4-activity during time, an additional experiment was 
carried out transfecting HT1080 cells with ZFN4-encoding plasmids and 
extracting genomic DNA after 72h instead of the customary 48h. Transfection 
efficiencies were assessed by transfecting HT1080 and K562 cells with 2 µg 
of pmaxGFP expression plasmid (Lonza). GFP expression was measured on 
FACS machine at 48h after transfection and the efficiency was expressed as 
the percentage of GFP positive cells among the total population (Section 
2.6.9). Transfection efficiencies in both HT1080 and K562 experiments were 
estimated to be 80% or more (data not shown).   
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Figure 4.4 ZFN4 overview.  
a) β-globin gene representation with exons in red and the ZFN4 target site 
(TS-4) in yellow. The target sequences TS-1, TS-2 and TS-3 for the ZF 
domains generated with the modular assembly approach are also indicated 
(arrows). b) TS-4 sequence and binding of ZFN4. The ZFN4-L DBD is 
composed of four fingers and binds a 12 bp half site (in bold) while the ZFN4-
R DBD has six fingers and binds a 18 bp half site (in bold). Heterology with 
the δ-globin gene is indicated by underlined nucleotides. The MwoI restriction 
site (GCNNNNNNNGC) used to confirm ZFN4’s cleavage activity is 
highlighted in green (see Section 4.1.3 for the assay). The heterodimerising 
FokI domains (red/- and black/+) are represented as in Fig. 4.1. c) Summary 
of binding sites for ZFN4-DBDs. Sequences are shown on the 3’-5’ orientation 
as this corresponds to the N-to-C terminal orientation of the ZFN amino-acid 
sequence.  
GTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTG!
CAGACGGCAATGACGGGACACCCCGTTCCACTTGCAC  !
a) 
b) 
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4.2.3 Detection of ZFN4-induced gene modifications at the β-
globin endogenous locus by the use of Surveyor assay 	  
Due to ZFN4’s activity and the following NHEJ events used to repair possible 
DSBs, the genome of each transfected cells should contain modified (mono- 
or bi-allelic modifications) or unmodified β-globin loci. In order to detect 
possible ZFN4-induced indels, a 394 bp region located in the β-globin locus 
and encompassing TS-4 was PCR-amplified using as a template the genomic 
DNA from transfected HT1080 and K562 cells (see Section 2.7.2). For each 
experiment, negative controls were carried out using as a PCR template the 
genomic DNA from HT1080 or K562 cells transfected with a control plasmid 
(pGP-FF). The primers used were provided by Sigma along with the ZFN4 
expression vectors (for the complete sequence of the two primers see Section 
2.7.2). The PCR products were subjected to a cycle of melting and 
reannealing in order to promote the formation of heteroduplexes between 
unmodified and modified PCR products. Afterwards, the mixture of homo and 
heteroduplexes was treated with the Cel-I nuclease and the digested products 
were visualised on a 8% polyacrylamide gel (DNA-PAGE) (see Section 2.3.2 
for the DNA-PAGE protocol and Section 2.7.2 and Fig. 4.2 for the Cel-I assay 
protocol and schematic).  
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Figure 4.5 Cel-assays detect ZFN4-induced NHEJ events at 
the β-globin locus in human K562 and HT1080 cells.  
a) Analysis of ZFN4 activity at the β-globin locus of K562 cells. Lane M is a 
100 bp ladder (NEB). Cells were transfected with control DNA (lane 1), ZFN4 
expression plasmids (lane 2) or ZFN4-encoding mRNA (lane 3 and 4). 
Genomic DNA for lanes 3 and 4 was obtained from two separated 
transfection. Genomic DNA isolated from cells 48h after transfection was used 
to amplify a 394 bp β-globin gene fragment carrying TS-4. All PCR products 
were digested with the Cel-I endonuclease before visualisation by DNA-PAGE 
(8% polyacrylamide gel). b) Analysis by the Sigma team (DNA-PAGE carried 
out on a 10% polyacrylamide gel). Lane 1: un-transfected K562 cells, K562 
cells transfected with ZFN4 expression plasmids (lane 2) or with ZFN4-
encoding mRNA (lane 3). c) Detection of ZFN4 activity at the β-globin locus in 
HT1080 cells. Cells were transfected with control DNA (lane 1), ZFN4 
expression plasmids (lane 2 and 3) or ZFN4-encoding mRNA (lane 4). 
Genomic DNA was isolated 48h (lanes 1,2 and 4) or 72 h (lane 3) after 
transfection.  
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After the Cel-I treatment, the PCR sample should contain a mixed 
population made of uncut 394 bp fragments derived from homoduplexes and 
two distinct fragments of 219 and 175 bp derived from Cel-I-digested 
heteroduplexes. However, when the digested products were visualised on 
polyacrylamide gels, two additional bands of ≈ 150 and ≈ 240 bp were 
identified (Fig. 4.5 a and c). These bands were found also in negative control 
samples indicating the possible presence of a Single Nucleotide 
Polymorphism (SNP) carried by one of the two alleles in both K562 and 
HT1080 cells. A similar bands pattern was also identified by the independent 
testing conducted by Sigma’s team (Fig. 4.5 b). The possible presence of 
SNPs in the exon 1 was confirmed by examining the map of the human β-
globin gene found in the web archive of the NCBI website (NCBI Gene ID: 
3043 (NCBI)). In addition to a graphic representation of the exons, to the 
complete sequence of the gene and to a list of clinically relevant mutations, 
the map also lists all the known SNPs with their relative position in the gene. 
The NCBI archive indicated the presence of a wide family of SNPs located in 
the region of the β-globin gene’s exon 1. Although the presence of too many 
SNPs in the genomic region that has been PCR-amplified for the Cel-I assay 
prevented the possibility of establishing the correct SNP responsible for the 
digestion pattern noticed in the assay, the possible link between the additional 
bands in the assay and the presence of a SNP was partially confirmed.  
In addition to these constitutive ZFN4-independent products, ZFN4-
dependent Cel-I products of the expected sizes (219 bp and 175 bp) were 
detected. No substantial difference in the amount of these products was 
noticed between cell lines (HT1080 and K562) or between modes of ZFN4 
expression (plasmid and mRNA forms) (Fig. 4.5 a and c). Moreover, no 
increase in ZFN4 activity (i.e. intensity of Cel-I products) was noticed in 
genomic DNA obtained from transfected HT1080 cells that were incubated for 
72h before genomic DNA isolation (Fig. 4.5 c, lane 3).  
Frequencies of heteroduplex formation (used as an evaluation of ZFN4 
activity) were estimated by comparing the relative intensity of the digested 
products with known amounts of 100 bp ladder (NEB) (details in Section 
2.7.2). The frequency was estimated to be ≈ 1-2% in both HT1080 and K562 
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cells, much lower than the estimate of 10% made by the Sigma’s team. The 
assays described in this thesis were carried out employing the same 
experimental conditions as the ones used in the Sigma assay and transfection 
efficiencies were consistently high during all experiments, therefore the 
reason for this discrepancy is unclear. It could be ascribed to possible 
differences in the two batches of K562 cells used or to a suboptimal 
performance of the Cel-I assay in detecting and cleaving heteroduplexes. It is 
noticeable that, in the analysis by Sigma (Fig 4.5 b, lanes 2 and 3), the 
intensity of the ZFN4-dependent Cel-I products is clearly greater than that of 
the constitutive products, whereas this is not the case in the analysis carried 
out in this project (Fig 4.5 a, lanes 2-4). This observation argues against 
variations between the two analyses in the efficiency of Cel-I digestion, 
because reduced Cel-I activity should reduce the intensities of all Cel-I so that 
the ratio of intensities between constitutive and ZFN4-induced products 
should remain constant. Differences between K562 cells used in the two 
different analyses therefore seems the more likely explanation for the different 
estimates of ZFN4-mediated cleavage. ZFNs cutting efficiencies may vary 
greatly from one cell line to another due to differences in the chromatin 
structure and accessibility of the target sequence (Urnov, Rebar et al. 2010; 
Carroll 2011). Although the cell line used in both experiments was nominally 
the same, K562 is known to be particularly prone to genomic rearrangements 
that could create a great level of heterology between different laboratory 
stocks of K562 (Dimery, Ross et al. 1983; Wu, Voelkerding et al. 1995). 
Sigma’s team, when consulted about the discrepancy between the two Cel-I 
assay results, also suggested a reduced ZFN4 activity due to possible 
differences in the two K562 cell lines. To rule out possible contamination of 
the K562 cell population with other cell lines or possible substantial genomic 
rearrangements that could have affected the frequency of ZFN4-induced 
DSBs, 107 K562 cells were handed over to the Leukaemia Cytogenetics Unit 
at Hammersmith Hospital (London) for Fluorescence In Situ Hybridisation 
(FISH) by use of a BRC/ABL dual-colour probe (Kreatech Diagnostic) and for 
karyotyping analysis (G-banded chromosome analysis). The two analyses 
excluded a possible contamination of the K562 cell population by other cell 
types and the few chromosomal abnormalities identified were subjected to 
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cell-to-cell variation and were largely consistent with the published karyotype 
of K562 cells (Naumann, Reutzel et al. 2001).  
  
4.2.4 Alternative detection of gene modification by MwoI 
restriction digestion 	  
Thanks to an MwoI restriction site located within TS-4 (Fig. 4.4 b), it was 
possible to independently confirm ZFN4’s cleavage activity by an alternative 
approach to the Cel-I assay. The 394 bp TS-4 region of the β-globin gene was 
PCR-amplified using the same primers used in the Cel-I assays and, as a 
template, the same genomic DNA from K562 cells transfected with ZFN4 
expression plasmids or mRNA used in the Cel-I assay previously described. 
Theoretically, all of the 394 bp PCR product from untransfected cells should 
be digested by MwoI to form two fragments of 164 bp and 230 bp. By contrast 
a proportion of the 394 bp PCR products derived from ZFN4-treated cells 
should be resistant to MwoI digestion due to the loss of the MwoI site resulting 
from NHEJ-mediated repair of ZFN4-induced DSBs.  
MwoI restriction digestion was carried out on PCR products amplified from 
the same genomic DNA used for the Cel-I assay (see Fig. 4.5 a). Afterwards, 
digestion products were visualised by DNA-PAGE on an 8% polyacrylamide 
gel (for the full description of the MwoI experiment see Section 2.7.3). MwoI 
restriction digestion patterns (Fig. 4.6 a) were compared with the results 
obtained in the Cel-I assay and the relative intensity of the uncut 394 bp 
product was estimated by the same approach used in Section 4.1.2. The 
ZFN4 cutting efficiencies estimated in the MwoI experiment were found to be 
comparable to the ones obtain by the Cel-I assay confirming the initial 
assessment of a 1-2% ZFN4 cutting efficiency.  
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Figure 4.6 MwoI assay detects ZFN4-induced NHEJ events at 
the β-globin locus while Cel-I assay does not at the δ-globin 
locus in human K562 cells.  
Lanes M of both pictures are a 100 bp ladder (NEB) a) Detection by MwoI 
assay of ZFN4 activity at the β-globin locus. K562 cells were transfected with 
control DNA (lane 1 and 2), ZFN4 expression plasmids (lane 3) or ZFN4-
encoding mRNA (lane 4). Lane 1: MwoI-undigested PCR product; Lanes 2-4: 
PCR products were digested with MwoI before DNA-PAGE. b) Analysis of 
ZFN4 activity at the δ-globin locus of K562 cells. Cells were transfected with 
control DNA (lane 1), ZFN4 expression plasmids (lane 2) or ZFN4-encoding 
mRNA (lane 3 and 4). Lanes 3-4 were from two separated transfections. 
Genomic DNA isolated from cells 48h after transfection was used to amplify a 
811 bp fragment carrying the homologous region of the δ-globin gene. All 
PCR products were digested with the Cel-I endonuclease before visualisation 
by DNA-PAGE (8% polyacrylamide gel).  
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4.2.5 Testing for ZFN4-induced off-target cleavage events at 
the δ-globin locus 	  
As mentioned in Section 4.1.1, the risk of ZFN-induced off-target cleavage is 
one of the major problems related to the use of ZFNs in a possible therapeutic 
approach.  
Although the use of FokI domains with an obligate heterodimer 
conformation (see Section 4.1.1) should greatly reduce it, the risk of off-target 
cleavage events could still be substantial if the chosen target sequence 
shares some degree of homology with other regions of the genome. This risk 
is particularly high for ZFNs designed to target the β-globin locus because the 
gene is part of a family of globin genes that share a high degree of homology 
(see Section 1.3). 
In order to identify possible sequences partially homologous to TS-4, a 
BLAST query of the human genome was performed following the same 
criteria used in Section 3.2.1. As expected, the query identified as the most 
probable off-target site a 40 bp region of the δ-globin gene 
(GACTGCTGTCAATGCCCTGTGGGGCAAAGTGAACGTGGAT). The 
sequence shares a high degree of homology with the β-globin target site with 
only 5 bases (underlined in the above sequence) out of 40 that are different 
from TS-4 (for a complete comparison of the β- and δ- globin sequences see 
Appendix 1). 
To identify off-target cleavage events at the δ-globin locus, genomic DNA 
samples that showed ZFN4 activity at the β-globin locus in the Cel-I assay 
(Section 4.1.2 Fig. 4.5 a lanes 1-4) were used as templates for the PCR 
amplification of an 811 bp region of the δ-globin gene encompassing the 
possible off-target site (for the primers used see Section 2.6.1). In the case of 
undesired ZFN4-induced cleavage at this site, the Cel-I assay would 
generate, on the polyacrylamide gel, two bands of ≈ 322 and 489 bp.  
The Cel-I assay was performed on the amplified δ-globin PCR products 
and the DNA-PAGE of the treated samples (Fig. 4.6 a, lanes 1-4) showed the 
characteristic 811 bp band of undigested product but failed to show any sign 
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of digestion products. ZFN4-mediated cleavage at δ-globin gene was thus 
undetectable, and certainly less than at the β-globin locus.  
 
4.3 Discussion 
 
4.3.1 Detection of ZFN4-induced gene modifications at the β-
globin endogenous locus by the use of Surveyor assay 
and MwoI restriction digestion 	  
Although Sigma’s CompoZr Custom ZFN Service provided a “ZFN-candidate 
validation” step where ZFN4’s cleavage efficiency was tested in a suitable cell 
line (in this case K562 cells) using the mismatch detection assay (Cel-I 
assay), the decision to independently assess ZFN4’s cleavage activity at the 
target locus was taken in order to identify possible discrepancies between the 
two different K562 populations (the one used by Sigma and the one used in 
this project) and also to test ZFN4 in a different cell line (HT1080). In addition, 
Sigma’s CompoZr Custom ZFN Service was a new and expensive 
technology/service and was therefore important to confirm that ZFN4 worked 
as claimed.  
As expected, cleavage at the target locus was identified, by Cel-I assay, 
only in cells transfected with ZFN4-encoding plasmids or mRNA. The 
manufacturer’s technical manual, provided along with the ZFN4 kit, suggests 
the testing of both ZFN expression forms because of possible variable levels 
of DNA/mRNA uptake in different cell types and also because of the different 
modalities of protein expression. While the expression plasmids are supposed 
to generate ZFNs at a constant level during the period of 48-72h, the mRNA 
should produce a short burst of ZFNs reducing the exposure of the cells to the 
proteins. Moreover, the lack of promoters in the mRNA form is an additional 
advantage when testing ZFNs in different cell lines due to the reduced 
variability in levels of protein expression, variability that is usually induced by 
compatibility issues between promoters and cell types. 
The experiments presented in Fig. 4.5 show that intensities of 
heteroduplex-digested bands were approximately equivalent (at least for 
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genomic DNA extracted after 48h) for both types of ZFN4-encoding nucleic 
acid (plasmids or mRNA) and between different cell lines (K562 and HT1080). 
These observations confirmed the initial validation step carried out by Sigma 
and also proved the ability of ZFN4 to promote gene modifications with a 
similar efficiency in a completely different cell line.  
However, when the ZFN4 cutting efficiencies were estimated by 
comparing the intensities of cleaved and uncleaved PCR products, they were 
found to be up to one order of magnitude lower than the efficiency estimated 
by the Sigma team (1-2% cutting efficiency compared to Sigma’s 10%). The 
difference in efficiencies was substantial therefore an in depth analysis of the 
factors that could affect the assay was carried out. 
Transfection efficiencies were monitored during all the experiments and 
were always found to be above 80% therefore the reduced ZFN4 activity 
could not be ascribed to ineffective delivery of expression vectors or mRNA. 
Another possible reason for the discrepancy could have been the necessary 
modifications made to the Cel-I assay protocol. In theory, the Cel-I manual 
provided by Transgenomics recommends to perform the Cel-I digestion 
directly in the PCR buffer, immediately after the melting/reannealing step. 
However, as stated in the manufacturer’s protocol, the Cel-I endonuclease 
efficiently cleaves heteroduplexes only in a very narrow pH window and can 
be also affected by additives present in the PCR buffer. The PCR buffer used 
in this project was not compatible with the reaction conditions required by the 
Cel-I assay (and described in the manufacturer’s protocol) therefore the PCR 
products had to be purified and resuspended in a suitable buffer prior to Cel-I 
digestion (for the complete protocol see Section 2.7.2). This additional step 
and possibly a reduced rate of heteroduplex formation could have affected the 
assay in a significant way. The MwoI approach (MwoI restriction digestion, 
Section 4.1.3) does not require the formation of PCR heteroduplexes 
therefore it was a very useful method to confirm the initial Cel-I assessment. 
However, when the presence of ZFN4-induced gene modifications at the 
target locus were investigated with this totally different approach the 
intensities of undigested bands, characteristic of modified β-globin loci, were 
approximately equivalent to the one found in the Cel-I assay (Fig. 4.6 b). 
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When consulted about the possible reasons for the perceived 
discrepancies between the two Cel-I assays, Sigma’s ZFN Technical Liaison 
suggested a possible difference, due to genomic instabilities, in the two K562 
populations used. Nevertheless, FISH and karyotyping analyses conducted 
on the cell population by an independent group (see Section 4.1.2) failed to 
identify substantial differences between the K562 cell line used in this project 
and the published karyotype of K562 cells (Naumann, Reutzel et al. 2001). 
Sigma does not specify which method is used to quantify the cutting 
efficiencies of novel ZFNs therefore one possible explanation to the lower 
level of ZFN4 activity found in this project could be derived from differences in 
the NHEJ quantification methods used by the two groups. However in an 
informal conversation with members of the Sigma team during a recent ZFN 
conference (EBML, Heidelberg, Dec 2011) Dr Porter (personal 
communication) was told that further Cel-I assays of ZFN4 at Sigma gave 
cleavage estimates of approximately 2%. Thus, although this statement has 
not been formally reported, it seems likely that the estimate of 1-2% cleavage 
identified in this project may be more reliable than the original Sigma estimate 
of 10%.  
    
4.3.2 Detection of possible ZFN4-induced off-target cleavage 
events at the δ-globin locus 	  
The risk of off-target cleavage has become an increasing concern for the 
development of a safe and reliable therapeutic approach based on ZFN-
induced gene correction but still a definitive method capable of identifying all 
possible off-target events occurring in vivo in the entire genome has to be 
created. The current approaches are mainly based on an “in silico” method 
based on the identification of possible targets by the use of search algorithms 
like BLAST and on “in vitro” selection methods like SELEX (see Section 6.3.3) 
(Perez, Wang et al. 2008; Hockemeyer, Soldner et al. 2009; Li, Haurigot et al. 
2011; Sebastiano, Maeder et al. 2011). 
In the case of the β-globin gene, the risk of undesired gene modifications 
at additional loci is elevated due to the wide similarities shared by all the 
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globin genes (β,ε,γ and δ-globin). However, this high degree of homology was 
also useful to test the specificity of ZFN4. By the use of “in silico” analysis 
(see Section 4.1.4) it was clear that a 40 bp sequence of the δ-globin locus 
was the most similar site with a homology rate of ≈ 87% (only 5 bp out 40 are 
different). To assess ZFN4’s specificity, genomic DNA samples that showed 
evidence of ZFN4-induced indels were subjected to an additional Cel-I 
screening but this time focused on the δ-globin gene. The experiment failed to 
detect cleavage events at this site or at least not at the same frequencies as 
the ones found for the β-globin gene. Unfortunately, the possibility of off-target 
cleavage at this locus cannot be completely excluded due to the nature of the 
assay used. As stated in the manufacture’s manual, the Cel-I assay is 
effective in detecting gene modification at a specific locus only if they occur 
with a frequency of at least 1% (percentage of mutated genes respect to the 
whole gene population). In the case of ZFN4, cutting efficiencies at the target 
site were already at the limit of detection therefore very low frequencies of off-
target cleavage would pass unnoticed. However, this partial assessment of 
the risk of off-target cleavages can be supported by the data found by Zou et 
al. (as fully described in Section 6.3.3). This group of researchers used a GFP 
correction assay (as the one described in Chapter 5) to investigate possible 
ZFN4-induced gene modifications at highly homologous sites of the ε,γ and δ-
globin genes but they could not detect any (Zou, Mali et al. 2011). More in-
depth analysis (possible approaches are examined in Section 6.3.3) is 
required because in a possible therapeutic approach also very low levels of 
off-target cleavage could compromise the efficacy of the technique. If it is 
considered that, in a hypothetical gene therapy approach for β-thalassaemia 
or sickle cell anaemia, bone marrow cells obtained by the patient would be 
genetically corrected and then transplanted back into the patient a possible 
ZFN-induced mutation at the level of an oncogene of a single cell could 
confer, back in to the patient, a proliferative advantage that could promote the 
onset of leukaemia. 
In a study carried out by Pattanayak et al. in 2011, a novel approach was 
used to extensively test the specificities of active ZFNs (Pattanayak, Ramirez 
et al. 2011). Traditional methods (Segal, Dreier et al. 1999; Bulyk, Huang et 
al. 2001; Meng, Thibodeau-Beganny et al. 2007) have been used to 
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characterise the binding specificity of monomeric ZF-DBDs in search for 
possible off-target half sites but these approaches are based on the 
assumption that binding of one ZF-DBD monomer would not affect the binding 
of the other ZF-DBD monomer. The new approach developed by Pattanayak 
et al., instead, tried to assess cleavage specificities of full ZFNs heterodimers 
by the use of an in vitro selection method that is able to interrogate a vast 
library of partially randomised ZFNs target sites (these libraries should contain 
all possible DNA sequences that differ from the wild type target site by 7 or 
fewer point mutations). The experiment was performed using two well-
characterised ZFNs: the CCR5-224-ZFN (part of an HIV therapeutic approach 
that is currently at the stage of clinical trials) and the VF2468-ZFN (part of an 
anti-cancer therapeutic approach). In the case of the CCR5-224-ZFN, the 
study identified, in vitro, 37 sites of the human genome that could be cleaved 
by the ZFN. Of these 37 sites 9 were actively cleaved in vivo in K562 cells 
and of these 9 sites only one, the CCR2 gene, was previously identified by 
traditional methods as a possible off-target site. The study interestingly 
indicated that off-target cleavage is directly proportional to the ZFN 
concentration, that ZFNs can cleave, at significant frequencies, any sequence 
that differs from the intended target sequence by three or less nucleotides 
and, more importantly, that there is a compensation effect between half sites 
of a target sequence where perfect binding of a ZF-DBD can promote 
tolerance in the binding affinity of the other ZF-DBD reducing, therefore, the 
overall specificity of the ZFN (Pattanayak, Ramirez et al. 2011).  
Off-target cleavage is probably the main drawback for the creation of a 
reliable therapeutic approach based on ZFNs and therefore the development 
of safer molecular tools is of the highest importance. One promising approach 
is based on the implementation of a nickase to stimulate gene targeting. 
Nickases are a family of enzymes capable of producing Single Strand Breaks 
(SSB or “nicks”) at specific loci. Although not efficiently as DSBs, nicks have 
been shown to stimulate HR and could be used as an alternative to traditional 
ZFNs and TALENs technologies based on the use of FokI domains (Lee, 
Neiditch et al. 2004; van Nierop, de Vries et al. 2009). A recent study from 
Ramirez et al. indicated that the inactivation of the catalytic residues in one of 
the FokI monomer of standard ZFNs could generate efficient nickases 
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capable of targeting any desired locus in the genome. A striking feature of this 
novel molecular tool is the reduced rate of mutations induced by NHEJ at both 
on and off target sites (Ramirez, Certo et al. 2012). The newly created 
nickase used in the study was able to promote HR in a GFP reporter assay 
(as the one used in Chapter 5) even though at a lower frequency than its 
parental ZFN (0.14% and 0.29%, respectively) but when it was tested in the 
Traffic Light Reporter assay (TLR), a fluorescent repair assay capable of 
measuring HR and NHEJ frequencies at the same time (Certo, Ryu et al. 
2011), the results showed that, while ZFN-induced DSBs are preferentially 
repaired by NHEJ than by HR, nicks at the target locus are instead 
preferentially repaired by HR. Indirectly, this study suggests also a possible 
reduction in the frequencies of mutations at off-target sites where nickase-
induced SSBs would be repaired by HR using the sister chromatid as a 
template.        
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5 Chapter 5: Development and use of an assay for 
ZFN4-induced homology-directed repair 
 
5.1 Overview 
 
After the initial assessment of ZFN4-induced NHEJ events by the use of the 
Cel-I assay, a Homology Directed Repair (HDR) assay was designed in order 
to measure ZFN4’s ability to promote HR in human cell lines and, at the same 
time, to compare its efficiency to I-SceI endonuclease. 
I-SceI is a well-characterized rare homing endonuclease that recognizes a 
long DNA sequence of 18 bp (TAGGGATAACAGGGTAAT). This long target 
sequence has the advantage of occurring only once in every 7x1010 bp (of 
random sequence), a frequency so low that the sequence is expected to 
occur only once every 20 mammalian-sized genomes conferring I-SceI a high 
degree of specificity (Jasin 1996). Therefore, thanks to its unique specificity, 
this homing endonuclease has been extensively used to study the gene repair 
pathways by the introduction of its target sequence in mammalian cell models 
and it has been shown to greatly promote HR by the production of DSBs 
(Jasin 1996; Pierce, Johnson et al. 1999; Pierce, Hu et al. 2001).  
The HDR assay developed in this project was based on the existing 
reporter system designed and published by Maria Jasin’s group (Pierce, 
Johnson et al. 1999). In these studies, a modified GFP expression plasmid 
(pDR-GFP-HR) was designed to carry two disrupted copies of the eGFP gene 
separated by a puromycin resistance cassette (pgk-puro): one copy, called 
SceGFP and under the control of a CMV (CytoMegaloVirus) promoter, is a 
complete eGFP gene that has been disrupted by an I-SceI target site and two 
in-frame termination codons, while the second copy, iGFP, is missing the 
promoter region at the 5’ end and is also truncated at the 3’ end (see Fig. 5.1 
a). The reporter plasmid pDR-GFP-HR is able to express fully functional GFP 
only if a gene conversion event occurs between the SceGFP gene and the 
iGFP where the iGFP sequence is used as an intra-chromosomal repair 
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template (Fig. 5.1 b). False positives derived by the competing NHEJ and 
Single Strand Annealing (SSA) pathways, which could re-arrange the two 
GFP genes in a functional one, are avoided thanks to the double truncation at 
the 5’ and 3’ ends of the iGFP repair template (Fig. 5.1 c) (Pierce, Johnson et 
al. 1999).  
The reporter plasmid pDR-GFP-HR is stably transfected in a suitable 
mammalian cell line and the assay is carried out transiently transfecting the 
newly created cell line with an I-SceI expression plasmid. Levels of HR events 
induced by DSBs produced by I-SceI can be easily quantified through Flow 
Cytometry, typically 48h after transfection. The percentage of GFP positive 
cells among the whole cell population provides a measure of the ability of I-
SceI to cleave its chromosomal target and promote HDR of the resulting DSB. 
In 1999 Jasin’s group used the pDR-GFP-HR system in AA8 hamster cells 
and demonstrated that expression of I-SceI was able to promote HR at the 
target locus with a frequency of 5%. By comparison, un-transfected cells 
showed less than 0.01% of GFP positive cells (Pierce, Johnson et al. 1999).  
To determine whether ZFN4 could similarly stimulate HDR, and compare 
its efficiency to I-SceI, it was decided to modify pDR-GFP-HR so that it 
included the target  site for ZFN4. 
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Figure 5.1 Principle of the DR-GFP reporter plasmid.  
a) Graphic representation of pDR-GFP-HR. The plasmid carries two copies of 
the eGFP gene separated by a Pgk-Puro resistance cassette. The Sce-GFP 
is interrupted by the insertion of the I-SceI target sequence (shown in the blow 
up) which includes two in-frame termination codons (underlined). The iGFP 
gene instead is an eGFP truncated at the 5’ and 3’ ends and functions as a 
intra-chromosomal repair template during HR events. b) I-SceI-induced 
homology directed repair. An I-SceI induced DSB at the target locus is 
repaired by intra-chromosomal HR using the iGFP gene as a repair template. 
Expression of functional GFP is then easily monitored by flow cytometry. c) 
Non-conservative repair pathways. Fusion of the two GFP genes derived by 
NHEJ or SSA or non-conservative HR rearrangements does not produce a 
functional GFP gene due to the truncated 3’ end of the iGFP sequence.    
iGFP 
I-SceI target site 
SceGFP Pgk-PuroR 
TAGGGATAACAGGGTAAT!
ATCCCTATTGTCCCATTA !
iGFP 
I-SceI 
SceGFP 
iGFP GFP+ 
Homologous direct repair 
Pgk-PuroR 
Pgk-PuroR 
a) 
b) 
iGFP 
SceGFP 
c) 
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5.2 Results 
 
5.2.1 Creation of the reporter plasmid pDR-GFP-ZFN4 
 
To assess the ability of ZFN4 to promote HR a modified pDR-GFP-HR 
reporter plasmid was designed to be used in HT1080, K562 and DG75 cells. 
The advantage of using the well characterised pDR-GFP-HR was due to the 
possibility of flanking the already existing I-SceI target sequence with TS-4 
(ZFN4’s target sequence) and, therefore, to be able to assess ZFN4-induced 
HR and at the same time to directly compare the frequency of events with the 
one induced by I-SceI. The first step involved the introduction of the 40 bp 
target sequence for the ZFN4 (TS-4) into the pDR-GFP-HR reporter plasmid. 
The pDR-GFP-HR plasmid, (kindly donated by Maria Jasin) was linearised by 
digestion with the I-SceI endonuclease at the level of the SceGFP gene. A 
short stretch of double stranded DNA (i.e. annealed synthetic 
oligonucleotides) was designed to introduce the new TS-4 target sequence 
and, at the same time, to regenerate the I-SceI site (for the detailed procedure 
see Section 2.5.2). The DNA sequence carrying TS-4 was cloned in the 
linearised SceGFP locus of the pDR-GFP-HR reporter plasmid immediately 
downstream of the reconstituted I-SceI target site generating the pDR-GFP-
ZFN4 reporter plasmid (Fig. 5.2 for a graphic representation of the construct 
and Appendix 3 for a partial sequence).  
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Figure 5.2 Structure of the pDR-GFP-ZFN4 reporter plasmid.  
a) The arrangement of cassettes in pDR-GFP-ZFN4 is shown and is similar to 
that in pDR-GFP-HR (see Fig 5.1), but includes a ZFN4 target site (TS-4; red 
bar) downstream of an I-SceI target site (blue bar). b) The nucleotide 
sequence of the region including I-SceI and ZFN4 recognition sequences. The 
ZFN4 target sequence (TS-4; red box) was cloned into the cleaved I-SceI site 
of pDR-GFP-HR (green nucleotides) on a pair of annealed oligonucleotides 
(black nucleotides). This regenerated the original I-SceI recognition site (blue 
box). The binding site for ZFN4-L and ZFN4-R are in bold. 
 
iGFP SceGFP Pgk-PuroR 
TAGGGATAACAGGGTAATATAGGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAATAACAGGGTAATATAG!
ATCCCTATTGTCCCATTATATCCAGACGGCAATGACGGGACACCCCGTTCCACTTGCACCTACTTATTGTCCCATTATATC!
a) 
b) 
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5.2.2 Stable transfection of adherent and suspension cells 
and selection of suitable clones  
 
The reporter plasmid pDR-GFP-ZFN4, linearised at a PvuI site, was stably 
transfected into HT1080 cells using electroporation (for the transfection 
protocol see Section 2.6.6). 48h after transfection puromycin selection was 
started and, thanks to the pgk-puro cassette located between the SceGFP 
and the iGFP sites, 12 colonies were isolated after 13 days and were 
singularly expanded. The remaining colonies left on plate (≈ 100 colonies) 
were trypsinised and plated in fresh media in presence of puromycin in order 
to create a pool of cells carrying the pDR-GFP-ZFN4 plasmid. The clones and 
pool of cells were renamed HT-DR-ZFN4 (see Table 5.1) and liquid nitrogen 
stocks were created for long-term storage to be used in the experiments 
described in the following chapter (for the creation of liquid nitrogen stocks 
see Section 2.6.4). 
To assess the ability of ZFN4 to promote HR in blood-derived cell lines, 
K562 (myeloid leukaemia) and DG75 (Burkitt lymphoma) cells were also 
stably transfected with pDR-GFP-ZFN4. Stable transfections were performed 
as for HT1080 cells (see Section 2.6.6) and puromycin selection was started 
after 48h but was carried out only on pools of K562 and DG75 cells without 
selection of single clones. These pools of stably transfected K562 and DG75 
were dubbed K-DR-ZFN4 and DG-DR-ZFN4, respectively (Table 5.1). 
As a form of control, HT1080 cells were also stably transfected with the 
original pDR-GFP-HR plasmid, were selected in puromycin and 10 clones 
plus a pool of cells (obtained by collecting the remaining ≈ 100 colonies) were 
isolated after 15 days. This set of stable transfectants was named HT-DR-
GFP, with a numerical suffix to indicate the clone number or a -P suffix to 
indicate a pool of clones (Table 5.1). HT-DR-GFP cells were used to compare 
the data published by Pierce et al (Pierce, Johnson et al. 1999) on AA8 
hamster cells with the ones obtained in this project for the HT1080 cell line 
and at the same time to identify possible discrepancies in HR frequencies 
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between pDR-GFP-HR and pDR-GFP-ZFN4 due to the presence of 40 
additional bp (TS-4) in the SceGFP gene of pDR-GFP-ZFN4. 
 
Table 5.1 Cell lines generated for the GFP reporter assay   
Parental cell 
line 
Transfected 
plasmid 
Cells selected in 
puromycin  
Name of novel 
cell lines 
pDR-GFP-HR 10 clones  HT-DR-GFP-1, -2, -3 etc. 
pDR-GFP-HR Pooled clones HT-DR-GFP-P 
pDR-GFP-ZFN4 12 clones  HT-DR-ZFN4-1, -2 ,-3 etc. 
HT1080 
pDR-GFP-ZFN4 Pooled clones HT-DR-ZFN4-P 
K562 pDR-GFP-ZFN4 Pooled clones K-DR-ZFN4-P 
DG75 pDR-GFP-ZFN4 Pooled clones DG-DR-ZFN4-P 
 
5.2.3 Homology-directed repair assays in pooled clones 
 
Initially, preliminary tests were carried out using the newly generated pools 
HT-DR-ZFN4-P, HT-DR-GFP-P, K-DR-ZFN4-P and DG-DR-ZFN4-P. I-SceI or 
ZFN4 expression plasmids were delivered to the HT1080 derivatives (HT-DR-
ZFN4-P and HT-DR-GFP-P) by lipofection, to K562 derivatives (K-DR-ZFN4-
P) by electroporation and to DG75 derivatives (DG-DR-ZFN4-P) by either 
lipofection or electroporation (Table 5.2)  
A schematic of the HDR experiments time line is shown in Fig. 5.3 and full 
description of the protocol is reported in Section 2.7.4. Unless differently 
specified, this protocol was used to perform all the following HDR 
experiments.  
The results of the initial set of experiments carried out on the pooled 
clones are shown in Table 5.2. 
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Figure 5.3 HDR assay schematic.  
Each HDR experiment described in this chapter was performed, unless 
differently specified, following the steps described in this figure.  a) Day 1: HT-
DR-GFP, HT-DR-ZFN4, K-DR-ZFN4 and DG-DR-ZFN4 cells (derived from 
pools of cells or from single clones) were plated (HT-DR-GFP and HT-DR-
ZFN4) or freshly sub-cultured (K-DR-ZFN4 and DG-DR-ZFN4) the day before 
transfection. Day 2: cells were transfected (lipofection or electroporation as 
specified in Section 2.7.4) with four different sets of plasmids as described in 
Section 2.7.4. Day 3: cells were left to recover at 37°C in presence of 5% 
CO2. Day 4: (48h after transfection) GFP expression for each sample was 
assessed by flow cytometry of 5x104 cells per sample. b) Flow cytometry 
example. Data were collected by two-colour fluorescent analysis (FL1 green 
fluorescence and FL2 orange fluorescence) and induced GFP expression was 
measured as the percentage of events falling below the diagonal (represented 
in the graph as a blue line).   
a) 
b) 
FL1 
FL
2 
NC ZFN4 I-SceI 
Day 1: 
plating of 
cells 
Day 2: 
transfection 
Day 3: 
cells 
recovery 
Day 4: 
flow 
cytometry 
%GFP+ cells 
 0.011  
%GFP+ cells 
 0.066  
%GFP+ cells 
 1.21  
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Table 5.2 HDR assay results for pooled clones 
% GFP+ cells 48h post-transf Host cells 
 
a Transf 
technique 
b no. of 
cells x105 c NC d I-SceI e ZFN4 f TE 
HT-DR-ZFN4-P LF 1 0.02 0.15 0.01 84 
HT-DR-ZFN4-P LF 1.5 0.01 0.05 0.01 62 
HT-DR-GFP-P LF 1 0.31 0.39 - 84 
HT-DR-GFP-P LF 1.5 0.19 0.25 - 63 
DG-DR-ZFN4-P LF 4 0.04 0.03 0.03 0.5 
DG-DR-ZFN4-P LF 60 0.03 0.04 0.03 0.5 
DG-DR-ZFN4-P EP 20 0.01 0.01 0.01 12 
K-DR-ZFN4-P EP 20 0.03 0.05 0.04 40 
a LF,  lipofection; EP, electroporation. See section 2.6.6 and 2.6.7 for detailed 
protocols. 
b Number of cells electroporated or plated the day before lipofection. 
c Negative controls. As a control, cells were transfected with the bacterial pGP-FF 
plasmid (see Section 3.1) that is not expressed in mammalian cells . 
d Cells transfected with I-SceI expression plasmid (pCβASce)  
e Cells transfected with ZFN4 expression plasmids. 
f Transfection efficiency: cells were transfected with a GFP expression plasmid 
(pmaxGFP; Lonza).  
 
Unfortunately, two main problems were noticed. First, although 
transfection efficiencies for HT-DR-GFP and HT-DR-ZFN4 were satisfactory 
(62-84%), transfection efficiencies following lipofection of DG-DR-ZFN4 (0.5 
%) and electroporation of DG-DR-ZFN4 and K-DR-ZFN4 (12-40%) were 
relatively low (Table 5.2). The protocol used for the electroporation of DG-DR-
ZFN4 and K-DR-ZFN4 was based on experiments of a former PhD student in 
our group (Jennifer Zobel; personal communication) who achieved 
transfection efficiencies of 70% or more in both cell lines. During the 
electroporation of DG-DR-ZFN4, Trypan blue staining (Section 2.6.5) 
indicated a high level of cell death 48h after transfection. Initially, such cell 
death was considered responsible for the low transfection efficiency.  
To reduce cell death and increase transfection efficiencies, a series of 
tests were carried out on DG-DR-ZFN4, increasing of the amount of cells 
used in the electroporation. Thus cell density was increased from 2x106 till 4, 
6 or 8x106 and cells were electroporated with pmaxGFP plasmid following the 
electroporation protocol described in Section 2.6.6. Although cell death was 
remarkably reduced, the transfection efficiencies were usually even lower 
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than the initial electroporation experiments: the highest efficiency obtained (for 
4x106 DG-DR-ZFN4 cells) was still only 0.5%.  
An alternative electroporation protocol was also tested on K-DR-ZFN4. 
Briefly, 3 x106 cells (instead of 6 x106) were electroporated with 6 µg of 
pmaxGFP plasmid following the protocol described in Section 2.6.6. The 
resulting transfection efficiency (43%) was an improvement. Nevertheless, 
given the apparently low level of ZFN4 activity suggested by the Cel-I assay 
(see Section 4.1.2), it was decided to pursue only methods that gave the 
highest transfection efficiencies ( > 60%).  
A second problem was that, although transfection efficiencies for HT-DR-
GFP-P (and HT-DR-ZFN4-P) were satisfactory (see Table 5.2) the levels of 
GFP expression induced by I-SceI (0.05%- 0.15%) (or by ZFN4) were lower 
than those (~ 6%) obtained by  Pierce et al. (Pierce, Johnson et al. 1999).  
Moreover, a relative high background of basal GFP expression was 
detected in most of the negative controls (Table 5.2). The high GFP 
background was close to the levels of GFP expression induced by I-SceI and 
more especially to the ones induced by ZFN4. The GFP basal expression was 
also detected by Pierce et al. in their 1999 paper (Pierce, Johnson et al. 1999) 
and could be explained by possible spontaneous HR events occurred in some 
of the cells that, subsequently, started to constitutively express functional GFP 
proteins.  
Due to the low levels of induced GFP expression and the relative high 
background detected in the negative controls, the use of pools of cells was 
discarded in favour of the use of single HT-DR-ZFN4 clones.  
 
5.2.4 Screening of individual clones in the HDR assays  
 
Ten out of the twelve HT-DR-ZFN4 clones that were previously selected 
(Section 5.3.2) were used in the HDR assay in order to identify the most 
suitable clone for more detailed analyses. The tests were performed by 
lipofection as before (section 2.7.4) at two different cell plating densities 
(1.0x105 and 1.5x105) on day 1 and the experiments were repeated twice for 
each clone at each cell density.  
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The data collected from the screening of HT-DR-ZFN4 clones highlighted 
key variables affecting the HDR assay. First, although they all carried the 
same reporter HT-DR-ZFN4, the different clones displayed different I-SceI- 
and ZFN4-induced GFP expressions. Most of them (HT-DR-ZFN4-2, -4, -5, -
7, -8, -9 and -10) showed very low levels of I-SceI- and ZFN4-induced GFP 
expression (on average ≈ 0.04% and ≈ 0.02% for I-SceI and ZFN4, 
respectively). These GFP levels were very close to un-induced GFP levels 
(negative controls: average ≈ 0.02%) and therefore these clones were 
discarded in favour of the remaining three (HT-DR-ZFN4-1, -3 and -6) whose 
I-SceI-induced GFP expression was more clearly in excess of the negative 
controls (Figure 5.4). This clonal variation in nuclease-inducible GFP 
expression probably reflects “chromosomal position effects” due to the 
random integration of the pDR-GFP-ZFN4 reporter plasmid in the genome 
indicating that different regions of the chromatin are more or less accessible 
to the nucleases used in these experiments or to HR following cleavage.  
A second important factor that greatly affected the assay was the density 
of cells plated at day 1. It is well know that cell density affects the efficiency of 
lipofection. However, the effect of cell density on nuclease-induced GFP 
expression appeared to be distinct from its effect on transfection efficiency (as 
confirmed by the experiments summarised in Table 5.4). During the 
preliminary tests, in order to identify the optimal cell density for the HDR 
assay, on day 1 two different cell densities were used: 1x105 and 1.5x105 per 
well. Due to the poor levels of GFP expression, an additional density of 4x105 
cells per well, was also tested for three of the clones that previously 
performed poorly in the assay (HT-DR-ZFN4-3, -4 and -5). Transfection 
efficiencies were consistently high (usually above 90%) but I-SceI- and ZFN4-
induced GFP expression was notably better at the lower cell densities. The 
best results were obtained with a density of 1x105 cells per well (see Figure 
5.4) while HT-DR-ZFN4-3, -4 and -5 clones at a density of 4x105 cells per well 
showed values of induced GFP expression similar the ones obtained for the 
relative negative controls (on average ≈ 0.02%).  
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Figure 5.4 I-SceI and ZFN4 induced GFP expression levels in 
three HT-DR-ZFN4 clones.  
Examples of GFP expression in the negative control or induced by I-SceI or 
ZFN4 are reported in the two diagrams as the percentage of GFP positive 
cells on the whole sample population (5x104 cells per sample). The HDR 
assay was performed for each clone at two different cell densities: a) 1.0x105 
cells per well and b) 1.5x105 cells per well. (N=1) 
b) 
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Although all the experiments were carried out using cells originated from 
new liquid nitrogen stocks in order to reduce to a minimum the number of cell 
passages (and therefore avoiding possible silencing of the HDR reporter 
gene), of the three clones that responded satisfactorily to the I-SceI treatment 
in the preliminary screening (HT-DR-ZFN4-1, -3 and -6) the HT-DR-ZFN4-6 
clone showed, in subsequent experiments, a substantial decrease in I-SceI 
and ZFN4 induced GFP expression. The initial test carried out at a cell density 
of 1.0x105 cells per well showed an I-SceI-induced GFP expression of 0.98% 
while two two following experiments, carried out at the same cell density, 
highlighted an I-SceI induced GFP expression of 0.32% and 0.05%, 
respectively. A similar reduction was noticed also for HT-DR-ZFN4-6 cells 
transfected with the ZFN4 expression plasmids. Due to the reduction in 
induced GFP expression and the difficulties in addressing the origins of the 
problem, the HT-DR-ZFN4-6 was not used in the following experiments. 
Some possible explanation for this decrease is examined in Section 5.4.2. 
The levels of I-SceI- or ZFN4-induced GFP expression during the 
experiments carried out in this project were consistently lower than the 5% 
GFP expression reported by Pierce et al. (Pierce, Johnson et al. 1999). In 
order to identify possible differences due to the presence of the additional 40 
bp ZFN4’s target sequence (TS-4), two clones (HT-DR-GFP-7 and -8) 
carrying the original pDR-GFP-HR reporter plasmid, which harbours only the 
I-SceI target sequence in the Sce-GFP gene, were used in a control test. The 
experiments were carried out following the same protocol previously 
described (see Figure 5.3) with cell densities per well plated at day 1 of 1x105 
and 1.5x105 for the HT-DR-GFP-8 and 1.5x105 for HT-DR-GFP-7 (see Table 
5.3). The results showed levels of I-SceI-induced GFP expression similar to 
the ones found for the HT-DR-ZFN4-1 clone arguing against a possible 
negative effect due to the presence of the additional ZFN4’s target sequence.  
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Table 5.3 HDR assay of HT-DR-GFP clones 
 
% GFP+ cells 48h post-transf Cell line 
a Transf. 
technique 
b no. of  
cells 
x105 c NC d I-SceI e TE 
HT-DR-GFP-8 LF 1 0 1.18 92 
HT-DR-GFP-8 LF 1.5 0 0.5 73 
HT-DR-GFP-7 LF 1.5 0 0.02 63 
a LF,  lipofection.  
b Number of cells per well plated the day before transfection. 
c Negative controls. Cells transfected with pGP-FF. 
d Cells trasnsfected with I-SceI expression plasmid (pCβASce)  
e Transfection efficiency: cells were transfected with a GFP expression plasmid 
(pmaxGFP; Lonza). 
 
5.2.5 Detailed analysis of the HT-DR-ZFN4-1 clone 
 
To increase confidence in the collected data, and to fully analyse the effect of 
the cell density on the levels of induced GFP expression, the HT-DR-ZFN4-1 
clone was selected to be used in following experiments due to its relative high 
response to I-SceI and ZFN4 treatment (see Fig. 5.5).  
In order to assess the possible effect of the cell density on the frequency 
of induced HR, four different cell densities were used to perform the HDR 
reporter assay. The day before each transfection (day 1), HT-DR-ZFN4-1 
clone was plated in a 24-well plate at increasing densities of 0.5x105, 1x105, 
1.5x105 and 2x105 cells per well (see Table 5.4). All the experiments were 
conducted on three different days indicated in Table 5.4 as Exp. 1, 2 and 3.  
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Figure 5.5 HDR assays of clone HT-DR-ZFN4-1.  
a) and b) The percentages of GFP positive cells for the negative control (NC), 
I-SceI and ZFN4 are reported in this diagrams as the mean obtained by the 
analysis of data collected from experiments carried out at cell densities of 0.5, 
1.0 and 1.5x105 cells per well. The mean and relative error bars shown in the 
two diagrams were obtained by pooling data obtained during the course of 
nine different experiments carried out at the above mentioned cell densities 
(statistical relevance of the assay was confirmed by the measuring of the p 
values * p= 3.8x10-7 and ** p=2.1x10-7).
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Table 5.4 HDR assays of clone HT-DR-ZFN4-1 
 
% GFP+ cells 48h post-transf 
a no. of 
cells x105  
b Expt 
c NC d I-SceI e ZFN4 f TE 
0.5 1 0.01 1.77 0.09 97 
0.5 1 0 1.92 0.1 nd 
0.5 2 0 1.13 0.05 95 
0.5 2 0.01 1.35 0.04 nd 
1 3 0.02 1.56 0.07 99 
1 3 0 1.83 0.09 nd 
1 1 0 0.71 0.06 95 
1.5 3 0.01 1.16 0.06 98 
1.5 3 0 1.21 0.05 nd 
2 3 0.01 0.46 0.04 98 
2 3 0.01 0.52 0.04 nd 
a Number of cells per well plated the day before lipofection. 
b The three experiments were carried out on three different days. 
c Negative controls. cells transfected with pGP-FF.  
d Cells trasnsfected with I-SceI expression plasmid (pCβASce)  
e Cells transfected with ZFN4 expression plasmids. 
f Transfection efficiency: cells were transfected with a GFP expression plasmid 
(pmaxGFP; Lonza, see Section 2.6.9). nd: not determined. 
 
Nuclease-induced GFP expression levels were found to be inversely 
correlated to the cell densities (Table 5.4 and Fig. 5.6), with the lowest GFP 
expression found at a density of 2x105 cells (with an average of 0.5% GFP 
expression for I-SceI and 0.04% for ZFN4). The effect of the cell density on 
the HDR assay is shown in Figure 5.6. This dependency of the levels of HR 
on the cell density can be explained by the difference in the two main DNA 
repair pathways (HR and NHEJ) used by the cell to correct possible DSBs 
where HR is preferentially used by cells to repair damage during DNA 
replication (more precisely in the S and G2 phases of the cell cycle) and 
therefore during active cell growth while the NHEJ pathway is mostly used by 
the cell during the G1/G0 phase of the cell cycle (Branzei and Foiani 2008). A 
possible hypothesis that could explain the dependence of HR levels to the cell 
density is that cells plated at low densities (e.g. 0.5x105 cells per well) on day 
1 were in an active replication state at the time of transfection (day 2) and 
were still growing when I-SceI or ZFN4 were expressed (day 2 and 3). On the 
other hand, cells plated at 2.0x105 cells per well probably would have reached 
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confluency before I-SceI or ZFN4 were expressed and would have already 
been in the G0 phase of the cell cycle.  
Despite the fact that GFP expression greatly varied with the changing of 
cell density, the ratio between levels of I-SceI and ZFN4 induced HR for each 
experiment was constant suggesting that the ability of ZFN4 to produce DSBs 
at the target locus and to promote HR is on average 20-fold lower than the 
one displayed by I-SceI (Figure 5.5). However, it is not possible to rule out 
that better expression of I-SceI (perhaps because it requires delivery of only a 
single expression plasmid) may have contributed to the higher proportion of 
GFP positive cells and expression levels of both I-SceI and ZFN4 should be 
assessed for example by Western blot.  
Chapter 5: Development and use of an assay for ZFN4-induced homology-directed 
repair 
	   165	  
 
Figure 5.6 Effect of the cell density on the levels of induced 
GFP expression for the HT-DR-ZFN4-1 clone. 
The diagram shows the difference in GFP expression induced in the negative 
control or by I-SceI and ZFN4 at cell densities of 0.5, 1.0, 1.5 and 2x105 cells 
per well. Each value is reported above the relative column as the percentage 
of GFP + cells on the whole cell population (5x104 cells per sample) 
measured by flow cytometry. 
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5.3 Discussion 
 
5.3.1 Creation of the reporter plasmid pDR-GFP-ZFN4 
 
The use in this project of the HDR assay based on the reporter plasmid pDR-
GFP-HR was thought to be a valuable approach to assess the frequencies of 
HR induced by ZFN4 and at the same time to compare them with the well 
characterised activity of the I-SceI endonuclease. Comparing the activity of 
different ZFNs or comparing different customised endonucleases like ZFNs 
and TALEN can be useful to assess the state of novel gene modification 
techniques and, more importantly, to identify the complex factors that can 
affect the frequencies of gene targeting in different cell lines. Unfortunately, 
many different factors affect the efficiency of engineered nucleases and 
therefore it is relatively difficult to compare different gene targeting 
techniques. The factors affecting frequencies of gene targeting can be broadly 
collected in three categories: the type of nuclease used, the type of delivery 
method and the type of cell line. Since the discovery that DSBs produced in 
the genome can greatly stimulate the frequencies of HR (Rouet, Smih et al. 
1994; Choulika, Perrin et al. 1995), different engineered nucleases like ZFNs 
(Wright, Thibodeau-Beganny et al. 2006; Maeder, Thibodeau-Beganny et al. 
2009; Sander, Dahlborg et al. 2011), TALENs (Cermak, Doyle et al. 2011; Li, 
Huang et al. 2011) and meganucleases (Grizot, Smith et al. 2009) have been 
developed as possible tools for gene targeting. Each of these nucleases has 
widely different binding and cutting efficiencies that affect their specificity and 
ability to promote HR and a wide range of binding efficiencies are also found 
within the same category of nucleases due to their modular nature (ZFNs and 
TALEN). Different delivery methods have been shown to affect the 
frequencies of gene targeting (Yanez and Porter 1998; Yanez and Porter 
1999; Carroll 2011) and different cell lines or organisms, where the gene 
modification has to be produced, require different types of delivery methods 
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for both the nucleases expression vectors and DNA targeting construct. 
Finally, the same nuclease can induce widely different levels of gene targeting 
when applied in different cell lines (Li, Haurigot et al. 2011; Zou, Mali et al. 
2011).  
The use of an HDR assay based on the pDR-GFP-HR reporter plasmid 
could be useful to compare the activity of different nucleases by expression of 
their efficiencies as the ratio between the percentage of GFP positive cells 
induced by the nuclease and the one induced by the “golden standard” I-SceI.  
 
5.3.2 Homology-directed repair assay 
 
Preliminary results carried out on pools of HT-DR-ZFN4 and HT-DR-GFP 
cells showed that the use of pools of cells was not ideal for assessing the 
efficiency of ZFN4 in inducing GFP expression mainly for two reasons. The 
results obtained from HT-DR-GFP pool showed relative high levels of GFP 
expression also in the negative controls making it difficult to measure any I-
SceI-induced GFP positive cells. Although not as high as in HT-DR-GFP cells, 
the GFP values obtained from the negative controls of HT-DR-ZFN4 were 
found to be close to those induced by ZFN4. This basal GFP expression can 
be easily explained by a possible spontaneous recombination, in some of the 
cells, between the two GFP cassettes that would at that point start to 
constitutively express the fluorescent protein. Due to the low levels of ZFN4 
cutting efficiency measured by the Cel-I assay (Section 5), the ZFN4 induced 
GFP expression was expected to be low and therefore GFP levels in the 
negative controls of the HDR assay had to be minimal in order to be able to 
easily discriminate between spontaneous HR events from the ones induced 
by either I-SceI or ZFN4.  
The second reason why the pools of HT-DR-ZFN4 cells were discarded in 
favour of individual clones was the relative low GFP expression induced by 
both I-SceI and ZFN4. The discrepancies found between the data collected in 
this project and the ones from Pierce et al. could be ascribed to differences in 
the different cell lines used (HT-1080 cells used in this project and AA8 
hamster cells used by Pierce et al.) or to differences in the transfection 
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methods (lipofection and electroporation, respectively). Although the 
differences in methodology and cell lines used in the two studies could explain 
them, the low levels of induced GFP expression made difficult to assess the 
activity of both I-SceI and ZFN4. By the following screening of ten individual 
HT-DR-ZFN4 clones it was clear that the low induced GFP expression 
measured in the pool was due to the fact that the majority of HT-DR-ZFN4 
cells had a very low response to treatment with I-SceI and ZFN4 with only 
three clones out of ten showing an acceptable level of response to the 
nucleases treatment. Although disappointing, these data could indicate a 
dependence of the nucleases ability to cut their specific target sequence to 
the chromatin structure where the pDR-GFP-ZFN4 reporter plasmid has 
randomly integrated. DNAse I treatment of genomic DNA has been 
extensively used to identify regions that are actively transcribed (euchromatin) 
from regions of the genome that are inactive (heterochromatin) (Kornberg and 
Lorch 1999). The difference in DNAse I accessibility to euchromatin and 
heterochromatin regions of the genome could be also extended to other types 
of nucleases and therefore, depending on the position where the pDR-GFP-
ZFN4 reporter plasmid randomly integrated, some HT-GFP-ZFN4 clones were 
more responsive to I-SceI and ZFN4 treatment than others.  
An additional factor that could have contributed to the low levels of 
induced GFP expression is the hypermethylation of pDR-GFP-ZFN4 reporter 
plasmids that underwent HR events. This phenomenon was examined by 
Cuozzo et al. in a 2007 study where they used the same HDR reporter assay 
developed by the Jasin group in Hela cells (Cuozzo, Porcellini et al. 2007). In 
their study, Cuozzo et al. showed how pDR-GFP-HR reporter plasmids that 
were subjected to I-SceI-induced HR were subsequently silenced by 
methylation and the levels of GFP expression tended to drop during the days 
after transfection. This effect was reversed if the cells carrying the reporter 
plasmid were treated with 5-aza-2-deoxycytidine for 48h after transfection with 
the I-SceI expression plasmid. The silencing effect was not observed in Hela 
cells transfected with a wild type GFP expression vector and therefore this 
effect could only be related to GFP genes that were targeted by HR events 
(Cuozzo, Porcellini et al. 2007).   
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A reduction in GFP expression levels was noticed in this project for the 
HT-DR-ZFN4-6 clone. The initial, relatively high, GFP expression induced by 
I-SceI or ZFN4 was followed, in subsequent experiments, by a drastic 
reduction in the percentage of GFP positive cells. This reduction can not be 
explained by a silencing of the pDR-GFP-ZFN4 reporter plasmid because of 
the continuous selection pressure imposed by puromycin that should have 
prevented the silencing of the reporter plasmid and also because each 
experiment carried out on HT-DR-ZFN4 cells was performed using fresh cell 
samples (and therefore subjected to low numbers of cell passages) originated 
from liquid nitrogen stocks. However, it is possible that the HT-DR-ZFN4-6 
clone was not, in reality, a population of cells originated from a single colony 
but a cell population originated from multiple clones. If these multiple clones 
had the pDR-GFP-ZFN4 reporter plasmid randomly integrated in different 
regions of the chromatin, the relatively high GFP expression detected in the 
first experiments would have been produced by clones with different levels of 
response to the I-SceI and ZFN4 treatment. It is possible that in subsequent 
experiments one of the clones (one with low levels of I-SceI- and ZFN4-
induced GFP expression) could have acquired a growth advantage reducing 
the overall response of HT-DR-ZFN4-6 to I-SceI and ZFN4 treatment.  
The data collected on experiments carried out on the HT-DR-ZFN4-1 
clone indicated that I-SceI (≈ 1.4%) was 20 times more efficient than ZFN4 (≈ 
0.07%) in promoting HR at the target locus. The 20-fold difference between I-
SceI and ZFN4 induced GFP positive cells was constant throughout all the 
experiments and was not affected by the different cell densities that were 
tested. By comparison, Zou et al., who used ZFN4 in a study published in 
2011 (Zou, Mali et al. 2011), carried out a similar GFP correction assay in 
293T cells and detected a percentage of ZFN4-induced GFP positive cells of 
0.16%. The data collected in this project and the one found by Zou et al. are 
difficult to compare due to the different cell lines used (HT1080 and 293T 
cells, respectively) and due to the different types of GFP reporter plasmids 
used (the one used by Zou et al. has a different promoter upstream of the 
GFP gene and the repair template was not included in the same reporter 
plasmid but was transiently transfected along the ZFN4 expression plasmids). 
However, the differences in ZFN4’s efficiencies reported in the two studies 
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show how the activity of the engineered nucleases varies greatly depending 
on both the cell line and the type of assay used to test them and highlight the 
need for a more standardised approach to evaluate different nucleases 
activities. This last consideration supports the idea of using I-SceI as a “gold 
standard” that would allow expressing the efficiencies of possible customised 
nucleases not as a simple percentage of induced GFP positive cells, which 
varies greatly depending on the cell type, on the transfection technique and 
the reporter assay used, but as a ratio between the activity of I-SceI and the 
nuclease to be tested. All the factors that affect the frequencies of ZFN 
induced HR events would also affect the ones induced by I-SceI therefore the 
ratio between the two values should be more or less constant also if the 
experimental conditions varies.  
Different cell densities greatly affected the overall frequency of HR events 
induced by both I-SceI and ZFN4. Cells at lower densities were more 
responsive to treatment with the nucleases indicating that cells in a state of 
active replication are more prone to correct possible DSBs by the HR 
pathway. The dependence of the ZFNs’ efficiencies on the cell cycle, on the 
accessibility of the DNA target locus (chromatin structure) and the possible 
silencing effect observed on genes that underwent HR (Cuozzo, Porcellini et 
al. 2007) are all limiting factors that have to be addressed in order to develop 
an effective gene targeting approach for the treatment of any possible genetic 
disease. These factors are even more relevant for the development of a ZFN-
based gene therapy for β-thalassemia or sickle cell anaemia where the gene 
correction of disease-causing mutation has to be made in undifferentiated 
HSCs or iPS cells. Two papers (Sebastiano, Maeder et al. 2011; Zou, Mali et 
al. 2011) already showed that ZFN-induced gene targeting of the β-globin 
locus in iPS cells occurs with very low frequencies even when using drug 
resistance on the targeting construct to induce positive selection. Although the 
development of novel high-affinity ZFNs or the use of alternative nucleases 
like TALEN will improve the efficiency of gene targeting in HSCs and iPS 
cells, in order to create an effective and, more importantly, safe therapeutic 
approach there will still be the need to better understand all the complex 
factors that could affect HR and therefore the gene correction of possible 
genetic diseases in relevant cell types.     
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6 Chapter 6: Targeted integration at the endogenous 
locus 
 
6.1 Overview 	  
After assessing ZFN4’s cutting efficiency and its ability to promote HR in a 
model GFP-based assay (Chapter 5), the next step was to demonstrate the 
efficacy of ZFN4 to promote gene targeting at the endogenous HBB locus. 
This requires cells to be transiently transfected with ZFN4 expression 
plasmids in conjunction with a DNA repair template homologous to the 
targeted region. Although the expression of ZFNs should greatly increase the 
frequency of HR between the repair template and the target locus, the low 
cutting efficiency estimated for ZFN4 suggested the need for a reliable and 
quick method to select and analyze putative targeting events. For this reason 
it was decided to develop a β-globin gene targeting construct in which a 
selectable marker gene (PuroR, conferring resistance to puromycin) is flanked 
by two extended regions of homology with the β-globin gene. The construct 
was designed so that the puromycin resistance cassette is positioned within 
the ZFN4 target sequence: in this way, possible targeted clones would no 
longer be susceptible to cleavage by ZFN4 excluding the risk of damaging the 
selectable marker. Alternative targeting construct designs were possible but 
were rejected because they were considered inefficient to use. The PuroR 
cassette, for example, could be located in other positions of the construct 
leaving the ZFN4 target site intact but this could lead to cleavage by ZFN4 not 
only of the targeting construct before HR occurs (which may reduce targeting 
efficiency) but also of targeted loci following HR with the risk of damaging, 
through NHEJ, the PuroR cassette if close to the target site. Although this 
problem could be avoided by introducing silent mutations in the ZFN4 target 
sequence of the targeting construct, this would not avoid other potential 
problems such as the chance of crossover events between the PuroR cassette 
and the mutated ZFN4 site so that the resistance cassette does not integrate 
(Fig. 6.1). Other factors that could reduce the frequency of gene targeting are 
the amount of heterology between the target gene and the targeting construct 
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and the distance between the ZFN target site and the site where the 
heterology region (the resistance cassette) should be introduced (Elliott, 
Richardson et al. 1998; Moehle, Rock et al. 2007). Therefore, placing the 
resistance cassette (that has a size of 1.4 kb) precisely at the centre of the 
target site flanked by extended regions of homology should partially 
compensate for this problem (more details in discussion, Section 6.3.1). 
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Figure 6.1 Alternative targeting construct designs.  
a) The two homology regions of the targeting construct and of the target gene 
are in yellow. The ZFN target site is in red while the puromycin cassette is in 
green. A ZFN-induced DSB and successive HR between the homology 
regions will introduce the PuroR cassette at the target locus and at the same 
time will disrupt the ZFN target site preventing further ZFN cleavage of the 
successfully targeted gene. b) In this construct-design the position of the 
PuroR cassette in the targeting construct is shifted leaving the ZFN target site 
intact. In this type of design ZFNs could cleave the targeting construct before 
HR occurs and could also cleave possible targeted genes with the risk of 
disrupting the PuroR cassette through NHEJ.  C) This alternative design 
introduces in the construct a modified target site (in blue) that cannot be 
cleaved by ZFNs. This would circumvent the problematic examined in b) but 
the targeting construct would still be inefficient: the PuroR cassette would be 
integrated in the gene only if a double-crossover event would occur between 
points 1 and 3 (indicated in figure) but not in the case of a double crossover 
between points 1 and 2.   
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6.2 Results 
 
6.2.1 Creation of a targeting construct specific for the β-
globin gene 	  
Following the above considerations, an initial targeting construct (pBL-TV-TC, 
Fig. 6.2 c) was designed as a puromycin resistance cassette (driven by the 
SV40 promoter) flanked by a left homology arm of 2 kb and a right homology 
arm of 2.5 kb. Two sets of different primers (see Section 2.5.3) were designed 
in order to PCR amplify the two arms of homology and to introduce at the 
same time suitable restriction sites for easy cloning. Genomic DNA from K562 
cells was used as a template for the PCR reactions while a high-fidelity Taq 
polymerase (Phusion from Thermo Scientific) was used in order to reduce the 
risk of introducing unwanted mutations that could reduce the rate of homology 
between construct and target site. The first pair of primers (HAL-F and HAL-
R) amplified a 2 kb region 3 bp upstream of the TS-4 while the second pair of 
primers (HAR-F and HAR-R) amplified a 2.5 kb region 15 bp downstream of 
the target site (Figure 6.2 b). The newly created homology arms were then 
digested with the specific restriction enzymes (described in Section 2.5.3) and 
cloned in the pBL-Puro plasmid in two sites flanking the resistance cassette. 
This first targeting construct was called pBL-TV-TC and had a size of 8.8 kb 
(Fig. 6.2 c).  
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Figure 6.2 Design of targeting constructs.  
a) Part of HBB exon1 sequence (red) showing the TS-4 target site 
(highlighted yellow) and the HAL-R and HAR-F primers (underlined) used to 
amplify the homology arms. b) Map (roughly to scale) of the β-globin gene 
region showing exons 1, 2 and 3 (red boxes), TS-4 (yellow segment) and the 
locations and orientations of PCR primers (arrows) used to amplify the 
homology arms. Chromosomal regions flanking the left and right regions of 
homology are depicted in grey. c) Map of the initial targeting construct (pBL-
TV-TC; vector DNA omitted; for a full map see Appendix 1) with DNA depicted 
as in b) showing the puromycin resistance cassette (green arrow) located 
between the two homology arms. Regions of homology between the pBL-TV-
TC and the target locus are indicated by dashed lines between b) and c). The 
ApaI and KpnI sites, used to generate the final targeting construct (pTV-TC4) 
are indicated. d) Map of the final targeting construct pTV-TC4 (vector DNA 
omitted; for a full map see Appendix 3). Due to difficulties originated during 
the detection by PCR screening (see Section 6.2.1) of the positive control 
pBL-TV-pc construct when integrated in the genomic DNA of transfected cells, 
the original pBL-TV-TC targeting construct had to be modified by the 
shortening of the left homology arm by taking advantage of the two ApaI and 
KpnI sites indicated in c). e) DNA sequence of junctions between the PuroR 
cassette (green) and homology arms (red) in both pTV-TC4 and pBL-TV-TC. 
Sites for EcoRI and ClaI used when cloning the Puromycin cassette are 
underlined (additional information in Materials and Methods; Section 2.5.3).       
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To detect and confirm targeting events at the β-globin locus, a specific 
PCR assay was developed based on primers PT1-F and PT1-R.  The target-
specific primer (PT1-F) binds to the globin locus immediately upstream of the 
left homology arm of pBL-TV-TC, while the construct-specific primer (PT1-R) 
binds within the PuroR cassette (Fig 6.3 a). In this way only authentic targeting 
events should generate a characteristic 2.5 kb PCR product (the PCR assay 
is described further in Fig. 6.3). In order to optimise and test the efficiency of 
the assay, a positive control plasmid (pBL-TV-pc; Fig 6.3 b) was generated 
from pBL-TV-pc by adding a 23 bp sequence to the end of the left hand 
homology arm (see Section 2.5.3). This 23 bp sequence was homologous to 
the PT1-F primer but included a novel SpeI site immediately upstream of the 
left homology arm. While the pBL-TV-pc amplification products is almost 
identical to that expected from a targeted clone, it differs in that it is 
susceptible to cleavage by SpeI. Thus any false-positive PCR assays 
resulting from contamination of test assays with pBL-TV-pc can be eliminated 
by showing that the PCR is sensitive to digestion with SpeI.  
Initially, amplification (PCR condition reported in Section 2.5.3) from pBL-
TV-pc alone was used to confirm the correct size (2.5 kb) of the PCR product 
(Fig 7.3 d, lane 3). The PCR reaction was then repeated (same PCR condition 
of Section 2.5.8) mixing 7 pg pBL-TV-pc with 4 µl (≈ 0.3 µg) of genomic DNA 
isolated from untransfected K562, in order to asses the ability of the assay to 
detect small copy numbers of target in the presence of genomic DNA. 7 pg of 
pBL-TV-pc was calculated to be around 7x105 copies of the plasmid. In 
comparison, 4 µl of genomic DNA were considered to have 4x104 copies of 
each β-globin allele (Genomic DNA was extracted from 106 cells and 
resuspended in 100 µl therefore 4 µl would contain 4x104 copies of each 
allele assuming 100% recovery). The expected 2.5 kb PCR product was 
detected on agarose gel in both reactions (plasmid alone or plasmid plus 
genomic DNA) Fig. 6.3. 
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Figure 6.3 PCR assays for targeted integration.  
a) Expected structure of pBL-TV-TC (left hand region only) after targeted 
integration. DNA is represented as in Fig 6.2. A 2.5 kb PCR product 
diagnostic for targeted integration is expected for primers PT1-F/PT1-R, as 
indicated. b) Structure of pBL-TV-pc (left hand region only). pBL-TV-pc has 
the same structure as pBL-TV-TC except for an additional 29 nucleotides 
(grey), cloned immediately upstream of the left homology arm, that binds to 
PT1-F and includes an SpeI site, as indicated. Expected PCR products using 
the alternative set of primers are shown below pBL-TV-pc map. c) Expected 
structure of the left hand portion of pBL-TV-TC after targeted integration. The 
PCR product from primers PT3-F and PT2-R diagnostic for targeted 
integration of pTV-TC4 is shown below the map. d) PCR reactions using PT1-
F and PT1-R primers. Lane 1: 7 pg of pBL-TV-pc plasmid mixed in 4 µl (0.3 
µg) of K562 genomic DNA. Lane 2: pBL-TV-pc integrated in K562 genomic 
DNA (0.3 µg). Lane 3: pBL-TV-pc plasmid alone (7 pg). e) Temperature 
gradient (50°C to 60°C ) PCR using PT1-F and PT1-R primers. The PCR 
reaction resulted positive only for samples containing 7 pg pBL-TV-pc plasmid 
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mixed in 4 µl of K562 genomic DNA (bottom part of the picture). When pBL-
TV-pc was integrated in K562 genomic DNA the PCR resulted negative (top 
part of the picture) except for a band in the first line (temp. 50°C ) due to 
possible aspecific binding of the primers. f) Successful PCR reaction using 
PT3-F and PT2-R primers gave the characteristic 1.4 kb PCR product. Lane 
1: pBL-TV-pc integrated in K562 genomic DNA (0.3 µg). Lane 2: genomic 
DNA from untransfected K562 cells (0.3 µg). Line 3: positive control, 7 pg 
pBL-TV-pc plasmid mixed in 4 µl of K562 genomic DNA. 
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In a third stage, pBL-TV-pc was stably integrated in the genome of both 
K562 and HT1080 cells (see Section 2.6.6). Cells were selected in puromycin 
for 15 days and then genomic DNA was extracted. 0.3 ug of each of these two 
genomic DNA samples were then used as a template in order to test the 
ability of the PCR assay to detect the presence of the construct when 
integrated in the genome. Unfortunately, no product was detected either for 
the K562 cells (Fig. 6.3 d, lane 2) or the HT1080 cells (not shown). To 
address the problem, different PCR conditions were explored: in a first 
attempt, a gradient of annealing temperature (between 50°C and 60°C) was 
used to optimise the reaction but the PCR still resulted negative (Fig. 6.3 e). 
Next, in the attempt to resolve possible secondary structure that could 
interfere with the reaction, 1.5 µl of Dimethyl Sulfoxide (DMSO) were added to 
the 50 µl PCR reaction. Also in this case the PCR reaction resulted negative 
(data no shown). As a last attempt, the concentration of MgCl2 was increase 
from 0.5 mM to a maximum of 1.5 mM but, still, the PCR did not produce any 
product (data not shown). During the creation of the targeting construct pBL-
TV-TC, the PCR reaction used to amplify the left homology arm resulted to be 
highly efficient therefore it was assumed that problems during PCR 
amplification using PT1-F and PT1-R were due to poor designing of the 
primers, to differences between polymerases (high-fidelity Phusion used in 
the creation of pBL-TV-TC vs Dream Taq used in the PCR screening) or to 
some secondary structure (e.g. hairpin-like structures) of the DNA region 
immediately upstream of the left homology arm (Nelms and Labosky 2011). 
Secondary structure are usually associated to high GC content therefore the 
sequence to be amplified by PT1-F and PT1-R was inspected for a possible 
high GC-content that could have affected the PCR reaction but the overall 
percentage of GC was found to be ≈ 35% (determined by the Ape plasmid 
editor software). The sequence was also searched for smaller specific GC-
rich regions but none were identified (sequences of pBL-TV-TC and of the β-
globin gene in Appendix 3). Therefore, in order to overcome these difficulties, 
it was decided to design a new set of primers and consequently to modify the 
original pBL-TV-TC targeting construct. 
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A new reverse primer (PT2-R) that would bind immediately upstream of 
the PuroR cassette’s ORF and two other forward primers (PT2-F and PT3-F) 
that would bind downstream of the first PT1-F (Fig 6.3 b) were created. The 
PCR reaction was repeated on the previously extracted genomic DNA 
(containing the integrated pBL-TV-pc) using primer pairs PT2- F/PT2-R or 
PT3-F/PT-2R. Under the PCR conditions chosen (see Section 2.5.3) the 1.8 
kb PCR product from primers PT2-F/PT2-R was not detected (data not 
shown) but the expected 1.4 kb PCR product from primers PT3-F/PT2-R was 
readily detected (Fig. 6.3 f). Based on this result, a new targeting construct, 
pTV-TC4 (Fig 6.3 c), was generated from pBL-TV-TC.  Apart from a 
shortened left homology arm of 1.4 kb that no longer extends far enough 
upstream to include the PT3-F sequence, pTV-TC4 is identical to pBL-TV-TC.  
As described in detail in the following sections, gene targeting experiments 
were carried out co-transfecting cells with ZFN4-encoding sequences, in the 
form of mRNA or expression plasmids, and with variable amount of pTV-TC4 
targeting construct. Cells were then selected in puromycin for 15 days and 
possible targeting events were detected through two different methods: PCR 
screening with primers PT3-F/PT2-R and Southern blot. 
 
6.2.2 Transfection of K562 cells with pTV-TC4 and selection of 
Puro-resistant clones 	  
K562 cells were transfected, by nucleofection (Section 2.6.8), with ZFN4 in 
the form of expression plasmids or mRNA, and with increasing amounts of 
pTV-TC4 targeting construct, in order to identify a possible correlation 
between the frequency of targeting events and the concentration of pTV-TC4. 
Three experiments were carried out with three different amounts of pTV-TC4 
(2,4 and 8 µg in experiments 1, 2 and 3, respectively, Table 6.1). Each 
experiment involved two nucleofections, one in which nucleic acid encoding 
both ZFN4 subunits was used, the other, a negative control, in which 4 µg of 
an unrelated plasmid (pGP-FF) (experiments 1 and 2) or only 4 µg of ZFN4L 
(experiment 3) was used. When ZFN4(L)  and ZFN4(R) were co-transfected, 
the nucleic acid was mRNA (experiments 1 and 2) or DNA (experiment 3). 
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The mRNA was provided by Sigma in the form of pre-mixed aliquotes 
containing 2 µg of each expression construct (ZFN4(L) and ZFN4(R)). In each 
nucleofection, one million K562 cells were nucleofected. Transfected cells 
were left to recover for 48h in an incubator at 37 °C in presence of 5% CO2 
and then puromycin selection was started. Transfected cells were divided into 
two batches: bulk selection on the first batch of around half a million cells was 
used in order to create a pool of puromycin resistant clones. The resulting 
population was split using some for storage in liquid nitrogen and some to 
prepare genomic DNA. The second batch of cells, instead, was plated in 96-
wells plates at limiting dilution in presence of puromycin in order to obtain 
wells of cells derived from individual (or a very few) PuroR cells. Cells 
transfected with 2 and 4 µg of pTV-TC4 (experiments 1 and 2) were plated at 
density of 103 cells per well while cells transfected with 8 µg of pTV-TC4 
(experiment 3), which were expected to have a higher percentage of targeting 
events, were plated at a density of 0.5x103 cells per well.  
Experiments 1 and 2 were carried out in parallel using cells from a single 
culture and nucleofection reagents from Lonza (Section 2.6.8). Expt 3 was 
carried out with a distinct culture, at a later date, and using nucleofection 
reagents from Mirus (2.6.8). To determine the transfection efficiency, 1 million 
cells from each of these two cultures were nucleofected with a GFP 
expression plasmid (pMaxGFP; Lonza) in parallel with the experimental 
nucleofections and under conditions that were otherwise identical. The 
percentage of GFP positive cells was determined by flow cytometically 48h 
after nucleofection (Section 2.6.8). Thus transient transfection efficiencies of 
72% (expts 1 and 2) and 47% (expt 3) were determined.  
Puromycin selection of the three targeting experiments was carried out for 
15 days. Afterwards, the number of wells containing PuroR cells was counted 
for each transfection (Table 6.1, row 9). Using Poisson statistics these 
numbers were converted into the frequency of PuroR clones generated  (Table 
6.1, row 10 and 11). In experiments 1 and 2, expression of ZFN4 stimulated 
the frequency of PuroR cells 11.8- and 35.3-fold, respectively. This indicated 
that ZFN4 promotes the integration of pTV-TC4 into the genome (presumably 
at the β-globin locus, although this was yet to be confirmed) and suggested a 
possible correlation between the amount of targeting construct and the 
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number of ZFN4-dependent integration events. In experiment 3, however, 
ZFN4 expression resulted in only a 1.4-fold increase in the frequency of PuroR 
cells, largely as a result of the relatively high frequency in the absence of 
ZFN4 expression (14 to 22-fold higher than in experiments 1 and 2  [using row 
11 data]). Thus, compared to experiments 1 and 2, the relatively high 
concentration of pTV-TC4 used in experiment 3 (or possibly the use of 
modified nucleofection conditions) appears to have promoted ZFN4-
independent integration of pTV-TC4 much more than the integration in ZFN4-
expressing cells which was almost unchanged compared to experiment 2. At 
this point it was not known whether PuroR cells generated when ZFN4 was 
expressed represented random or targeted integrations. To address this 
question, and to determine whether ZFN4-induced increases in PuroR cells 
represented increases in targeted integrations, it was necessary to test PuroR 
cells for targeted integration at the β-globin locus. 
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Table 6.1 Effect of ZFN4 on HBB gene targeting in K562 cells  
  Expt 1 Expt 2 Expt 3 
1 ZFN4L  mRNA - 2 - 2 - - 
2 ZFN4R  mRNA - 2 - 2 - - 
3 ZFN4L  DNA - - - - 4 2 
4 ZFN4R  DNA - - - - - 2 
5 pTV-TC4 2 2 4 4 8 8 
6 Unrelated plasmid (pGP-FF) 4 -  4 - - - 
7 Transfection efficiency (%) 72 72 72 72 47 47 
8 Number of plated cells/well 1x10
3 
1x10
3
 1x10
3 
1x10
3 
0.5x10
3
 0.5x10
3
 
9 PuroR wells/96-well plate 5/96 43/96 3/96 63/96 33/96 47/96 
10 Average PuroR
 
cells/well 0.053 0.59 0.032 1.06 0.34 0.49 
11 Frequency of PuroR
 
cells (%) 0.005 0.059 0.003 0.106 0.068 0.098 
12 
PCR+ clones/PuroR clones 0/5 19/20 1/3 19/20 0/18 16/20 
13 Relative targeting frequency (%) 0 95 33 95 0 80 
14 
Absolute targeting frequency (%) 0 0.077 0.001 0.139 0 0.167 
 
1-6 1 million cells were transfected with the indicated nucleic acids (ug), distributed in 
96-well plates and selected in puromycin 
7   Percentage of GFP+ cells at 48h in a parallel nucleofection (see text). 
10    –lnF0 where F0= fraction of wells with no PuroR cells (Poisson distribution). 
11 (row 10/row 8) x 100 
13    Row 12 expressed as percentage 
14    Product of rows 11 and 13 divided by row 7 
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6.2.3 PCR screening of puromycin resistant cells  	  
The PCR assay based on primers PT3-F and PT2-R (section 6.2, Fig. 6.3 c) 
was then used to screen PuroR cells and discriminate genuine targeting 
events from PuroR cells generated by the random integration of pTV-TC4.  
In order to reduce both time and costs, it was decided to screen for 
possible targeting events using a colony PCR approach where lysates 
obtained from a small number of puromycin resistant cells would be used as a 
direct template for the PCR reaction (Section 2.4.7). Increasing numbers (103, 
104 and 105) of K562 cells stably transfected with pBL-TV-pc positive control 
(described in Chapter 6.2) were used to identify the minimum amount of cells 
to be used in the assay. PCR reactions using lysates from 103 cells gave a 
very faint signal while lysates from 105 cells originated extensive smears 
when the PCR products were run on agarose gel (data not shown). Of this 
three, the most effective number of cells for the detection of targeting events 
was found to be 104 cells and therefore 104 of PuroR cells from wells of the 
96-well plates in experiments 1 and 2 (Table 6.1) were analysed by PCR.  
In practice, however, it was found that the diagnostic 1.4 kb PCR product, 
when detected by colony PCR, was often very faint (Fig 6.4 a), in contrast to 
the signal obtained in the same assay using positive control cells (K562 with 
randomly integrated pBL-TV-pc) The colony PCR assay was thus close to its 
limit of sensitivity in detecting targeted cells and it was necessary to carry out 
the colony PCR assay multiple times in order to distinguish those cells that 
were consistently unable to generate the 1.4 kb product (PCR-negative) from 
those that could, albeit inconsistently, generate the 1.4 kb product (PCR-
positive). Although the PCR-positive cells were almost all from cells that had 
been transfected with ZFN4-encoding mRNA, the colony PCR assay was 
considered too time consuming and it was decided instead to expand cells 
until there were enough (1 million cells) to prepare genomic DNA and then 
perform a standard PCR reaction. 
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Figure 6.4 PCR assay for the detection of targeting events.  
a) Example of screening for targeting events using colony PCR assays. An 
agarose gel electrophoretic analysis is shown of 13 assays, each on 104 cells 
from a single well of a 96-well plate in experiment 2 (Table 7.1, + ZFN4 
mRNA). Although the diagnostic 1.4 kb PCR product was not detected in 
samples 3,5,7 and 13, when the analysis was repeated a second time the 
samples resulted positive (not shown). b) Example of negative controls during 
PCR screening. Each PCR reaction was paired with negative controls in order 
to rule out possible false positives due to contamination. Line 1: genomic DNA 
from untransfected K562. Line 2: genomic DNA from untransfected HT1080. 
Line 3: PCR reaction without any template. c) Example of screening for 
targeting events using PCR assays on genomic DNA isolated from cultures 
originating from single wells from experiment 3 (Table 7.1; + ZFN4 plasmids). 
Of the 5 cultures analysed only one (lane 2) was negative and when the 
analysis was repeated (not shown) this sample was again negative, 
confirming it to be a non-targeted clone. d) PCR assay carried out on genomic 
DNA originated from pools of cells. Lane 1: negative control, untransfected 
K562 cells. Lane 2: K562 transfected with only 2 µg of pTV-TC4 (second 
negative control). Lane 3: K562 transfected with only 4 µg of pTV-TC4 (third 
negative control). Lane 4 and 5: K562 transfected with ZFN4(L) +ZFN4(R) 
and 2 or 4 µg pTV-TC4, respectively. 
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When the PCR assay was repeated on genomic DNA the 1.4 kb bands 
present on the agarose gel were clearer and the intensity was more constant 
between samples (Fig. 6.4 c). To address the possibility that cultures testing 
positive reflected contamination (either with a plasmids such as pBL-TV-pc, or 
genomic DNA from a targeted culture) negative control assays were carried 
out in genomic DNA from untransfected K562 and HT1080 cells and these 
always failed to generate the 1.4kb PCR product. This excludes 
contamination of PCR reagents but cannot exclude the possibility that some 
genomic DNA preps from non-targeted cultures were contaminated. Although 
the original targeting construct (pBL-TV-TC) was designed so that 
contamination with pBL-TV-pc could be indicated by sensitivity to SpeI-
digestion, this was not possible with the final targeting construct, (pTV-TC4). 
Subsequent analyses by Southern blots (see Section 6.2.4) however suggest 
that contamination was not a problem.  
Initial PCR screening of genomic DNA was carried out on the pools of 
PuroR cells from experiments 1 and 2 (section 6.2.2). The 1.4 kb band, 
characteristic of possible targeting events, was found only in samples coming 
from cells transfected with both ZFN(L) and ZFN(R) and pTV-TC4 (Fig. 6.4 
d)., This result clearly suggests that the increased frequencies of PuroR cells 
seen when cultures were transfected with ZFN4 mRNA were indicative of 
increased frequencies of targeted integration. 
To estimate the proportion of PuroR cells that had undergone gene 
targeting as a result of ZFN4 expression the same PCR assay was used to 
screen genomic DNA obtained from the cells in a selection of puromycin 
resistant wells from each of the three experiments (Table 6.1, row 12). Based 
on the proportion of PCR-positive wells detected in this way, the relative 
targeting efficiency (% of PuroR cells that were targeted) and absolute 
targeting efficiency (% of transfected cells that were targeted) were estimated 
for each nucleofection (Table 6.1, rows 13 and 14, respectively). In the 
negative controls (no ZFN4 expression or expression of only ZFN4(L)) the 
relative targeting efficiency was generally low: 0/5 (0%), 1/3 (33%), and 0/18 
(0%) in experiments 1, 2 and 3, respectively. Given the small sample size, 
particularly in experiment 2, these values are necessarily rough estimates. 
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Nevertheless, the value for experiment 3 (0/18) provides strong evidence that 
the relatively high frequency of PuroR cells obtained in the absence of ZFN4 
(0.068%) reflects random integration of pTV-TC4. When ZFN4 was 
expressed, however, the relative targeting frequency was high (80-95%), and 
the absolute targeting efficiencies were hugely stimulated, in all three 
experiments. These data therefore clearly suggest a strong correlation 
between the expression of ZFN4 and the frequency of gene targeting of the β-
globin gene.  
 
6.2.4 Confirmation of targeting events by Southern Blot 
analysis 	  
Although they are widely used to detect targeting events, PCR assays can 
give false positives, for instance by contamination. Even if contamination is 
ruled out, it has been shown that under some conditions a clone with a 
randomly integrated targeting construct can generate the PCR product 
indicative of a targeting event (see Section 6.3.2) (Frohman MA and Martin 
GR 1990). It was therefore important to confirm by another method that 
putative targeted clones identified by PCR were genuinely targeted. For this 
reason, targeting of the β–globin gene was confirmed using Southern Blot 
analysis. A specific radioactive probe of ≈ 600 bp was designed to bind 
immediately upstream of the region of homology between the β-globin gene 
and the left arm of the pTV-TC4 targeting construct (Section 2.3.4). Digestion 
of genomic DNA with HindIII restriction enzyme would generate, in the 
untargeted β-globin gene, a fragment of 7.8 kb while digestion of successful 
targeted loci would yield a fragment of 3.7 kb due to the introduction of a 
novel HindIII sites located immediately upstream of the puromycin resistant 
cassette (Figure 6.5 a). Both of these fragments should bind the probe. 
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Figure 6.5 Southern blot analysis of K562 and PCR-positive 
PuroR derivatives.  
a) Map of β-globin gene that has (top) or has not (bottom) undergone gene 
targeting with pTV-TC4.  DNA is depicted as in Fig 6.2 and the position of the 
probe used for Southern blotting (yellow) and diagnostic HindIII fragments are 
indicated. b) Autoradiograph of an agarose gel that was blotted and probed 
with the 32P-labelled probe shown in a). Samples loaded and electrophoresed 
on the gel were HindIII-digested genomic DNA from untransfected K562 cells 
(lane 1, NC) or from PuroR cells obtained after transfections of K562 (see 
Table 6.2) with ZFN4 expressing mRNA and either 2 µg (Experiment 1: lanes 
2,4,5) or 4 ug (Experiment 2: lanes 3,6,7) of targeting construct. The genomic 
DNA was isolated from pools of PuroR cells (lanes 2,3) or from individual wells 
obtained after limiting dilution (lanes 4-7).  
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Southern blot analysis was carried out on 6 PCR-positive samples 
obtained following the expression of ZFN4 in experiments 1 and 2 (Table 6.1). 
For each experiment genomic DNA was isolated from a pool of PuroR cells 
and from two of the wells of PCR positive PuroR cells. The DNA was digested 
overnight with HindIII and then hybridized with the 32P-labelled probe (see 
Section 2.4.5). The Southern blot confirmed targeting for all samples tested, 
showing the expected bands for wild type (7.8kb) and targeted β-globin (3.7 
kb) alleles while the negative control (genomic DNA originated from a pool of 
cells from experiment 1 that were transfected with the negative control 
plasmid pGP-FF and pTV-TC4) yielded only the wild-type band at 7.8 kb 
(Figure 6.5).  The relative intensity of the two bands was generally similar 
suggesting that, as expected for clones that had undergone gene targeting at 
one of their two β-globin alleles, or for populations consisting mostly of such 
clones. Not so for lane 1 where the 7.8 kb band resulted to be more intense 
that the 3.7 kb band. This is due probably to the fact that the cell population of 
this specific pool of cells was not originated by only targeting events but also 
by PuroR cells where pTV-TC4 was randomly integrated in the genome. But 
this does not agree with Table 6.2 that shows relative targeting frequencies 
were 95% in both expt 1 and expt 2. 
 
6.2.5 Measure of cell viability after transfection with ZFN4 	  
From the experiments carried out during the GFP correction assay (Chapter 
5) an increased tendency towards cell death was noticed for samples 
expressing ZFN4 relative to negative controls samples that were not 
expressing any nucleases. These observations (based on the appearance of 
cells under phase contrast microscopy 48 h after transfection) were highly 
qualitative. Nevertheless, the GFP assay was repeated many times and the 
cell-death phenomenon was consistently observed in each sample expressing 
ZFN4, but not in the negative controls. Cyto-toxicity induced by ZFNs has 
been previously reported in several studies and has been measured using a 
range of different assays including cell viability measurement, quantification of 
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apoptosis or through the use of specific antibodies for phosphorylated histone 
H2AX or p53 tumour suppressor-binding protein 1 (Bibikova, Golic et al. 2002; 
Alwin, Gere et al. 2005; Beumer, Bhattacharyya et al. 2006; Miller, Holmes et 
al. 2007; Szczepek, Brondani et al. 2007; Cathomen and Joung 2008). In 
order to quantify a possible negative effect of ZFN4 on cell viability, HT1080 
cells were transfected (using nucleofection) either with pZFN4(L) and 
pZFN4(R) (2 µg each) or with 4 µg of pZFN4L alone. Immediately after 
transfection the cells were counted with a haemocytometer (Section 2.6.5) 
and then were plated with serial dilutions onto 10 cm plates. Following 10 
days culture without selection, numbers of colonies were counted and used as 
an indication of cell viability/colony forming units (Table 6.2). The collected 
data suggested that co-expression of the two ZFN4 sub-units could have a 
negative effect on cell survival: plates containing cells that were expressing 
only one of the two sub-units had almost double the amount of colonies. 
These figures suggest a possible apoptotic effect due to DSBs produced by 
ZFNs but, with this single experiment, it was not possible to properly assess 
and quantify it. The experiment should be repeated several times in order to 
exclude possible experimental errors due to differences in transfection 
conditions or errors during the cell counting.  
 
Table 6.2 Cell viability assay 
a number of cells plated b ZFN4(L) c ZFN4(L) + ZFN4(R) 
200 29 15 
500 58 27 
 
a 1 million HT1080 cells were transfected (nucleofection) with only one (ZFN4(L)) or 
with both two sub-units (ZFN4(L) + ZFN4(R)), were counted immedialty after using 
an haemocytometer and were plated at two different densities (200 cells or 500 cells 
per plate). Colony forming units were counted after 10 days.  
b Samples were transfected with 4 µg of ZFN4(L) 
c Samples were transfected with 2 µg of ZFN4(L) and 2 µg of ZFN4(R) 
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6.3 Discussion 
 
6.3.1 Creation of a targeting construct specific for the β-
globin gene  	  
Detection of HR events, and therefore detection of gene targeting, in 
mammalian cells can be quite difficult due to the very low frequencies usually 
obtained. Although the use of ZFNs should increase the frequency of gene 
targeting of around 1000-fold, the low cutting efficiency of ZFN4 noticed 
during the Cel-I assay (Chapter 4) suggested that a correspondingly low 
frequency of targeting events might be obtained. For this reason a specific 
targeting construct carrying a selectable marker flanked by two extended 
regions of β–globin homology was developed to allow rapid and easy 
screening of possible targeting events. The targeting construct was designed 
taking in account two different aspects that could have affected the frequency 
of gene targeting: the amount of heterology between the target gene and the 
targeting construct and the distance between the ZFN cleavage site and the 
position of the resistance cassette to be introduced. The efficiency of gene 
addition at a specific locus is in inverse proportion to the length of foreign 
DNA that has to be introduced: a study from 2007 showed that targeted 
integration efficiencies at the same locus were affected by the length of the 
heterology in the constructs: the introduction of a simple 12 bp tag sequence 
would occur with a 15% frequency but the introduction of a 1.5 kb gene would 
only occur with a 5% frequency (Moehle, Rock et al. 2007). An extended 
stretch of uninterrupted homology flanking the heterology region should 
improve the frequency of HR (Waldman and Liskay 1988) and therefore it was 
decided that the PuroR cassette would be flanked by two long left and right 
homology arms. The relationship between the distance of the DSB in the 
target gene and the heterology region to be introduced has been analysed in 
a paper from 1998 (Elliott, Richardson et al. 1998). In the study, a targeting 
construct was used to correct a defective NeoR cassette integrated in mouse 
embryonic stem cells (ES cells) and at the same time to introduce silent 
mutations (unique restriction sites) at different distances from the DSB. Elliot 
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et al. showed how, already at a distance of 100-200 bp from the DSB, 
mutations carried by the targeting construct are introduced with very low 
frequencies (only 16-17% of the NeoR colonies incorporated the mutation) 
compared to mutations only 8 bp away (83% incorporated the desired 
mutation) (Elliott, Richardson et al. 1998). For this reason, the two homology 
arms were design to introduce, during HR, the PuroR cassette directly at the 
locus of the DSB (Fig. 6.1 a and 6.2). 
Although this type of design should maximise the frequency of gene 
conversion at the target locus, a lasting factor could negatively affect the 
efficiency of HR. When the DSB is introduced by ZFN4, the two ends at the 
cleavage site will have in total a 60 bp region of heterology with the targeting 
construct (see Fig. 6.2 a). During the HR repair pathway, the two regions of 
dsDNA at the DSB will be subject to 5’ to 3’ end resection in order to produce 
long stretches of 3’-end ssDNA that will then invade the DNA repair template 
during the D-loop formation and be used as a priming agent during DNA 
synthesis (more details about DNA repair mechanism in Section 1.8). 
However, in order to be effective as a primer, the 3’-end should be completely 
homologous to the repair template (Paques and Haber 1999). In the case of 
the β-globin targeting construct the presence of this 60 bp heterology could in 
theory reduce greatly the frequencies of gene targeting. Although the cellular 
mechanism is not completely clear, studies in two model organisms (S. 
Cerevisiae and S. Pombe) have identified two sets of proteins involved in the 
processing of heterologous 3’-end ssDNA: Rad1p-Rad10p and Rad16p-
Swi10p in S. Cerevisiae and S. Pombe, respectively. After invasion of the D-
loop by the 3’-end ssDNA, these two sets of proteins (and probably their 
human equivalent XPF-ERCC1) have the function of recognising and remove 
the regions of mismatch (Paques and Haber 1999; Farah, Cromie et al. 2009). 
Although their effect on HR frequencies is not yet clear, the presence of 
heterology regions at the ZFNs’ cleavage sites is going to be a constant 
feature of most of the gene targeting constructs. This is due to the fact that, 
after gene targeting has occurred, additional ZFN cutting has to be avoided in 
order to reduce the risk of damaging the newly corrected gene. This is usually 
accomplished by introducing silent mutations at the ZFN binding site that will 
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prevent the ZFN to cut both the targeting construct and the corrected 
endogenous gene.  
In order to discriminate between genuine targeting events and random 
integration, a specific PCR reaction was developed. A forward primer (PT1-F) 
binds outside the left region of homology and a reverse primer (PT1-R) binds 
immediately upstream of the selectable marker (puromycin). Unfortunately, 
when the PCR reaction was tested using the positive control pBL-TV-pc, it 
was immediately clear that the PCR reaction was able to detect the positive 
control in its plasmid form but not when integrated in the genome of 
transfected cells. To circumvent this problem different PCR conditions and 
reagents were tested (section 6.2.1) but still the PCR reaction resulted to be 
unreliable. GC-rich sequences tend to reduce the efficiency of the PCR 
amplification due to the formation of secondary structures but when the 
sequence to be amplified was checked for possible GC-rich regions none 
were found. The use of the high fidelity Phusion polymerase was considered 
but the possible beneficial advantage in using this more efficient reagent was 
counterbalanced by the relative high costs of the product. This factor was 
considered especially relevant due to the amount of puromycin resistant cells 
to be screened. Therefore, in order to overcome the difficulties in the PCR 
amplification, a new set of primers (PT2-F, PT3-F and PT2-R) was designed 
(for more details see Section 6.2.1 and Fig. 6.3). The newly created PT2-F 
and PT2-R were tested but failed in producing any PCR product. On the other 
hand, when PT3-F and PT2-R primers were used, the PCR reaction became 
more efficient and reproducible on samples containing pBL-TV-pc integrated 
in the genome. Although this last PCR reaction was finally effective in 
producing the desired product (1.4 kb), it was still not clear which factors were 
affecting the two previous sets of primers (PT1-F, PT1-R and PT2-F, PT2-R). 
Following these results the original targeting construct (pBL-TV-TC) was 
modified (to make pTV-TC4) reducing the length of the left homology arm 
from 2 kb to 1.3 kb in order to take in account the modified PCR assay.  
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6.3.2 PCR screening, Southern blot and gene targeting 
frequencies 
  
Initially, the decision of performing the PCR screening directly on cell-lysates 
was made with the aim of reducing the time spent in expanding the cells (104 
cells for the colony PCR compared to ≈ 106 cells for genomic extraction) and 
the costs for the genomic extraction. Unfortunately, although the preliminary 
tests carried out on K562 cells stably transfected with pBL-TV-pc resulted 
consistent in producing the characteristic 1.4 kb band, when the colony PCR 
was performed using cells from puromycin resistant wells the signal greatly 
varied between different samples (Fig. 6.4 a) and in many cases was found to 
be at the limit of detection or completely absent. Two possible factors could 
be responsible for the discrepancy: the preliminary tests and the successive 
positive controls were performed using a pool of K562 cells with the pBL-TV-
pc plasmid randomly integrated in the genome. It could be possible that some 
of the K562 cells had multiple copies of the pBL-TV-pc plasmid integrated in 
the genome or that some of the pBL-TV-pc molecules integrated in regions of 
the genomic DNA that were more “accessible” to the PCR screening 
compared to the β-globin locus. A second factor affecting the PCR screening 
could be related to human errors occurred during the preparation of the 
samples: the PCR screening was performed on a substantial number of 
samples and errors in the counting of the cells or during the isolation of the 
pellet could have affected the performance of the assay. The first step of the 
colony PCR protocol (Section 2.4.7) involved the spinning of the sample to 
remove the media, washing with PBS and again spinning and removal of the 
buffer. Due to the small size of the cell pellet, it is possible that part of the cell 
population was lost during these initial steps effectively reducing the number 
of genomic template.   
Gene targeting frequencies were assessed by transfecting K562 cells with 
ZFN4 and increasing amounts of targeting construct pTV-TC4 (section 6.3). 
The relative frequencies of targeting events for these experiments were used 
as a way to assess the risk of random integration during a possible 
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therapeutic approach. Data collected during limiting dilution in multi-wells 
plates of cells transfected with 2 or 4 µg of targeting construct (experiments 1 
and 2) showed that the expression of ZFN4 was responsible for the increase 
in number of PuroR colonies. Out of a total of 192 wells plated at limiting 
dilution (Tabe 6.2 experimets 1 and 2) only 8 became PuroR after transfection 
with only the targeting construct, compared with 106 wells when transfected 
with the targeting construct and ZFN4 mRNA. Moreover, the PCR assay 
showed that a high percentage (≈ 95%, Table 6.1, row 13) of PuroR wells 
derived by cells transfected with both ZFN4 and targeting construct were due 
to genuine targeting events. The data show that, at these concentrations of 
pTV-TC4 (2 and 4 µg), gene targeting of the β-globin gene would not be 
greatly affected by the risk of oncogenesis induced by random integration. 
Random integration of the targeting construct could occur at a sensitive 
genomic site leading to the activation of a possible proto-oncogene. This 
occurrence has been reported in a famous case study where children with 
severe combined immunodeficiency (SCID) were treated with a retrovirus-
mediated gene therapy approach (for more details Section 1.4). Although the 
technique was effective in curing their disease, 4 patients developed leukemia 
from insertional mutagenesis (Hacein-Bey-Abina, Garrigue et al. 2008). 
Despite the fact that gene targeting does not rely on the random integration of 
a therapeutic vector, the risk of insertional mutagenesis is still a factor to take 
in account due to the large number of DNA template present in the cell during 
gene correction. This negative aspect could be possibly seen in experiment 3: 
the difference between cells expressing or not expressing ZFN4 in presence 
of 8 µg of pTV-TC4 (Table 6.1 expt 3) was much less pronounced than the 
previous experiments. In a therapeutic context, this increase in random 
integration would mean a higher risk of insertional oncogenesis. The use of 
high concentrations of targeting construct to promote higher frequencies of 
gene targeting must therefore be limited to ensure that such risks are avoided.  
Although the PCR screening assay was based on specific primers that 
should only promote amplification when HR events occurred, in reality a 
number of artefacts could produce false positives affecting the reliability of the 
assay. Contamination of the samples to be screened with the pBL-TV-pc 
positive control or with genomic DNA from other targeted cells is the main risk 
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but also possible false positive due to Polymerase Halt-Mediated Linkage of 
Primers (PHLOP) should be considered. During the initial phases of the PCR 
reaction, if the Taq polymerase is prematurely interrupted during synthesis, it 
is possible that the two truncated DNA strands (one for each primer) could 
share regions of partial homology. The annealing of the two truncated strands 
in the following cycles could be used as a template creating false positives 
(Martin 1990). To rule out possible PCR artefacts due to contamination of the 
samples with the positive control or due to PHLOP artefact, it was decided to 
corroborate the PCR assay with Southern Blot analysis and a selection of 
PCR positive samples were selected for further investigation (Chapter 6.2.5). 
The use of Southern blot analysis is widely employed in conjunction to PCR 
assays and DNA sequencing to confirm targeting events and has been used 
also by Zou et al. and Sebastiano et al. in their β-globin targeting experiments 
(Sebastiano, Maeder et al. 2011; Zou, Mali et al. 2011). The selection of 
samples that resulted positive in the PCR assay were found also positive in 
the Southern blot assay while the negative control showed only the 7.8 kb 
band characteristic of the wild type β-globin gene. The relative similar 
intensity of the bands for the 7.8 kb and the 3.7 kb bands indicated that, as 
expected, the targeting of the β-globin locus in this cells was limited to only 
one of the two alleles. This was not true for the pool of cells derived by 
experiment 1 (sample in lane 2, Fig. 6.5) where the 7.8 kb band (wild type β-
globin gene) resulted more intense than the 3.7 kb band. This fact may 
suggest a higher presence of PuroR cells due to random integration of the 
targeting construct but, at the same time, would contradict the data obtained 
with the PCR assay (Section 6.2.3, Table 6.1 row 13). In order to clarify the 
reason of this discrepancy the Southern blot assay should be repeated and, to 
increase the strength of the statistical analysis, the PCR assay should be 
extended at a wider population of PuroR wells.  
Despite the fact that gene targeting levels are affected by the type of cell 
line to be used, due to both varying levels of HR and ZFN accessibility to the 
target site, it is useful to compare the data obtained in this research and the 
one published by Zou et al. in 2012 (Zou, Mali et al. 2011). Zou et al. used the 
same ZFN pair (ZFN4) to produce gene targeting in iPS cells derived from 
bone marrow stromal cells (MSCs) from a patient with sickle cell disease 
Chapter 6: Targeted integration at the endogenous locus 
	   197	  
(SCD). Despite the use of a targeting construct containing a negative 
selection for the counter-selection of randomly integrated vectors, only 4 out 
of 300 selected clones (a relative targeting frequency ≈1%) resulted positive 
in the PCR screening for targeted integration at the β-globin locus (Zou, Mali 
et al. 2011) and only 1 of these resulted positive in the Southern blot analysis 
(the other 3 clones stopped proliferating or did not show up in the Southern 
blot analysis). In a similar study, Sebastiano et al. targeted the β-globin locus 
in iPS cells using a different set of 3 different ZFNs (ZFNA, B and C, see 
Table 6.3) (Sebastiano, Maeder et al. 2011). Although the relative frequency 
of targeting events was 10-fold higher than the frequency measured by Zou et 
al, of all selected clones, on average, only 13% resulted positive in the PCR 
screening and the frequency was significantly less than the figure of 95% 
obtained for this project in K562 cells. These striking differences in targeting 
frequencies can not be explained only by differences in transcriptional status 
of the targeted gene because the β-globin locus is silent in both K562 
(Rutherford, Clegg et al. 1981) and iPS cells. Zou et al. suggest, as an 
explanation, a possible silencing effect of the selectable markers at the target 
locus. Possible epigenetic modification could target preferentially 
unfavourable loci (in this case the β-globin gene) and this could explain the 
high number of resistant clones due to randomly integrated vectors compared 
to the number of targeted ones. These low levels of relative frequency could 
be explained by a generally low level of HR in iPS cells or a relative low 
frequency of HR events at loci that are not actively expressed (Hockemeyer, 
Soldner et al. 2009).  
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Table 6.3 Frequencies of ZFN-induced gene modification at the β-
globin locus 
c Gene targeting 
ZFN 
a Cell 
type 
Cel-I 
assay 
b Selection 
Rel.freq. Abs.freq. 
Ref. 
d ZFN4 K562 1% Puro 95% 0.08% 1 
e ZFN4 K562 1% Puro 95% 0.14% 1 
f ZFN4 K562 1% Puro 80% 0.17% 1 
ZFN4 iPSC - Hygro-GCV 0.3% - 2 
ZFNA 293T 13% - - - 3 
ZFNB PriFib 1% - - - 3 
ZFNC PriFib 2% - - - 3 
ZFNA iPSC - Neo 8% - 3 
ZFNB iPSC - Neo 21% - 3 
ZFNC iPSC - Neo 10% - 3 
a K562 (erythroleukeia), 293T (embryonic kidney), iPSC (induced pluripotent stem 
cells from SCD patients), PriFib (primary fibroblasts) 
b Puro (puromycin), Hygro (hygromycin) GCV (gancyclivir), Neo (neomycin) 
c Gene targeting frequencies: Rel.freq. (relative frequency), Abs.freq. (absolute 
frequency) 
d ZFN4 co-transfected with 2µg targeting construct (pTV-TC4) 
e ZFN4 co-transfected with 4µg targeting construct (pTV-TC4) 
f ZFN4 co-transfected with 8µg targeting construct (pTV-TC4) 
1 Data reported in this project 
2 (Zou, Mali et al. 2011) 
3 (Sebastiano, Maeder et al. 2011) 
 
Absolute frequencies of targeting events at the β-globin gene were highly 
stimulated by expression of ZFN4 (from 0.001% in absence of ZFN4 to values 
of 0.16% in cells expressing ZFN4). These frequencies are ≈10 times lower 
than the frequency of cleavage of the β-globin gene as estimated by Cel-I 
assay (Chapter 4). These values were lower than expected: targeting of a 
different locus (F9 gene) in K562 cells by Li et al. were only 3 times lower than 
the frequency of cleavage (Li, Haurigot et al. 2011). Although frequencies 
increased with the increase in amount of targeting construct (from 0.07% to 
0.16%), also the number of randomly integrated events tended to increase 
therefore ZFNs with increased cutting efficiencies will be necessary to 
improve absolute frequencies. 
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 Although the data collected in this project, and those described by Zou et 
al. and Sebastiano et al., are encouraging for the development of a 
therapeutic gene targeting approach, the low absolute frequencies obtained 
will require the use of targeting constructs with selectable markers that can be 
used to easily isolate possible targeted clones. The absolute frequencies for 
the Zou and Sebastiano papers were not reported but it could be assumed 
that they were lower than the one identified in this project due to the 
difficulties encountered when working with iPS cells. 
As a way to compare the aim and results of this thesis with the actual 
status of ZFNs induced gene-targeting techniques, it could be useful to briefly 
examine the results obtained by Li et al. The study was based on the delivery 
of ZFN and targeting construct through an AVV8 delivery method on a mice 
model of haemophilia. Therefore the conditions were quite different from the 
ones examined in this project (Li, Haurigot et al. 2011). Nevertheless, the 
differences between cleavage and targeting efficiency and the differences of 
targeting efficiencies between different cell lines can be compared to the data 
obtained in this project and in Zou et al. paper. The ZFN used by Li et al. had 
a cleavage efficiency, measured by Surveyor assay, of 45% (one of the 
highest reported till now). When ZFN-induced gene targeting was measured 
in K562, the absolute frequency was found to be 18% but when the targeting 
efficiency was measured in the mice model it dropped to ≈2%. These figures 
show the actual difficulties encountered when moving from a model study to a 
more complex system or when moving from one cell type to another and 
suggest the need of a better understanding of the processes and conditions 
that affect HR in different cell lines. Increasing the efficiencies of novel ZFNs 
is only one of many aspects to be addressed: improved targeting construct 
design, improved delivery methods and a deeper understanding of HR 
mechanics are all factors to be considered in order to improve the safety and 
efficiency of future therapeutic approaches. 
Chapter 6: Targeted integration at the endogenous locus 
	   200	  
 
6.3.3 Measure of cell viability after transfection with ZFN4 	  
Various studies have reported a tendency of cells expressing functional 
ZFNs to undergo apoptosis and different approaches have been used to 
investigate and measure the induced cell death (Bibikova, Golic et al. 2002; 
Alwin, Gere et al. 2005; Beumer, Bhattacharyya et al. 2006; Miller, Holmes et 
al. 2007; Szczepek, Brondani et al. 2007; Cathomen and Joung 2008). In the 
case of this project, possible ZFN4-induced cell death was noticed during by 
phase-microscopic examination of cells expressing ZFN4, both during the 
GFP correction assay (described in Chapter 5) and also during the targeting 
experiments described in this chapter. The first observations had only a 
qualitative aspect and until then it was not possible to confirm or quantify the 
possible negative effect on cell survival. In order to confirm the occurrence of 
ZFN4-induced cell death, and obtain an estimate of its extent, a simple cell-
viability assay based on serial dilutions was used. The results (Table 6.2) 
suggested a ~50% reduction in plating efficiency as a result of ZFN4 
expression. This assay is by no means a definitive approach to investigate 
ZFN-induced apoptosis, and further and more precise analysis would be 
required. The experiments should be repeated in order to acquire enough 
data to produce a statistical significance and a second approach, like the 
employment of apoptotic markers, should be used to confirm the initial 
observation. Although important for a possible transition to a therapeutic 
approach, the in-depth assessment of a possible negative effect of ZFNs on 
cell survival was considered less relevant for the experiments detailed in this 
chapter and therefore was limited to this brief test. The peak in ZFNs 
expression, and therefore the possible apoptotic effect is thought to occur 
during the first 48h immediately after transfection and should be taken in 
consideration when analysing data from experiments with adherent cells. This 
was not considered relevant for the experiments that were carried out on 
K562 suspension cells. As fully explained in Section 6.2.3, 1 million K562 cells 
were transfected (using nucleofection) with or without both pZFN4(L) and 
pZFN4(R) and different amounts of targeting construct, they were left to 
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recover for 48h and then, before been subject to limiting dilution and 
puromycin selection, they were counted with a haemocytometer in 
combination with a cell-viability dye (Section 2.6.5). This approach has been 
used to take into account the different levels of cell survival and to plate, after 
limiting dilution, the same number of living K562 cells before starting 
selection. Nevertheless the 2-fold loss of viabilty is of interest. Usually ZFN-
induced cell death has been ascribed to excessive cleavage at off-target sites 
in the genome (Cathomen and Joung 2008) but the use of forced 
heterodimers in the FokI domain (as was the case in ZFN4) should reduce the 
frequency of off-target cleavage.  Low frequencies of off-target cleavage by 
ZFN4 were suggested, by different means, both in this project (in the case of 
δ-globin; Section 4.2.5, Fig. 4.6 b) and by Zou et al. (in ε,γ and δ-globin gene). 
The Surveyor assay used in this project (Chapter 4) is by no means a 
definitive way to assess off-target cleavage events at the δ-globin locus due to 
its low accuracy (the assay was already barely able to detect on-target 
cleavages) but the approach taken by Zou et al. supports the idea of low 
levels of ZFN4-induced off-target cleavages. In their paper, a GFP correction 
assay, similar to the one described in Section 5 of this thesis, was used to 
investigate cleavage events at the β-globin gene and at highly homologous 
sites of the β-locus genes (ε,γ and δ-globin genes). Significant levels of ZFN4-
induced cleavage were detected only for the β-globin site and not for the ε,γ 
and δ-globin sites  (Zou, Mali et al. 2011). It is therefore difficult to explain the 
two-fold increase in cell death in terms of off-target cleavages and more in 
depth analysis would be required. Until now, the search of possible off-target 
sites has been implemented through queries on BLAST (Basic Local 
Alignment Search Tool) algorithm but this tool is not adequate for the task and 
may miss possible off-target sites. A recent paper (2011) introduced a new 
web-based software (ZFN-Site) that has been specifically developed for this 
type of task (Cradick, Ambrosini et al. 2011). The software is able to carry out 
two different type of searches: one “basic search” where the intended target 
site is used as a base for the query and one “relaxed specificity search” where 
information’s about each ZFN subunits’ specificity (left and right) is taken into 
account. This second function allows for the search of possible off-target sites 
implementing the query with information from SELEX studies (Systematic 
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Evolution of Ligands by Exponential Enrichment) or similar approaches where 
single ZF proteins specificity has been examined (Cradick, Ambrosini et al. 
2011).  
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7 Chapter 7: Final discussion 
 
7.1 Overview 	  
The development of a potential gene targeting therapy for the cure of β-
thalassaemia and sickle cell anaemia would be a tremendous benefit for the 
world population and, more importantly, for those countries that are, at the 
same time, more affected by these type of diseases and do not have enough 
financial resources to provide adequate healthcare to all afflicted individuals. 
Due to the strict relationship with Plasmodium falciparum (the cause of 
malaria), these diseases are prevalent in sub-tropical or tropical areas where 
economic struggle has hampered efforts to address the needs of 
globinopathies patients. Furthermore, only two therapeutic solutions are 
available for β-thalassaemia and sickle cell anaemia: one, blood transfusion, 
is only a palliative approach that is affected by serious contraindications while 
the other, bone marrow transplantation is limited by donor availability (see 
Section 1.1). 
This project has tried to address all these problems by developing the 
basis for a potential therapeutic approach for monogenic β-globin diseases 
based on gene correction of the β-globin locus mediated by ZFNs.  
A gene-targeting based therapy would be more affordable than life-long 
blood transfusion/iron chelation therapies because it would require only a 
single treatment; at the same time, it would solve the lack of bone marrow 
donors because the hypothetical patient would be the source of his/her own 
donor cells (after the duly correcting the disease-causing mutation).  
     
7.2 Open-source or commercial approach?  	  
In the course of this project, both open-source and commercial methods were 
used to obtain a functional ZFN specific for the β-globin gene. This double 
strategy has created the opportunity to compare the two widely different 
approaches from both a practical and ethical point of view. 
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 The development by the Zinc Finger Consortium and other groups of 
protocols and reagents for the design and production of ZFNs has created the 
opportunity for research groups to generate ZFNs at an affordable price, while 
also contributing to the improvement of the technologies involved. An open-
source approach has the advantage of promoting a collective effort where 
shared ZF archives and knowledge are vital for the fast and efficient 
development of novel ZFN platforms. This process has also the advantage of 
reducing the production costs allowing a greater number of researchers to use 
this technology. Cost-related issues are of fundamental importance to patients 
that could be able to benefit from a ZFN-based therapy. A wide range of 
genetic diseases (known as rare diseases) occurs with a very low frequency 
affecting a small percentage of the world population. These low incidences 
have the effect of limiting the amount of funding devoted to the research into 
potential therapies (due to the low impact of the disease on the world 
population) and also reduce the interest of the private sector due to the 
restricted size of the market and the expected low profit from the sale of rare-
disease drugs. In contrast, non-commercial, low-cost ZFN technologies are 
more likely to, be implemented by rare-disease research groups with limited 
funding and the cost-benefit would be also transferred to the patient where the 
costs of any resulting ZFN-therapy would not be increased by the price of 
royalties to be paid to the owners of the underlying intellectual properties. 
Unfortunately, the first open-source approaches, like the one used in this 
project, are difficult and time-consuming to implement and the low rate of 
effective ZFNs produced with these methods has been a limiting step to the 
creation of reliable therapeutic procedures. The interest of the scientific 
community, however, has brought increasing numbers of researchers into the 
field and new, robust and easier protocols like the OPEN or CoDA systems 
have been developed (Maeder, Thibodeau-Beganny et al. 2009; Sander, 
Dahlborg et al. 2011).  
On the other hand, the monopoly on the ZFN market imposed by Sangamo 
Bioscience (that has the majority of patents on zinc finger technologies) has, 
in the opinion of some researchers, promoted the progress of the field and 
reduced the costs of acquiring licences from different parties 
(Chandrasekharan, Kumar et al. 2009). The centralization resulting from 
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Sangamo’s monopoly and the associated extensive financial effort has 
brought a large number of scientists to work within the same company, 
promoting close collaboration and accelerating the development of new 
technologies. Chandrasekharan argues also that a monopoly of the ZFNs 
market would not affect public researchers due to the fact that “academic 
scientists routinely ignore patents and private-sector patentees 
correspondingly refrain from enforcing their patents” (Chandrasekharan, 
Kumar et al. 2009). For the sake of transparency, it should be noted that 
Chandrasekharan was one of the first researcher to sell a ZFN-license to 
Sangamo and sat on the company’s advisory board for several years (Scott 
2005). 
Undoubtedly, purchasing ZFNs from Sigma (that has acquired the license 
from Sangamo) has the advantage of greatly reducing the effort and the time 
spent in creating and testing ZFNs. The company designs, validates and 
provides the final product in less than four months allowing the researcher to 
dedicate more time to the actual application of the nuclease and the 
development of a hypothetical therapy. Unfortunately the costs of purchasing 
a ZFN is still prohibitive (£20,000 for a custom nuclease) and, unlike the open-
source approaches that allows the creation of multiple ZFNs specific for any 
desired gene with only one kit, Sigma’s prices are related to individual ZFN 
requiring a new purchase for every new gene or DNA sequence to be 
targeted. 
In the case of this project, additional doubts were cast on the transparency 
and reliability of the company. Sigma offers ZFNs under two different prices: 
“off the shelf” ZFNs that have been already created are sold for £9,000 while 
custom nucleases, due to the costs of development, are sold at full price. In 
case of two different research groups simultaneously requesting a ZFN for the 
same target sequence, Sigma demands the full price from both groups 
reasoning that, in order to preserve the privacy of all involved parties, they 
cannot disclose purchase requests made by other costumers. This was 
probably the case for this project were the custom ZFN4 was also purchased 
by another lab around the same time and without the knowledge of the two 
research groups involved in the acquisition (Zou, Mali et al. 2011). Although 
the privacy and interest of the costumer has to be preserved at all costs, the 
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secrecy adopted by the company allowed them to double the profit at the 
expense of publicly funded groups. 
A second issue is related to the validation step performed by Sigma: while the 
company, at the time of the purchase, reported a 10% cutting efficiency of 
ZFN4 measured by Cel-I assay, a later conversation with an employee of the 
company revealed a totally different cutting efficiency with a reduction of 5 fold 
on the previous assessment (see Section 4.2.1). In the case of a big company 
like Sigma, only a rough estimation of ZFNs’ efficiencies can reasonably be 
expected due to the large number of molecules that has to be processed 
everyday, but such a 5 fold overestimate can greatly affect the work of the 
research group that ordered the nuclease, especially if the financial effort 
required to acquired a tailored ZFN is considered.  
An additional point can be made about overestimation in cutting efficiencies: 
although the development of ZFN-based therapeutic treatments is still at its 
infancy and substantial work has yet to be done by researchers, it has been 
increasingly clear that highly efficient ZFNs will be required in the future in 
order to develop a reliable approach for the cure of rare monogenic diseases. 
While ZFNs with low cutting efficiencies can still be used for research 
purposes to obtain valuable results, thanks to the use of efficient transfection 
and selection methods in well characterized research models (e.g. cell lines 
like K562, HEK293 cells or model organisms like mice), such low-efficiencies 
are likely to be compounded during clinical applications by numerous factors 
such as sub-optimal transfection efficiencies, limited accessibility of target 
stem cells (e.g. HSCs or iPS cells) and low frequencies of HR in such cells. 
Some of the factors that could affect future therapeutic applications will be 
addressed in the following sections.  
In view of these considerations, a low cutting efficiency of 10% (the figure 
suggested by the Sigma team during their initial assessment) for ZFN4 would 
probably not be of therapeutic value but could at least have been a solid base 
for subsequent developments. Instead, the 2% cutting efficiency identified 
here for ZFN4 was already at the limit of detection in the Cel-I assay and was 
similarly limiting in both the HDR reporter assay and in the targeting of the 
endogenous gene in K562 cells. Sigma-Aldrich states in its commercial advert 
for custom ZFNs that thanks to their nucleases “single or biallelic edits occur 
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in 1-20% of clone population” (Sigma-Aldrich). Although the Sigma service is 
directed towards research applications, ZFNs need to move, in the near 
future, to clinical settings where frequencies of 1-20% will not be enough. In 
my opinion, in addition to improved delivery methods and a better 
understanding of the factors that determine gene targeting efficiencies in 
different tissues and cell types, it will be necessary to design multiple ZFNs for 
each possible monogenic disease gene in order to find the most effective one. 
If such a set of ZFNs had to be ordered from Sigma at the price of £20,000 for 
each nuclease, the relative costs of the research process would be too high 
for the small charities and funding bodies that finance the research of rare 
monogenic diseases. The high costs of the final ZFN-based gene therapy 
would be also transfered to the single patient or the National Health System 
reducing, in the end, the number of treated patients. 
 
7.3 Challenges for gene targeting in HSCs and iPS cells 
 
Haematopoietic Stem Cells (HSCs) would be the preferred target cells in a 
possible ex-vivo therapeutic approach of β-thalassaemia based on ZFNs. The 
safe and specific gene editing of HSCs could in theory not only cure 
thalassaemias but could also be used to treat a wide range of genetic or 
acquired diseases including SCID, sickle cell anaemia or AIDS. Unfortunately, 
both traditional gene therapy and gene targeting in HSCs have encountered 
many obstacles that have delayed the potential therapeutic benefits of these 
two, otherwise promising, approaches. In addition to the now well known risks 
of inducing leukaemias by the integration of traditional viral vectors close to 
proto-oncogenes (as the SCID clinical trial showed (Hacein-Bey-Abina, 
Garrigue et al. 2008)), the clinical application of HSC gene therapy/gene 
targeting is affected by a series of technical difficulties derived by the intrinsic 
complexity of working with HSCs. One main obstacle is the limited number of 
HSCs that can be obtained from a patient: the CD34 marker is usually used to 
select and “enrich” stem cell populations but it seems that only a fraction of 
CD34+ cells are genuine HSCs. Therefore there is a continuing need to 
develop more effective methods to expand, ex-vivo, these limiting number of 
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HSCs (Kiem, Jerome et al. 2012). The inherent difficulties of expanding stem 
cells while, at the same time, maintaining their self-renewal ability and 
engraftment capacity are also factors that limit the efficacy of many other 
possible clinical applications and therefore, in order to obtain long-term 
therapeutic advantages, the auto-transplant of HSCs that do not have a 
competitive advantage requires preventive and possibly toxic myeloablative 
treatments like chemotherapy or irradiation (Riviere, Dunbar et al. 2012).  
The limited number of HSCs that can be used also requires a high level of 
transfection efficiency (obtained by viral vector delivery or other means like 
nucleofection) in order to maximise the chances of reaching sufficient levels of 
ZFN-induced gene correction with effective therapeutic advantages and 
transfection issues are also increased by the need of co-transfecting along the 
ZFN expression vectors the DNA repair template (Urnov, Rebar et al. 2010). 
The second limiting step in obtaining sufficient levels of gene correction is 
inherently linked to the ZFN’s cutting efficiency and ability to promote HR 
events in HSCs. 
The first effective gene targeting mediated by ZFNs of an endogenous 
gene in HSCs has been carried out in 2007 by Lombardo et al. This group, 
using an integration-defective lentiviral vector as delivery method, managed to 
obtain targeted gene addition by HR of a GFP construct into the CCR5 locus 
with frequencies up to 0.11% compared to frequencies of 0.005% in the 
absence of the ZFN (Lombardo, Genovese et al. 2007). Since then, 
researchers have put a lot of effort towards the development of improved 
gene targeting approaches for HSCs, but frequencies are still relatively low for 
actual therapeutic applications. The only ZFN-based approach in HSCs that 
has reached a clinical trial stage is a ZFN-gene therapy for AIDS but this 
approach involves the knocking-out (by NHEJ-mediated DSB repair) of the 
CCR5 gene that is relatively easy compared to HR-mediated gene correction 
(Kiem, Jerome et al. 2012). The CCR5 gene expresses a non-functional 
receptor protein that is used by the HIV virus to enter CD4+ T-cells. The lack 
of the receptor has no known negative effects and, moreover, individuals that 
are homozygous for a CCR5 mutation seems to be HIV resistant. The 
connection between CCR5 mutations and HIV resistance was confirmed even 
further by the so called “Berlin patient” case where an HIV-positive patient 
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was transplanted with HSCs from an individual that was homozygous for a 
CCR5 mutation. Three and an half years later the “Berlin patient” was 
completely free of any traceable HIV infection even without antiretroviral 
therapy. This case opened also the way to possible HIV treatments based on 
the transplant of CCR5-mutated HSCs. In order to obviate to the very low 
number of CCR5- individuals that could be used as HSCs donors, Sangamo 
developed an alternative approach based on a ZFN specific for the CCR5 
gene (Maier, Brennan et al. 2013). The technique, which is now in a Phase2 
clinical trial, involves the delivery of a CCR5-specific ZFN in CD4+ T-cells 
from HIV-positive patients by transduction with an Ad5/F35 adenoviral vector. 
Expression of the ZFN will produce DSBs at the CCR5 locus that, in absence 
of repair template, would be repaired by the error-prone NHEJ pathway and 
subsequent disruption of the CCR5 gene (Maier, Brennan et al. 2013). 
Transduced CD4+ cells will be then auto-transplanted back into the patients. 
Initial reports on the first six patients to be treated with the CCR5-specific ZFN 
showed promising results. After being infused with 10 billion transduced cells, 
the patients had the antiretroviral treatments suspended for twelve weeks and 
the levels of CD4+ cells were monitored. The number of CD4+ T-cells 
increased during time and the transduced cells were found to be persistent in 
the circulation also after one year (AIDS patient care report, 2011, “HIV/AIDS 
and STD updates”). 
A possible alternative to HSCs is the use of iPS cells derived from, for 
example, skin cells obtained from the patient to be treated. Gene targeting of 
iPS cells has the advantage of having a potentially unlimited amount of 
treatable cells. Although frequencies resulted to be low, successful ZFN-
induced gene targeting of the human β-globin gene in iPS cells has been 
recently obtained by two different groups (Sebastiano, Maeder et al. 2011; 
Zou, Mali et al. 2011). Unfortunately, the use of iPS cells in possible clinical 
applications is quite controversial: additional studies have to be carried out in 
order to address the risk related to the “reprogramming” techniques used to 
create iPS cells and this type of cell has still to be fully characterised in order 
to identify possible genotoxic effects. Additionally, safe methods to induce 
HSC differentiation into erythroid lineages have yet to be found and the ZFN-
treated cells that are successfully transplanted back in to the patient have to 
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express durable and acceptable levels of the therapeutic or corrected gene 
without suffering gene silencing (Sebastiano, Maeder et al. 2011; Zou, Mali et 
al. 2011; Riviere, Dunbar et al. 2012). 
 
7.4 Closing comments 	  
The data reported in this study and the ones published by Sebastiano et al. 
and Zou et al. (Sebastiano, Maeder et al. 2011; Zou, Mali et al. 2011) show 
that the successful ZFN-induced gene targeting of the human β-globin gene is 
feasible and the results are encouraging for the development of a possible 
therapeutic treatment for both β-thalassaemia and sickle cell anaemia.  
Unfortunately the absolute gene targeting frequency of 0.1% obtained with 
ZFN4 and reported in this thesis is far too low to be of any use without a 
selectable marker. One possibility, explored successfully by Li et al. in their 
ZFN-induced gene targeting of a haemophilia mouse model (Li, Haurigot et al. 
2011), is the use of a targeting vector that carries a selectable marker flanked 
by two loxP sites. The drug selection can be used to “enrich” the cell 
population of successfully targeted cells and then can be easily removed by 
Cre-induced recombination. This approach, though, would be effective only on 
iPS cells due to the need for prolonged expansion in order to obtain 
acceptable amounts of corrected cells to be of any therapeutic value.  
Ultimately, in order to create a successful therapeutic approach for β-
globin disorders based on any nucleases technology, a series of technical 
advances have to be acquired.  
First, new and more efficient engineered nucleases have to be developed 
based on traditional ZFNs or on novel systems like TALENs. Such nucleases 
should be not only more effective in producing DSBs and inducing HR events 
but should also be safer with reduced risks of off-target cleavages. In order to 
make them safer, improved validation systems have to be developed based 
on both bioinformatic approaches for the prediction of probable off-target sites 
and also on effective assays for the detection of unwanted DSBs events 
(Urnov, Rebar et al. 2010).  
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Second, a better understanding of the cellular mechanisms that affect the 
frequencies of HR and NHEJ have to be acquired in order to improve the low 
frequencies of gene targeting events noticed in HSCs and iPS cells. Third, in 
the case of HSCs, additional methods for the identification and isolation of 
stem cells should be developed in order to increase the number of possible 
target cells for the therapy (Kiem, Jerome et al. 2012).  
Finally, long term expression of therapeutic or corrected genes should be 
obtained and maintained constantly in order to produce effective therapeutic 
approaches that do not require successive and repeated treatments. Gene 
silencing induced by epigenetic modifications has been shown to affect 
exogenous/ectopic genes but, more recently, also to affect endogenous 
genes that underwent gene correction by HR (Cuozzo, Porcellini et al. 2007). 
Therefore additional research has to be carried out in order to understand the 
link between epigenetic modifications and silencing of both exogenous DNA 
sequences used for therapeutic gene augmentation and endogenous genes 
that have undergone HDR. 
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Appendix 1 
 
a. β- and δ-globin sequences alignment 
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The two β and δ DNA sequences reported in this appendix were obtained 
from the NCBI web archive and were aligned (only for graphic representation) 
using the Ape-A plasmid editor software. The actual search for possible 
homologies was carried out by use of the BLAST algorithm from NCBI as 
described in Section 3.2.1. The three target sequences (from top to bottom) 
TS-1, TS-2 and TS3 are in capitol letters.  
 
 
b. ZF-DBDs coding sequences 
In the following section the coding sequences for the six ZF-DBDs are 
reported. Each ZF-DBD is made of four different ZF modules and each ZF 
module is composed by a constant sequence (small letters) and a variable 
sequence (capital letters in bold) that codes for the amino acids responsible 
for the binding specificity. 
 
 
ZF1-R: 
ZF-60-71-106-94, sequence: 
5’−tctagacccggggagaagccttacaaatgcccagaatgtggaaagagttttagc
ACTTCTGGACATCTTGTGAGAcaccagagaacacataccggggagaagccttacaaa
tgcccagaatgtggaaagagttttagcCAGTCTGGAGACCTTAGAAGAcaccagaga
acacataccggggagaagccttacaaatgcccagaatgtggaaagagttttagcAGG
TCTGACCATCTCACCACAcaccagagaacacataccggggagaagccttacaaatgc
ccagaatgtggaaagagttttagcCTAAGAAACATCTCGCAGAAcaccagagaacac
ataccggtggatcctctgcacagt−3’ 
 
ZF1-L: 
ZF-92-103-89-90, sequence: 
5’−tctagacccggggagaagccttacaaatgcccagaatgtggaaagagttttagc
ACTTCTGGAAATCTCACAGAAcaccagagaacacataccggggagaagccttacaaa
tgcccagaatgtggaaagagttttagcACTACCGGAGCACTCACAGAAcaccagaga
acacataccggggagaagccttacaaatgcccagaatgtggaaagagttttagcGAA
AGGTCTCATCTCAGAGAGcaccagagaacacataccggggagaagccttacaaatgc
ccagaatgtggaaagagttttagcTCTAAGAAAGCACTCACAGAAcaccagagaaca
cataccggtggatcctctgcacagt−3’ 
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ZF2-R: 
ZF-73-104-83-93, sequence: 
5’−tctagacccggggagaagccttacaaatgcccagaatgtggaaagagttttagc
GATTGTAGGGATCTCGCTAGAcaccagagaacacataccggggagaagccttacaaa
tgcccagaatgtggaaagagttttagcAGGGAAGATAATCTCCATACAcaccagaga
acacataccggggagaagccttacaaatgcccagaatgtggaaagagttttagcGAA
AGGTCTCATCTCAGAGAGcaccagagaacacataccggggagaagccttacaaatgc
ccagaatgtggaaagagttttagcACTTCTCATTCCCTCACAGAAcaccagagaaca
cataccggtggatcctctgcacagt−3’ 
 
 
 
 
ZF2-L:  
ZF-73-93-77-77, sequence: 
5’−tctagacccggggagaagccttacaaatgcccagaatgtggaaagagttttagc
GATTGTAGGGATCTCGCTAGAcaccagagaacacataccggggagaagccttacaaa
tgcccagaatgtggaaagagttttagcACTTCTCATTCCCTCACAGAAcaccagaga
acacataccggggagaagccttacaaatgcccagaatgtggaaagagttttagcACT
ACCGGAAATCTCACAGTGcaccagagaacacataccggggagaagccttacaaatgc
ccagaatgtggaaagagttttagcACTACCGGAAATCTCACAGTGcaccagagaaca
cataccggtggatcctctgcacagt−3’ 
 
ZF3-R: 
ZF-106-75-82-77, sequence: 
5’−tctagacccggggagaagccttacaaatgcccagaatgtggaaagagttttagc
AGGTCTGACCATCTCACCACAcaccagagaacacataccggggagaagccttacaaa
tgcccagaatgtggaaagagttttagcGATTCTGGAAATCTCAGAGTGcaccagaga
acacataccggggagaagccttacaaatgcccagaatgtggaaagagttttagcCAA
CTTGCACATCTCAGAGCTcaccagagaacacataccggggagaagccttacaaatgc
ccagaatgtggaaagagttttagcACTACCGGAAATCTCACAGTGcaccagagaaca
cataccggtggatcctctgcacagt−3’ 	  
ZF3-L:	  
ZF-69-96-74-103, sequence: 
5’−tctagacccggggagaagccttacaaatgcccagaatgtggaaagagttttagc
GATCCTGGAGCACTCGTGAGAcaccagagaacacataccggggagaagccttacaaa
tgcccagaatgtggaaagagttttagcACTAAGAACTCTCTCACAGAAcaccagaga
acacataccggggagaagccttacaaatgcccagaatgtggaaagagttttagcCAA
AGGGCAAATCTCAGAGCTcaccagagaacacataccggggagaagccttacaaatgc
ccagaatgtggaaagagttttagcACTACCGGAGCACTCACAGAAcaccagagaaca
cataccggtggatcctctgcacagt−3’ 
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Appendix 2 
 
Human HBB ZFN4-(L) 
 
Map: 
 
 
Sequence (colour coding follows the one used in the map): 
tcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaata
gtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacata
acttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtc
aataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatg
ggtggactatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgcc
aagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgccca
gtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgc
tattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttga
ctcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggca
ccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaat
gggcggtaggcgtgtacggtgggaggtctatataagcagagctctctggctaactag
agaacccactgcttactggcttatcgaaattaatacgactcactatagggagaccca
agctggctagcgtttaaacttaagctgatccactagtccagtgtggtggaattcgcc
atggactacaaagaccatgacggtgattataaagatcatgacatcgattacaaggat
gacgatgacaagatggcccccaagaagaagaggaaggtgggcatccacggggtaccc
gccgctatggctgagaggcccttccagtgtcgaatctgcatgcgtaacttcagtgac
cgctccaacctgtcccgccacatccgcacccacaccggcgagaagccttttgcctgt
gacatttgtgggaggaaatttgcccagtccggcgacctgacccgccataccaagata
cacacgggatctcagaagcccttccagtgtcgaatctgcatgcgtaacttcagtcgc
NLS 817..837
Triple\Flag 745..810
CMV\prmt 23..614
BGH\pA 1856..2080
KanR 2253..3047
pUC\ori 3347..4020
huHBB_pZFN4(L)
4032 bp
ZF-DBD 745..1206
FokI 1207..1800
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tccgacaccctgtcccagcacatccgcacccacaccggcgagaagccttttgcctgt
gacatttgtgggaggaaatttgcccagtccggctccctgacccgccataccaagata
cacctgcggggatcccagctggtgaagagcgagctggaggagaagaagtccgagctg
cggcacaagctgaagtacgtgccccacgagtacatcgagctgatcgagatcgccagg
aacagcacccaggaccgcatcctggagatgaaggtgatggagttcttcatgaaggtg
tacggctacaggggaaagcacctgggcggaagcagaaagcctgacggcgccatctat
acagtgggcagccccatcgattacggcgtgatcgtggacacaaaggcctacagcggc
ggctacaatctgcctatcggccaggccgacgagatggagagatacgtggaggagaac
cagacccggaataagcacctcaaccccaacgagtggtggaaggtgtaccctagcagc
gtgaccgagttcaagttcctgttcgtgagcggccacttcaagggcaactacaaggcc
cagctgaccaggctgaaccacatcaccaactgcaatggcgccgtgctgagcgtggag
gagctgctgatcggcggcgagatgatcaaagccggcaccctgacactggaggaggtg
cggcgcaagttcaacaacggcgagatcaacttcagatcttgataactcgagtctaga
gggcccgtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatct
gttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtc
ctttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctatt
ctggggggtggggtggggcaggacagcaagggggaggattgggaagacaatagcagg
catgctggggatgcggtgggctctatggcttctactgggcggttttatggacagcaa
gcgaaccggaattgccagctggggcgccctctggtaaggttgggaagccctgcaaag
taaactggatggctttctcgccgccaaggatctgatggcgcaggggatcaagctctg
atcaagagacaggatgaggatcgtttcgcatgattgaacaagatggattgcacgcag
gttctccggccgcttgggtggagaggctattcggctatgactgggcacaacagacaa
tcggctgctctgatgccgccgtgttccggctgtcagcgcaggggcgcccggttcttt
ttgtcaagaccgacctgtccggtgccctgaatgaactgcaagacgaggcagcgcggc
tatcgtggctggccacgacgggcgttccttgcgcagctgtgctcgacgttgtcactg
aagcgggaagggactggctgctattgggcgaagtgccggggcaggatctcctgtcat
ctcaccttgctcctgccgagaaagtatccatcatggctgatgcaatgcggcggctgc
atacgcttgatccggctacctgcccattcgaccaccaagcgaaacatcgcatcgagc
gagcacgtactcggatggaagccggtcttgtcgatcaggatgatctggacgaagagc
atcaggggctcgcgccagccgaactgttcgccaggctcaaggcgagcatgcccgacg
gcgaggatctcgtcgtgacccatggcgatgcctgcttgccgaatatcatggtggaaa
atggccgcttttctggattcatcgactgtggccggctgggtgtggcggaccgctatc
aggacatagcgttggctacccgtgatattgctgaagagcttggcggcgaatgggctg
accgcttcctcgtgctttacggtatcgccgctcccgattcgcagcgcatcgccttct
atcgccttcttgacgagttcttctgaattattaacgcttacaatttcctgatgcggt
attttctccttacgcatctgtgcggtatttcacaccgcatacaggtggcacttttcg
gggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgta
tccgctcatgagacaataaccctgataaatgcttcaataatagcacgtgctaaaact
tcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaa
aatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaa
aggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaa
accaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttcc
gaaggtaactggcttcagcagagcgcagataccaaatactgtccttctagtgtagcc
gtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgct
aatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttgga
ctcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtg
cacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtga
gctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaag
cggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggta
tctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatg
ctcgtcaggggggcggagcctatggaaaaacgccagcaacgcggcctttttacggtt
cctgggcttttgctggccttttgctcacatgttcttgactct 
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Human HBB ZFN4-(R) 
 
Map: 
 
Sequence (colour coding follows the one used in the map): 
gactcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagtta
ttaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgt
tacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt
gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacg
tcaatgggtggactatttacggtaaactgcccacttggcagtacatcaagtgtatca
tatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcatta
tgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagt
catcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcg
gtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgtt
ttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgac
gcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctctctggct
aactagagaacccactgcttactggcttatcgaaattaatacgactcactataggga
gacccaagctggctagcgtttaaacttaagctgatccactagtccagtgtggtggaa
ttcgccatgagatctgactacaaagaccatgacggtgattataaagatcatgacatc
gattacaaggatgacgatgacaagatggcccccaagaagaagaggaaggtgggcatt
catggggtacccgccgctatggctgagaggcccttccagtgtcgaatctgcatgcgt
aacttcagtcgtagtgacagcctgagccggcacatccgcacccacacaggcgagaag
ccttttgcctgtgacatttgtgggaggaaatttgccgacagcagcaaccgcaaaacg
cataccaagatacacacgggcggacaacggcccttccagtgtcgaatctgcatgcgt
aacttcagtcgctccgccgccctgtcccgccacatccgcacccacaccggcgagaag
KanR 2439..3233
BGH\pA 2042..2266
huHBB_pZFN4(R)
4212 bp
CMV\prmt 29..620
3Flag 757..822
NLS 829..849
ZF-DBD 757..1398
FokI 1399..1998
pUC\ori 3533..4206
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ccttttgcctgtgacatttgtgggaggaaatttgcccgcctggacaaccgcaccgcc
cataccaagatacacacgggcggaggcggatctcagaagcccttccagtgtcgaatc
tgcatgcgtaacttcagtcgctccgcccacctgtcccgccacatccgcacccacacc
ggcgagaagccttttgcctgtgacatttgtgggaggaaatttgcccgctccgacgcc
ctggcccgccataccaagatacacctgcggggatcccagctggtgaagagcgagctg
gaggagaagaagtccgagctgcggcacaagctgaagtacgtgccccacgagtacatc
gagctgatcgagatcgccaggaacagcacccaggaccgcatcctggagatgaaggtg
atggagttcttcatgaaggtgtacggctacaggggaaagcacctgggcggaagcaga
aagcctgacggcgccatctatacagtgggcagccccatcgattacggcgtgatcgtg
gacacaaaggcctacagcggcggctacaatctgcctatcggccaggccgacgagatg
cagagatacgtgaaggagaaccagacccggaataagcacatcaaccccaacgagtgg
tggaaggtgtaccctagcagcgtgaccgagttcaagttcctgttcgtgagcggccac
ttcaagggcaactacaaggcccagctgaccaggctgaaccacaaaaccaactgcaat
ggcgccgtgctgagcgtggaggagctgctgatcggcggcgagatgatcaaagccggc
accctgacactggaggaggtgcggcgcaagttcaacaacggcgagatcaacttctga
taactcgagtctagagggcccgtttaaacccgctgatcagcctcgactgtgccttct
agttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggt
gccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagt
aggtgtcattctattctggggggtggggtggggcaggacagcaagggggaggattgg
gaagacaatagcaggcatgctggggatgcggtgggctctatggcttctactgggcgg
ttttatggacagcaagcgaaccggaattgccagctggggcgccctctggtaaggttg
ggaagccctgcaaagtaaactggatggctttctcgccgccaaggatctgatggcgca
ggggatcaagctctgatcaagagacaggatgaggatcgtttcgcatgattgaacaag
atggattgcacgcaggttctccggccgcttgggtggagaggctattcggctatgact
gggcacaacagacaatcggctgctctgatgccgccgtgttccggctgtcagcgcagg
ggcgcccggttctttttgtcaagaccgacctgtccggtgccctgaatgaactgcaag
acgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagctgtgc
tcgacgttgtcactgaagcgggaagggactggctgctattgggcgaagtgccggggc
aggatctcctgtcatctcaccttgctcctgccgagaaagtatccatcatggctgatg
caatgcggcggctgcatacgcttgatccggctacctgcccattcgaccaccaagcga
aacatcgcatcgagcgagcacgtactcggatggaagccggtcttgtcgatcaggatg
atctggacgaagagcatcaggggctcgcgccagccgaactgttcgccaggctcaagg
cgagcatgcccgacggcgaggatctcgtcgtgacccatggcgatgcctgcttgccga
atatcatggtggaaaatggccgcttttctggattcatcgactgtggccggctgggtg
tggcggaccgctatcaggacatagcgttggctacccgtgatattgctgaagagcttg
gcggcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcccgattcgc
agcgcatcgccttctatcgccttcttgacgagttcttctgaattattaacgcttaca
atttcctgatgcggtattttctccttacgcatctgtgcggtatttcacaccgcatac
aggtggcacttttcggggaaatgtgcgcggaacccctatttgtttatttttctaaat
acattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataata
gcacgtgctaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttga
taatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccc
cgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctg
cttgcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagct
accaactctttttccgaaggtaactggcttcagcagagcgcagataccaaatactgt
ccttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctac
atacctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtg
tcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcgggctg
aacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgag
atacctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcgga
caggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagcttccagg
gggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcg
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tcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacgc
ggcctttttacggttcctgggcttttgctggccttttgctcacatgttctt 
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Appendix 3 	  
pBL-TV-TC map: 
 
 
pBL-TV-TC partial sequence (regions of interest): 
cacgacgttgtaaaacgacggccagtgagcgcgcgtaatacgactcactatagggcg
aattggagctccaccgcggtggcggccgcATATCAGGGATGTGAAACAGGGTCTTGA
AAACTGTCTAAATCTAAAACAATGCTAATGCAGGTTTAAATTTAATAAAATAAAATC
CAAAATCTAACAGCCAAGTCAAATCTGCATGTTTTAACATTTAAAATATTTTAAAGA
CGTCTTTTCCCAGGATTCAACATGTGAAATCTTTTCTCAGGGATACACGTGTGCCTA
GATCCTCATTGCTTTAGTTTTTTACAGAGGAATGAATATAAAAAGAAAATACTTAAA
TTTTATCCCTCTTACCTCTATAATCATACATAGGCATAATTTTTTAACCTAGGCTCC
AGATAGCCATAGAAGAACCAAACACTTTCTGCGTGTGTGAGAATAATCAGAGTGAGA
TTTTTTCACAAGTACCTGATGAGGGTTGAGACAGGTAGAAAAAGTGAGAGATCTCTA
TTTATTTAGCAATAATAGAGAAAGCATTTAAGAGAATAAAGCAATGGAAATAAGAAA
TTTGTAAATTTCCTTCTGATAACTAGAAATAGAGGATCCAGTTTCTTTTGGTTAACC
TAAATTTTATTTCATTTTATTGTTTTATTTTATTTTATTTTATTTTATTTTGTGTAA
TCGTAGTTTCAGAGTGTTAGAGCTGAAAGGAAGAAGTAGGAGAAACATGCAAAGTAA
AAGTATAACACTTTCCTTACTAAACCGACATGGGTTTCCAGGTAGGGGCAGGATTCA
GGATGACTGACAGGGCCCTTAGGGAACACTGAGACCCTACGCTGACCTCATAAATGC
TTGCTACCTTTGCTGTTTTAATTACATCTTTTAATAGCAGGAAGCAGAACTCTGCAC
TTCAAAAGTTTTTCCTCACCTGAGGAGTTAATTTAGTACAAGGGGAAAAAGTACAGG
GGGATGGGAGAAAGGCGATCACGTTGGGAAGCTATAGAGAAAGAAGAGTAAATTTTA
GTAAAGGAGGTTTAAACAAACAAAATATAAAGAGAAATAGGAACTTGAATCAAGGAA
ATGATTTTAAAACGCAGTATTCTTAGTGGACTAGAGGAAAAAAATAATCTGAGCCAA
GTAGAAGACCTTTTCCCCTCCTACCCCTACTTTCTAAGTCACAGAGGCTTTTTGTTC
CCCCAGACACTCTTGCAGATTAGTCCAGGCAGAAACAGTTAGATGTCCCCAGTTAAC
CTCCTATTTGACACCACTGATTACCCCATTGATAGTCACACTTTGGGTTGTAAGTGA
Beta-left-homology 543..2594
PT3-F 1159..1182
PT2-F 848..870
M13-fwd 465..482
Tsv40e 2707..2657
Psv40e 3856..3660
M13-rev 6507..6487
ColE1 origin 7557..6875
AmpR 8314..7655
PBL-TV-TC-thesis
8774 bp
Beta-right-homology 4014..6433
PuroR 3567..2971
PT1-R 2968..2987
PT2-R 2637..2658
misc_feature 2522..2571
F1 ori 307..1
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CTTTTTATTTATTTGTATTTTTGACTGCATTAAGAGGTCTCTAGTTTTTTATCTCTT
GTTTCCCAAAACCTAATAAGTAACTAATGCACAGAGCACATTGATTTGTATTTATTC
TATTTTTAGACATAATTTATTAGCATGCATGAGCAAATTAAGAAAAACAACAACAAA
TGAATGCATATATATGTATATGTATGTGTGTATATATACACACATATATATATATAT
TTTTTCTTTTCTTACCAGAAGGTTTTAATCCAAATAAGGAGAAGATATGCTTAGAAC
CGAGGTAGAGTTTTCATCCATTCTGTCCTGTAAGTATTTTGCATATTCTGGAGACGC
AGGAAGAGATCCATCTACATATCCCAAAGCTGAATTATGGTAGACAAAACTCTTCCA
CTTTTAGTGCATCAACTTCTTATTTGTGTAATAAGAAAATTGGGAAAACGATCTTCA
ATATGCTTACCAAGCTGTGATTCCAAATATTACGTAAATACACTTGCAAAGGAGGAT
GTTTTTAGTAGCAATTTGTACTGATGGTATGGGGCCAAGAGATATATCTTAGAGGGA
GGGCTGAGGGTTTGAAGTCCAACTCCTAAGCCAGTGCCAGAAGAGCCAAGGACAGGT
ACGGCTGTCATCACTTAGACCTCACCCTGTGGAGCCACACCCTAGGGTTGGCCAATC
TACTCCCAGGAGCAGGGAGGGCAGGAGCCAGGGCTGGGCATAAAAGTCAGGGCAGAG
CCATCTATTGCTTACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACA
GACACCATGGTGCATCTGACTCCTGAGGAgaattcgatGATCCAGACATGATAAGAT
ACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTT
GTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAG
TTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGG
TTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCCTCTAG
AGTCGGTGGGCCTCGGGGGCGGGTGCGGGGTCGGCGGGGCCGCCCGGGTCGGCTTCG
GTCGGAGCCATGGGGTCGTGCGCTCCTTTCGGTCGGGCGCTGCGGGTCGTGGGGCGG
GCGTCAGGCACCGGGCTTGCGGGTCATGCACCAGGTGCGCGGTCCTTCGGGCACCTC
GACGTCGGCGGTGACGGTGAAGCCGAGCCGCTCGTAGAAGGGGAGGTTGCGGGGCGC
GGAGGTCTCCAGGAAGGCGGGCACCCCGGCGCGCTCGGCCGCCTCCACTCCGGGGAG
CACGACGGCGCTGCCCAGACCCTTGCCCTGGTGGTCGGGCGAGACGCCGACGGTGGC
CAGGAACCACGCGGGCTCCTTGGGCCGGTGCGGCGCCAGGAGGCCTTCCATCTGTTG
CTGCGCGGCCAGCCGGGAACCGCTCAACTCGGCCATGCGCGGGCCGATCTCGGCGAA
CACCGCCCCCGCTTCGACGCTCTCCGGCGTGGTCCAGACCGCCACCGCGGCGCCGTC
GTCCGCGACCCACACCTTGCCGATGTCGAGCCCGACGCGCGTGAGGAAGAGTTCTTG
CAGCTCGGTGACCCGCTCGATGTGGCGGTCCGGGTCGACGGTGTGGCGCGTGGCGGG
GTAGTCGGCGAACGCGGCGGCGAGGGTGCGTACGGCCCGGGGGACGTCGTCGCGGGT
GGCGAGGCGCACCGTGGGCTTGTACTCGGTCATGGAAGGTCGTCTCCTTGTGAGGGG
TCAGGGGCGTGGGTCAGGGGATGGTGGCGGCACCGGTCGTGGCGGCCGACCTGCAGG
CATGCAAGCTTTTTGCAAAAGCCTAGGCCTCCAAAAAAGCCTCCTCACTACTTCTGG
AATAGCTCAGAGGCCGAGGCGGCCTCGGCCTCTGCATAAATAAAAAAAATTAGTCAG
CCATGGGGCGGAGAATGGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTT
AGGGGCGGGACTATGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCT
GCTGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCATGCTT
TGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGACACACA
TTCCACAGatcaagcttatcgatCCTGGGCAGGTTGGTATCAAGGTTACAAGACAGG
TTTAAGGAGACCAATAGAAACTGGGCATGTGGAGACAGAGAAGACTCTTGGGTTTCT
GATAGGCACTGACTCTCTCTGCCTATTGGTCTATTTTCCCACCCTTAGGCTGCTGGT
GGTCTACCCTTGGACCCAGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGA
TGCTGTTATGGGCAACCCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTT
TAGTGATGGCCTGGCTCACCTGGACAACCTCAAGGGCACCTTTGCCACACTGAGTGA
GCTGCACTGTGACAAGCTGCACGTGGATCCTGAGAACTTCAGGGTGAGTCTATGGGA
CGCTTGATGTTTTCTTTCCCCTTCTTTTCTATGGTTAAGTTCATGTCATAGGAAGGG
GATAAGTAACAGGGTACAGTTTAGAATGGGAAACAGACGAATGATTGCATCAGTGTG
GAAGTCTCAGGATCGTTTTAGTTTCTTTTATTTGCTGTTCATAACAATTGTTTTCTT
TTGTTTAATTCTTGCTTTCTTTTTTTTTCTTCTCCGCAATTTTTACTATTATACTTA
ATGCCTTAACATTGTGTATAACAAAAGGAAATATCTCTGAGATACATTAAGTAACTT
AAAAAAAAACTTTACACAGTCTGCCTAGTACATTACTATTTGGAATATATGTGTGCT
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TATTTGCATATTCATAATCTCCCTACTTTATTTTCTTTTATTTTTAATTGATACATA
ATCATTATACATATTTATGGGTTAAAGTGTAATGTTTTAATATGTGTACACATATTG
ACCAAATCAGGGTAATTTTGCATTTGTAATTTTAAAAAATGCTTTCTTCTTTTAATA
TACTTTTTTGTTTATCTTATTTCTAATACTTTCCCTAATCTCTTTCTTTCAGGGCAA
TAATGATACAATGTATCATGCCTCTTTGCACCATTCTAAAGAATAACAGTGATAATT
TCTGGGTTAAGGCAATAGCAATATCTCTGCATATAAATATTTCTGCATATAAATTGT
AACTGATGTAAGAGGTTTCATATTGCTAATAGCAGCTACAATCCAGCTACCATTCTG
CTTTTATTTTATGGTTGGGATAAGGCTGGATTATTCTGAGTCCAAGCTAGGCCCTTT
TGCTAATCATGTTCATACCTCTTATCTTCCTCCCACAGCTCCTGGGCAACGTGCTGG
TCTGTGTGCTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAGTGCAGGCTGCCT
ATCAGAAAGTGGTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCTC
GCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACT
AAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACA
TTTATTTTCATTGCAATGATGTATTTAAATTATTTCTGAATATTTTACTAAAAAGGG
AATGTGGGAGGTCAGTGCATTTAAAACATAAAGAAATGAAGAGCTAGTTCAAACCTT
GGGAAAATACACTATATCTTAAACTCCATGAAAGAAGGTGAGGCTGCAAACAGCTAA
TGCACATTGGCAACAGCCCCTGATGCATATGCCTTATTCATCCCTCAGAAAAGGATT
CAAGTAGAGGCTTGATTTGGAGGTTAAAGTTTTGCTATGCTGTATTTTACATTACTT
ATTGTTTTAGCTGTCCTCATGAATGTCTTTTCACTACCCATTTGCTTATCCTGCATC
TCTCAGCCTTGACTCCACTCAGTTCTCTTGCTTAGAGATACCACCTTTCCCCTGAAG
TGTTCCTTCCATGTTTTACGGCGAGATGGTTTCTCCTCGCCTGGCCACTCAGCCTTA
GTTGTCTCTGTTGTCTTATAGAGGTCTACTTGAAGAAGGAAAAACAGGGGTCATGGT
TTGACTGTCCTGTGAGCCCTTCTTCCCTGCCTCCCCCACTCACAGTGACCCGGAATC
TGCAGTGCTAGTCTCCCGGAACTATCACTCTTTCACAGTCTGCTTTGGAAGGACTGG
GCTTAGTATGAAAAGTTAGGACTGAGAAGAATTTGAAAGGCGGCTTTTTGTAGCTTG
ATATTCACTACTGTCTTATTACCCTGTCATAGGCCCACCCCAAATGGAAGTCCCATT
CTTCCTCAGGATGTTTAAGATTAGCATTCAGGAAGAGATCAGAGGTCTGCTGGCTCC
CTTATCATGTCCCTTATGGTGCTTCTGGCTCTGCAGTTATTAGCATAGTGTTACCAT
CAACCACCTTAACTTCATTTTTCTTATTCAATACCTAGGTAGGTAGATGCTAGATTC
TGGAAATAAAATATGAGTCTCAAGTGGTCCTTGTCCTCTCTCCCAGTCAggtaccca
gcttttgttccctttagtgagggttaattgcgcgcttggcgtaatcatggtcatagc
tgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaa 
 
Red: Homology arms, left and right 
Light blue: PT2-F 
Green: PT3-F 
Yellow: PT1-R 
Dark blue: PT2-R 
Light brown: PuroR cassette 
Dark grey: Tsv40e terminator 
Pink: Psv40e 
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pTV-TC4 map: 
 
 
 
 
pTV-TC4 partial sequence (regions of interest): 
ttggagctccaccgcggtggcggccgctctagaactagtggatcccccgggctgcag
gaattcgatatcaagcttatcgataccgtcgacctcgagggggggccCTTAGGGAAC
ACTGAGACCCTACGCTGACCTCATAAATGCTTGCTACCTTTGCTGTTTTAATTACAT
CTTTTAATAGCAGGAAGCAGAACTCTGCACTTCAAAAGTTTTTCCTCACCTGAGGAG
TTAATTTAGTACAAGGGGAAAAAGTACAGGGGGATGGGAGAAAGGCGATCACGTTGG
GAAGCTATAGAGAAAGAAGAGTAAATTTTAGTAAAGGAGGTTTAAACAAACAAAATA
TAAAGAGAAATAGGAACTTGAATCAAGGAAATGATTTTAAAACGCAGTATTCTTAGT
GGACTAGAGGAAAAAAATAATCTGAGCCAAGTAGAAGACCTTTTCCCCTCCTACCCC
TACTTTCTAAGTCACAGAGGCTTTTTGTTCCCCCAGACACTCTTGCAGATTAGTCCA
GGCAGAAACAGTTAGATGTCCCCAGTTAACCTCCTATTTGACACCACTGATTACCCC
ATTGATAGTCACACTTTGGGTTGTAAGTGACTTTTTATTTATTTGTATTTTTGACTG
CATTAAGAGGTCTCTAGTTTTTTATCTCTTGTTTCCCAAAACCTAATAAGTAACTAA
TGCACAGAGCACATTGATTTGTATTTATTCTATTTTTAGACATAATTTATTAGCATG
CATGAGCAAATTAAGAAAAACAACAACAAATGAATGCATATATATGTATATGTATGT
GTGTATATATACACACATATATATATATATTTTTTCTTTTCTTACCAGAAGGTTTTA
ATCCAAATAAGGAGAAGATATGCTTAGAACCGAGGTAGAGTTTTCATCCATTCTGTC
CTGTAAGTATTTTGCATATTCTGGAGACGCAGGAAGAGATCCATCTACATATCCCAA
AGCTGAATTATGGTAGACAAAACTCTTCCACTTTTAGTGCATCAACTTCTTATTTGT
GTAATAAGAAAATTGGGAAAACGATCTTCAATATGCTTACCAAGCTGTGATTCCAAA
TATTACGTAAATACACTTGCAAAGGAGGATGTTTTTAGTAGCAATTTGTACTGATGG
TATGGGGCCAAGAGATATATCTTAGAGGGAGGGCTGAGGGTTTGAAGTCCAACTCCT
AAGCCAGTGCCAGAAGAGCCAAGGACAGGTACGGCTGTCATCACTTAGACCTCACCC
PT2-R primer 2119..2140LacO 6018..5996
M13-rev 5990..5970
T3 5952..5933
Beta-right-homology 3496..5915
ColE1 origin 7040..6358
AmpR 7797..7138
pTV-TC4
8123 bp
F1 ori 441..135
LacZ alpha 528..460
PuroR 3049..2453
Psv40e 3338..3142
Tsv40e 2189..2139
Beta-left-homology 754..2076
M13-fwd 599..616
T7 625..645
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TGTGGAGCCACACCCTAGGGTTGGCCAATCTACTCCCAGGAGCAGGGAGGGCAGGAG
CCAGGGCTGGGCATAAAAGTCAGGGCAGAGCCATCTATTGCTTACATTTGCTTCTGA
CACAACTGTGTTCACTAGCAACCTCAAACAGACACCATGGTGCATCTGACTCCTGAG
GAgaattcgatGATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAA
CTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTAT
TTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTA
TGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACA
AATGTGGTATGGCTGATTATGATCCTCTAGAGTCGGTGGGCCTCGGGGGCGGGTGCG
GGGTCGGCGGGGCCGCCCGGGTCGGCTTCGGTCGGAGCCATGGGGTCGTGCGCTCCT
TTCGGTCGGGCGCTGCGGGTCGTGGGGCGGGCGTCAGGCACCGGGCTTGCGGGTCAT
GCACCAGGTGCGCGGTCCTTCGGGCACCTCGACGTCGGCGGTGACGGTGAAGCCGAG
CCGCTCGTAGAAGGGGAGGTTGCGGGGCGCGGAGGTCTCCAGGAAGGCGGGCACCCC
GGCGCGCTCGGCCGCCTCCACTCCGGGGAGCACGACGGCGCTGCCCAGACCCTTGCC
CTGGTGGTCGGGCGAGACGCCGACGGTGGCCAGGAACCACGCGGGCTCCTTGGGCCG
GTGCGGCGCCAGGAGGCCTTCCATCTGTTGCTGCGCGGCCAGCCGGGAACCGCTCAA
CTCGGCCATGCGCGGGCCGATCTCGGCGAACACCGCCCCCGCTTCGACGCTCTCCGG
CGTGGTCCAGACCGCCACCGCGGCGCCGTCGTCCGCGACCCACACCTTGCCGATGTC
GAGCCCGACGCGCGTGAGGAAGAGTTCTTGCAGCTCGGTGACCCGCTCGATGTGGCG
GTCCGGGTCGACGGTGTGGCGCGTGGCGGGGTAGTCGGCGAACGCGGCGGCGAGGGT
GCGTACGGCCCGGGGGACGTCGTCGCGGGTGGCGAGGCGCACCGTGGGCTTGTACTC
GGTCATGGAAGGTCGTCTCCTTGTGAGGGGTCAGGGGCGTGGGTCAGGGGATGGTGG
CGGCACCGGTCGTGGCGGCCGACCTGCAGGCATGCAAGCTTTTTGCAAAAGCCTAGG
CCTCCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGGCCTCG
GCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGAACTG
GGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGGTTGCTGACTAA
TTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACAC
CTGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAGCCT
GGGGACTTTCCACACCCTAACTGACACACATTCCACAGatcaagcttatcgatCCTG
GGCAGGTTGGTATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCA
TGTGGAGACAGAGAAGACTCTTGGGTTTCTGATAGGCACTGACTCTCTCTGCCTATT
GGTCTATTTTCCCACCCTTAGGCTGCTGGTGGTCTACCCTTGGACCCAGAGGTTCTT
TGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAACCCTAAGGTGAA
GGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGCTCACCTGGACAA
CCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGTGACAAGCTGCACGTGGA
TCCTGAGAACTTCAGGGTGAGTCTATGGGACGCTTGATGTTTTCTTTCCCCTTCTTT
TCTATGGTTAAGTTCATGTCATAGGAAGGGGATAAGTAACAGGGTACAGTTTAGAAT
GGGAAACAGACGAATGATTGCATCAGTGTGGAAGTCTCAGGATCGTTTTAGTTTCTT
TTATTTGCTGTTCATAACAATTGTTTTCTTTTGTTTAATTCTTGCTTTCTTTTTTTT
TCTTCTCCGCAATTTTTACTATTATACTTAATGCCTTAACATTGTGTATAACAAAAG
GAAATATCTCTGAGATACATTAAGTAACTTAAAAAAAAACTTTACACAGTCTGCCTA
GTACATTACTATTTGGAATATATGTGTGCTTATTTGCATATTCATAATCTCCCTACT
TTATTTTCTTTTATTTTTAATTGATACATAATCATTATACATATTTATGGGTTAAAG
TGTAATGTTTTAATATGTGTACACATATTGACCAAATCAGGGTAATTTTGCATTTGT
AATTTTAAAAAATGCTTTCTTCTTTTAATATACTTTTTTGTTTATCTTATTTCTAAT
ACTTTCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCTTT
GCACCATTCTAAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCAATATCTC
TGCATATAAATATTTCTGCATATAAATTGTAACTGATGTAAGAGGTTTCATATTGCT
AATAGCAGCTACAATCCAGCTACCATTCTGCTTTTATTTTATGGTTGGGATAAGGCT
GGATTATTCTGAGTCCAAGCTAGGCCCTTTTGCTAATCATGTTCATACCTCTTATCT
TCCTCCCACAGCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCACTTTGGCA
AAGAATTCACCCCACCAGTGCAGGCTGCCTATCAGAAAGTGGTGGCTGGTGTGGCTA
ATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGTCCAATTTCTATTAA
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AGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAAGGGCCTT
GAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCAATGATGTATTTA
AATTATTTCTGAATATTTTACTAAAAAGGGAATGTGGGAGGTCAGTGCATTTAAAAC
ATAAAGAAATGAAGAGCTAGTTCAAACCTTGGGAAAATACACTATATCTTAAACTCC
ATGAAAGAAGGTGAGGCTGCAAACAGCTAATGCACATTGGCAACAGCCCCTGATGCA
TATGCCTTATTCATCCCTCAGAAAAGGATTCAAGTAGAGGCTTGATTTGGAGGTTAA
AGTTTTGCTATGCTGTATTTTACATTACTTATTGTTTTAGCTGTCCTCATGAATGTC
TTTTCACTACCCATTTGCTTATCCTGCATCTCTCAGCCTTGACTCCACTCAGTTCTC
TTGCTTAGAGATACCACCTTTCCCCTGAAGTGTTCCTTCCATGTTTTACGGCGAGAT
GGTTTCTCCTCGCCTGGCCACTCAGCCTTAGTTGTCTCTGTTGTCTTATAGAGGTCT
ACTTGAAGAAGGAAAAACAGGGGTCATGGTTTGACTGTCCTGTGAGCCCTTCTTCCC
TGCCTCCCCCACTCACAGTGACCCGGAATCTGCAGTGCTAGTCTCCCGGAACTATCA
CTCTTTCACAGTCTGCTTTGGAAGGACTGGGCTTAGTATGAAAAGTTAGGACTGAGA
AGAATTTGAAAGGCGGCTTTTTGTAGCTTGATATTCACTACTGTCTTATTACCCTGT
CATAGGCCCACCCCAAATGGAAGTCCCATTCTTCCTCAGGATGTTTAAGATTAGCAT
TCAGGAAGAGATCAGAGGTCTGCTGGCTCCCTTATCATGTCCCTTATGGTGCTTCTG
GCTCTGCAGTTATTAGCATAGTGTTACCATCAACCACCTTAACTTCATTTTTCTTAT
TCAATACCTAGGTAGGTAGATGCTAGATTCTGGAAATAAAATATGAGTCTCAAGTGG
TCCTTGTCCTCTCTCCCAGTCAggtaccccagcttttgttccctttagtgagggtta
attgcgcgcttggcgt 
 
Red: Homology arms, left and right 
Dark blue: PT2-R 
Light brown: PuroR cassette 
Dark grey: Tsv40e terminator 
Pink: Psv40e 
 
 
β-globin sequence plus surrounding: 
aagcttgaatagtttttcaggaactttgaatgctgatttagatttgaaactgaggct
ctgaccataaccaaatttgcactatttattgcttcttgaaacttatttgcctggtat
gcctgggcttttgatggtcttagtatagcttgcagccttgtccctgcagggtattat
gggtaatagaaagaaaagtctgcgttacactctagtcacactaagtaactaccattg
gaaaagcaacccctgccttgaagccaggatgatggtatctgcagcagttgccaacac
aagagaaggatccatagttcatcatttaaaaaagaaaacaaaatagaaaaaggaaaa
ctatttctgagcataagaagttgtagggtaagtctttaagaaggtgacaatttctgc
caatcaggatttcaaagctcttgctttgacaattttggtctttcagaatactataaa
tataacctatattataatttcataaagtctgtgcattttctttgacccaggatattt
gcaaaagacatattcaaacttccgcagaacactttatttcacatatacatgcctctt
atatcagggatgtgaaacagggtcttgaaaactgtctaaatctaaaacaatgctaat
gcaggtttaaatttaataaaataaaatccaaaatctaacagccaagtcaaatctgca
tgttttaacatttaaaatattttaaagacgtcttttcccaggattcaacatgtgaaa
tcttttctcagggatacacgtgtgcctagatcctcattgctttagttttttacagag
gaatgaatataaaaagaaaatacttaaattttatccctcttacctctataatcatac
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ataggcataattttttaacctaggctccagatagccatagaagaaccaaacactttc
tgcgtgtgtgagaataatcagagtgagattttttcacaagtacctgatgagggttga
gacaggtagaaaaagtgagagatctctatttatttagcaataatagagaaagcattt
aagagaataaagcaatggaaataagaaatttgtaaatttccttctgataactagaaa
tagaggatccagtttcttttggttaacctaaattttatttcattttattgttttatt
ttattttattttattttattttgtgtaatcgtagtttcagagtgttagagctgaaag
gaagaagtaggagaaacatgcaaagtaaaagtataacactttccttactaaaccgac
atgggtttccaggtaggggcaggattcaggatgactgacagggcccttagggaacac
tgagaccctacgctgacctcataaatgcttgctacctttgctgttttaattacatct
tttaatagcaggaagcagaactctgcacttcaaaagtttttcctcacctgaggagtt
aatttagtacaaggggaaaaagtacagggggatgggagaaaggcgatcacgttggga
agctatagagaaagaagagtaaattttagtaaaggaggtttaaacaaacaaaatata
aagagaaataggaacttgaatcaaggaaatgattttaaaacgcagtattcttagtgg
actagaggaaaaaaataatctgagccaagtagaagaccttttcccctcctaccccta
ctttctaagtcacagaggctttttgttcccccagacactcttgcagattagtccagg
cagaaacagttagatgtccccagttaacctcctatttgacaccactgattaccccat
tgatagtcacactttgggttgtaagtgactttttatttatttgtatttttgactgca
ttaagaggtctctagttttttatctcttgtttcccaaaacctaataagtaactaatg
cacagagcacattgatttgtatttattctatttttagacataatttattagcatgca
tgagcaaattaagaaaaacaacaacaaatgaatgcatatatatgtatatgtatgtgt
gtatatatacacacatatatatatatattttttcttttcttaccagaaggttttaat
ccaaataaggagaagatatgcttagaaccgaggtagagttttcatccattctgtcct
gtaagtattttgcatattctggagacgcaggaagagatccatctacatatcccaaag
ctgaattatggtagacaaaactcttccacttttagtgcatcaacttcttatttgtgt
aataagaaaattgggaaaacgatcttcaatatgcttaccaagctgtgattccaaata
ttacgtaaatacacttgcaaaggaggatgtttttagtagcaatttgtactgatggta
tggggccaagagatatatcttagagggagggctgagggtttgaagtccaactcctaa
gccagtgccagaagagccaaggacaggtacggctgtcatcacttagacctcaccctg
tggagccacaccctagggttggccaatctactcccaggagcagggagggcaggagcc
agggctgggcataaaagtcagggcagagccatctattgcttACATTTGCTTCTGACA
CAACTGTGTTCACTAGCAACCTCAAACAGACACCATGGTGCATCTGACTCCTGAGGA
GAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGA
GGCCCTGGGCAGgttggtatcaaggttacaagacaggtttaaggagaccaatagaaa
ctgggcatgtggagacagagaagactcttgggtttctgataggcactgactctctct
gcctattggtctattttcccacccttagGCTGCTGGTGGTCTACCCTTGGACCCAGA
GGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAACCCTA
AGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGCTCACC
TGGACAACCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGTGACAAGCTGC
ACGTGGATCCTGAGAACTTCAGGgtgagtctatgggacgcttgatgttttctttccc
cttcttttctatggttaagttcatgtcataggaaggggataagtaacagggtacagt
ttagaatgggaaacagacgaatgattgcatcagtgtggaagtctcaggatcgtttta
gtttcttttatttgctgttcataacaattgttttcttttgtttaattcttgctttct
ttttttttcttctccgcaatttttactattatacttaatgccttaacattgtgtata
acaaaaggaaatatctctgagatacattaagtaacttaaaaaaaaactttacacagt
ctgcctagtacattactatttggaatatatgtgtgcttatttgcatattcataatct
ccctactttattttcttttatttttaattgatacataatcattatacatatttatgg
gttaaagtgtaatgttttaatatgtgtacacatattgaccaaatcagggtaattttg
catttgtaattttaaaaaatgctttcttcttttaatatacttttttgtttatcttat
ttctaatactttccctaatctctttctttcagggcaataatgatacaatgtatcatg
cctctttgcaccattctaaagaataacagtgataatttctgggttaaggcaatagca
atatctctgcatataaatatttctgcatataaattgtaactgatgtaagaggtttca
tattgctaatagcagctacaatccagctaccattctgcttttattttatggttggga
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taaggctggattattctgagtccaagctaggcccttttgctaatcatgttcatacct
cttatcttcctcccacagCTCCTGGGCAACGTGCTGGTCTGTGTGCTGGCCCATCAC
TTTGGCAAAGAATTCACCCCACCAGTGCAGGCTGCCTATCAGAAAGTGGTGGCTGGT
GTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTCTTGCTGTCCAATTT
CTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACTGGGGGATATTATGAA
GGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTATTTTCATTGCaatgat
gtatttaaattatttctgaatattttactaaaaagggaatgtgggaggtcagtgcat
ttaaaacataaagaaatgaagagctagttcaaaccttgggaaaatacactatatctt
aaactccatgaaagaaggtgaggctgcaaacagctaatgcacattggcaacagcccc
tgatgcatatgccttattcatccctcagaaaaggattcaagtagaggcttgatttgg
aggttaaagttttgctatgctgtattttacattacttattgttttagctgtcctcat
gaatgtcttttcactacccatttgcttatcctgcatctctcagccttgactccactc
agttctcttgcttagagataccacctttcccctgaagtgttccttccatgttttacg
gcgagatggtttctcctcgcctggccactcagccttagttgtctctgttgtcttata
gaggtctacttgaagaaggaaaaacaggggtcatggtttgactgtcctgtgagccct
tcttccctgcctcccccactcacagtgacccggaatctgcagtgctagtctcccgga
actatcactctttcacagtctgctttggaaggactgggcttagtatgaaaagttagg
actgagaagaatttgaaaggcggctttttgtagcttgatattcactactgtcttatt
accctgtcataggcccaccccaaatggaagtcccattcttcctcaggatgtttaaga
ttagcattcaggaagagatcagaggtctgctggctcccttatcatgtcccttatggt
gcttctggctctgcagttattagcatagtgttaccatcaaccaccttaacttcattt
ttcttattcaatacctaggtaggtagatgctagattctggaaataaaatatgagtct
caagtggtccttgtcctctctcccagtcaaattctgaatctagttggcaagattctg
aaatcaaggcatataatcagtaataagtgatgatagaagggtatatagaagaatttt
attatatgagagggtgaaaccctcaaaatgaaatgaaatcagacccttgtcttacac
cataaacaaaaataaatttgaatgggttaaagaattaaactaagacctaaaaccata
aaaatttttaaagaaatcaaaagaagaaaattctaatattcacgttgcagccgtttt
ttgaatttgatatgagaagcaaaggcaacaaaaggaaaaataaagaagtgaggctac
atcaaactaaaaaatttccacacaaaaaacaaaacaatgaacaaatgaaaggtga 
 
Bold uppercase: exons 
Red: regions homologous with the left and right homology arms of pTV-TC4 
Yellow: ZFN4 target sequence 
Blue: PT3-F primer (PCR assay) 
Green: Southern-blot probe’s binding region 
 
 
 
 
 
